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SUMMARY OF THE THESIS 
 Upper gastrointestinal tract cancers originating from oesophagus, oesophago-
gastric junction or stomach constitute a major health problem around the world as well as 
in UK. Chapter 1 of the thesis describes the incidence, mortality, aetiology, staging, 
treatment and outcome of patients with oesophageal and gastric cancer. Each year 
approximately 8,000 people are diagnosed with oesophageal cancer and a similar number 
of people diagnosed with gastric cancer in UK. Early detection and surgery confers the 
greatest chance of long-term cure in oesophageal and gastric cancer.  However, upper GI 
cancer surgery is associated with considerable morbidity and mortality.  Postoperative 
mortality following gastro-oesophageal cancer resection is significant and has been 
reported as varying from 1%–23%.  Therefore, preoperative surgical risk assessment is a 
vital part of modern surgical practice. 
 Pathological TNM staging by American Joint Committee on Cancer (AJCC) is an 
established factor in predicting long term survival following resection of oesophageal and 
gastric cancer. However, it is increasingly recognised that, not only the intrinsic properties 
of tumour cells determine tumour spread but also the host inflammatory response has a 
vital role. Indeed, the systemic inflammatory response, as evidenced by elevated 
circulating concentrations of C-reactive protein, prior to surgery, has previously been 
shown to have independent prognostic value in patients with resectable gastro-oesophageal 
cancer. 
The overall aim of the thesis was to examine the inter-relationships between patient 
physiology, local and systemic inflammatory response and outcome (both short and long 
term), in patients undergoing resection for oesophageal and gastric cancer.   
Chapter 2 compared the POSSUM (Physiological and Operative Severity Score for 
the enUmeration of Mortality and morbidity) and mGPS (modified Glasgow prognostic 
score) models in prediction of post-operative outcome, both short and long term, in 121 
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patients undergoing resection of oesophago-gastric cancer. The results in this chapter 
demonstrated that, the POSSUM physiological score was an independent predictor of post-
operative complications. On the other hand, elevated systemic inflammatory response as 
evidenced by the mGPS and not, patient physiology or post-operative complications, was 
independently associated with poor cancer specific survival.  Therefore, results of the 
present study suggested that, pre-operative host related factors were important in 
determining both short and long term outcome following potentially curative resection of 
oesophago-gastric cancer.  
Chapter 3 examined the value of serial daily post-operative markers of systemic 
inflammatory response such as white cell count, albumin and C-reactive protein 
concentrations in the prediction of post-operative infectious complications in 136 patients 
following resection of oesophago-gastric cancer. The results showed that the magnitude of 
the systemic inflammatory response, in particular C reactive protein, following resection of  
oesophago-gastric cancer was associated with the development of post operative 
complications, in particular surgical site infections and anastomotic leak.  Furthermore, C 
reactive protein threshold of 180mg/l on post operative days 3 and 4 was shown to predict 
surgical site infection and anastomotic leak with good and very good diagnostic accuracy 
respectively.   
Chapter 4 compared the prognostic value of selected markers of systemic 
inflammatory response such as white cell count, neutrophil count, lymphocyte count, 
neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR) and mGPS in 112 
patients undergoing potentially curative resection of oesophageal cancer. The result 
demonstrated that, only mGPS was significantly associated with cancer specific survival 
and had prognostic value independent of pathological TNM stage. Therefore, an acute-
phase protein-based prognostic score, the mGPS, was established to have the superior 
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predictive value, compared to cellular components of the systemic inflammatory response 
in predicting survival in oesophageal cancer. 
Chapter 5 compared the prognostic value of selected markers of systemic 
inflammatory response such as white cell count, neutrophil count, lymphocyte count, 
neutrophil-lymphocyte ratio (NLR), platelet- lymphocyte ratio (PLR) and mGPS in 120 
patients undergoing potentially curative resection of gastric cancer. The result showed that, 
only mGPS was significantly associated with cancer specific survival and had prognostic 
value independent of pathological TNM stage. Therefore, an acute-phase protein-based 
prognostic score, the mGPS, was established to have the superior predictive value, 
compared to cellular components of the systemic inflammatory response in predicting 
survival in gastric cancer. 
Chapter 6 examined the relationship between tumour necrosis, tumour 
proliferation, local and systemic inflammatory response, microvessel density and survival 
in 98 patients undergoing potentially curative resection of oesophageal adenocarcinoma. 
The results suggested that, among the tissue based factors, tumour macrophage infiltration 
appeared to play a central role in the proliferative activity and coordination of the 
inflammatory cell infiltrate and was also independently associated with poor outcome in 
patients with oesophageal adenocarcinoma. There was no direct relationship between local 
and systemic inflammatory response, tumour necrosis and angiogenesis; suggesting that 
the mechanisms underlying the relationship between local and systemic inflammatory 
responses and cancer-specific survival are likely to be complex.   
Chapter 7 examined the relationship between tumour necrosis, tumour 
proliferation, local and systemic inflammation, microvessel density and survival in 104 
patients undergoing potentially curative resection of gastric cancer. The results suggested 
that, local peritumoural inflammatory infiltrate and intra tumoural necrosis appeared to 
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play a role in tumour proliferation and poor outcome in patients with gastric cancer. There 
was no direct relationship between local and systemic inflammatory responses, tumour 
necrosis and angiogenesis; suggesting that the mechanisms underlying the relationship 
between local and systemic inflammatory responses and cancer-specific survival are likely 
to be complex.   
In summary, preoperative patient’s physiological status (as measured by POSSUM 
model) has been shown to be a good predictor of short term outcome i.e. postoperative 
morbidity and mortality following resection of oesophago-gastric cancer. Moreover 
postoperative serial measurements of C-reactive protein have been shown to be a useful 
tool to predict infectious complications. An elevated systemic inflammatory response (as 
evidenced by the mGPS) preoperatively has been established to be a predictor of poor 
survival, independent of tumour stage in both oesophageal and gastric cancer.  Therefore, 
these results suggest that measurement of the mGPS should be performed routinely as part 
of preoperative clinical staging, to improve stratification of patients and therefore enable 
clinicians to optimise the treatment of patients with oesophageal and gastric cancer. 
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1 Chapter I: Introduction 
1.1 Epidemiology of oesophageal and gastric cancer 
1.1.1 Incidence and trends 
 Upper gastrointestinal tract cancers originating from oesophagus, oesophago-
gastric junction or stomach constitute a major health problem around the world as well as 
in UK. Each year about 8,000 people are diagnosed with oesophageal cancer and a similar 
number of people diagnosed with gastric cancer in UK (Cancerstats, 2006; 
www.cancerresearchuk.org). Oesophageal cancer was the 6th most common cause of 
cancer death in UK and about 7,400 people died with oesophageal cancer in UK in the year 
of 2006. About 5,300 people died of stomach cancer in UK in the year of 2006 and it was 
the 7th most common cause of cancer death in UK (Cancerstats, 2006; 
www.cancerresearchuk.org). 
 It was estimated that in the year 2008, about 44,700 new cases of oesophageal 
cancer were diagnosed in Europe and 38,600 people died from the disease (Ferlay, Parkin 
& Steliarova-Foucher 2010).  In 1970’s stomach cancer was the most commonly diagnosed 
cancer worldwide, but it gradually declined, accounting for around 9% of all newly 
diagnosed cancer in the West (Parkin, Stjernsward & Muir 1984, Pisani et al. 1999, Parkin 
et al. 2005). It was estimated that 149,200 new cases of gastric cancer were diagnosed in 
Europe in 2008, with 116,600 deaths attributable to the disease in the same year (Ferlay, 
Parkin & Steliarova-Foucher 2010).  
 Oesophageal cancer is divided in two major histological subgroups i.e. squamous 
cell carcinoma and adenocarcinoma (Siewert, Ott 2007).  There has been a significant 
change in the histological subtype and site of oesophageal and gastric cancers both in 
United States (Blot et al. 1991) and in Europe (Johnston, Reed 1991, Powell, McConkey 
1990). There has been a sharp rise in oesophageal adenocarcinoma in all parts of the world 
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and in both sex (Brown, Devesa & Chow 2008). It has increased approximately by six fold 
in United States (Pohl, Welch 2005) in the last three decades.  An epidemiological study 
on 22,759 patients with oesophageal cancer between 1975 and 2004 in USA showed 463% 
and 335% increase in the incidence of oesophageal adenocarcinoma in white men and 
women respectively (Brown, Devesa & Chow 2008). In northern European countries, in 
particular Scotland, adenocarcinoma of oesophagus is now the most common oesophageal 
cancer in male (Bosetti et al. 2008). Indeed, Scotland has the highest incidence of 
oesophageal adenocarcinoma in Europe (Anonymous 2002). On the other hand, the 
incidence of oesophageal squamous cell carcinoma has declined slightly in southern and 
western European countries, accounting for less than 30% of all oesophageal cancers in 
Western Europe and United States (Brown, Devesa & Chow 2008, Steevens et al. 2010). 
Within the stomach, there has been a significant change in the site of adenocarcinoma 
development with a noticeable increase of proximal and junctional tumours and sharp 
decline of distal gastric cancer incidence (Steevens et al. 2010, SEER 2010, Blot et al. 
1991).  
1.1.2 Age and Sex 
 Oesophageal and gastric cancers are predominantly diseases of old age and have 
male predominance (SEER 2010). In UK around 8 in 10 oesophageal cancers occur in 
people over 60 years of age. It has increased by 50 percent in men in UK over last 25 
years. The male to female ratio of all types of oesophageal cancer is approximately 3:2 
(CancerStats - Cancer Statistics for the UK 2010a).  In case of gastric cancer, 95% of new 
cases are in people aged 50 and over. It is more common in men (CancerStats - Cancer 
Statistics for the UK 2010b).  
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1.1.3 Geography and Ethnicity 
 The incidence of oesophageal cancer has a very wide variation across the world. 
The high prevalence areas are oesophageal cancer belt in Asia (which stretches from 
eastern Turkey through north-eastern Iran, northern Afghanistan and southern Russia to 
northern China) (Parkin 2004), southern and eastern Africa and Northern France (Corley, 
Buffler 2001) (Pickens, Orringer 2003).  Oesophageal squamous cell carcinomas are more 
common in the endemic areas as mentioned above. But the adenocarcinomas are more 
common in non endemic areas such as Western European countries and North America 
(Brown, Devesa & Chow 2008). The prevalence of gastric adenocarcinoma is high in East 
Asia, South America and Eastern European countries and the low in United States and 
Western European countries (Corley, Buffler 2001).   
 It has also been reported that there are wide variations in incidence of oesophageal 
and gastric cancer in different ethnic groups within a country.  For example, in United 
States, the most recent figures (2003-2007), showed that the overall incidence of 
oesophageal  cancer varies among different American ethnic groups.  African Americans 
have the highest age adjusted rates (5.4 cases per 100,000), followed by Whites (4.6 per 
100,000), Asians and Pacific islanders (2.4 per 100,000) (SEER 2010). Similar variation in 
the incidence among various ethnic groups is observed in gastric cancer.  In USA, the 
incidence of gastric cancer in African Americans is twice that of white Americans (12 and 
7 per 100,000 respectively).  The rate in Hispanics is 12 per 100,000 but the highest 
incidence is found in people from the Pacific Islands (13.2 per 100,000) (SEER 2010). 
 
1.1.4 Socio-economic factors 
 Higher incidence of oesophageal squamous cancer and gastric cancer has been 
shown to be linked with socio-economic deprivation in the UK (Anonymous 2002, 
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Brewster et al. 2000).  In contrast, oesophageal adenocarcinoma has been linked to the 
most affluent socio-economic groups (Powell, McConkey 1990, Dutta Roy et al. 2005).  
Incidence of oesophageal cancer has increased in higher socio-economic class and the 
incidence of gastric cancer has decreased in the deprived group (Dutta Roy et al. 2005). 
1.1.5 Mortality and Survival 
 Oesophageal and gastric cancer have demonstrated opposite trends in mortality 
over the last 30 years.  Oesophageal cancer mortality rates have increased.  In USA the 
rates have increased steadily between 1975 and 2007 from 3.7 to 4.3 per 100,000. On the 
other hand, mortality rates from gastric cancer have decreased rapidly during the same 
period in USA; from 8.5 per 100,000 to 3.6 deaths per 100,000 (SEER 2010). 
 Currently one year survival in UK is around 30% for oesophageal cancer patients 
(CancerStats - Cancer Statistics for the UK 2010a). In Scotland, age standardised five year 
survival for oesophageal cancer for the year 2003 -2007 in male and female was 10.1% and  
15.5% respectively (ISD Scotland 2010).   
 Over the last 25 years, five-year relative survival rate for stomach cancer has 
trebbled in Britain, and is around 15%  at present (CancerStats - Cancer Statistics for the 
UK 2010b). For gastric cancer, age standardised five year survival for the year 2003 -2007 
in Scotland for  male and female was 15.4% and  18% respectively (ISD Scotland 2010). 
1.2 Aetiology of Oesophageal and Gastric cancer 
1.2.1 Inheritance 
 A small proportion of oesophageal and gastric cancers are hereditary. Familial 
clustering of these tumours may be due to exposure to similar environmental factors. 
Inheritance certainly has a role in oesophageal squamous and adenocarcinoma albeit in a 
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small proportion (less than one percent in reported studies) (Lagergren et al. 2000, 
Hemminki, Jiang 2002).  Mutations of the gene for the calcium-dependent cell-adhesion 
protein E-cadherin (CDH1) have been found in inherited or familial gastric cancer 
(Fitzgerald, Caldas 2004). Almost all of these inherited gastric cancers are early onset, 
autosomal dominant, diffuse gastric cancers (Caldas et al. 1999, Guilford et al. 1998, 
Huntsman et al. 2001). Hereditary diffuse gastric cancer syndrome (HDGC) is associated 
with a 70% lifetime risk of gastric cancer (Robertson, Jankowski 2008). 
1.2.2 Lifestyle factors 
1.2.2.1 Smoking 
 Tobacco smoking has been recognised as an important risk factor for squamous cell 
carcinoma of the oesophagus and the effect is about nine fold compared with age and sex 
matched controls (Brown et al. 2001, Gallus et al. 2003).  Development of the oesophago-
gastric junctional tumour and gastric cancer has also been linked to smoking but to a lesser 
extent (Engel et al. 2003).  However, the role of smoking in oesophageal adenocarcinoma 
is not clear (Engel et al. 2003, Lagergren et al. 2000). 
1.2.2.2 Alcohol 
 Oesophageal squamous cancer and gastric adenocarcinoma are strongly associated 
with heavy alcohol intake (Lagergren et al. 2000, Bagnardi et al. 2001).  In contrast, 
oesophageal adeno-carcinoma and oesophago-gastric junctional tumours are not shown to 
be related to alcohol consumption (Engel et al. 2003, Lagergren et al. 2000, Gammon et al. 
1997) and therefore increasing incidence of these cancers is unlikely to be alcohol related. 
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1.2.2.3 Diet 
 The role of dietary intake in development of the oesophageal and gastric cancer is 
not clear.  A large case control study showed that, higher intake of animal based food 
increases the risk of adenocarcinoma of the oesophagus; where as plant-based food reduces 
the risk (Mayne et al. 2001).  Use of green leafy vegetables, citrus fruits and dietary fibre 
reduces the risk of oesophageal cancer (Cheng et al. 1992, Cheng et al. 1995, Terry et al. 
2001, Terry et al. 2001). Nitrosamines and their precursors (nitrate, nitrite and secondary 
amines) have been positively associated with development of oesophageal and gastric 
cancers (Mayne et al. 2001, Cheng et al. 1992). Studies have confirmed that nitrosative 
stress was created by the nitrate-derived nitric oxide generated within the lumen at the 
oesophago-gastric junction, where saliva encounters gastric acid and this may contribute to 
the high prevalence of mutagenesis at this site. Moreover luminal generation of nitric oxide 
from dietary nitrate via salivary nitrite is maximal at the gastroesophageal junction and 
cardia. This might explain the incidence of junctional cancer (Iijima et al. 2002, Iijima et 
al. 2003). On the other hand, antioxidants such as vitamin C, vitamin E and beta carotene 
are associated with reduced risk of these cancers (Terry et al. 2000, Serafini et al. 2002, 
Ekstrom et al. 2000).  Diets with poor fruit and vegetable intake have been associated with 
oesophageal cancer in the USA (Engel et al. 2003) and gastric cancer in Brazil (Nishimoto 
et al. 2002).  
1.2.2.4 Body mass index (BMI) 
 Higher BMI has been shown to be associated with an increased risk of oesophageal 
adenocarcinoma and carcinoma of the oesophago-gastric junction.  Various independent 
population based studies have shown this positive association (Abnet et al. 2008, Chow et 
al. 1998b, Lagergren, Bergstrom & Nyren 1999). Moreover recent systematic review and 
meta-analysis by Kubo et al supported a positive correlation between high BMI and the 
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increased risk of oesophageal and possibly for oesophago-gastric junction adenocarcinoma. 
(Kubo, Corley 2006). There is some evidence of an inverse association of BMI to 
oesophageal squamous cell carcinoma (Engeland, Tretli & Bjorge 2004, Vaughan et al. 
1995, Smith et al. 2008) but other population based studies found no evidence of 
association of increased BMI with gastric cancer or with squamous cancer of the 
oesophagus(Chow et al. 1998b, Lagergren, Bergstrom & Nyren 1999). More recently the 
link between obesity and the risk of cancer death was studied in a cohort of over 900,000 
patients in the USA (Calle et al. 2003).  They found that increasing BMI was associated 
with an increased risk of death in oesophageal and gastric cancer.  The link between 
obesity and the oesophageal and gastric adenocarcinoma is complex (Corley 2007). There 
is evidence that the body fat can mediate cancer risk through intermediary hormones that 
modulate inflammation (Stoll 2002, Kaaks, Lukanova 2001, Schoen et al. 2002, Lagergren 
2005).  Adipose-associated polypeptides such as leptin, adiponectin, insulin like growth 
factors and ghrelin have a plausible role for modifying cancer risk at the cellular level 
(Bolukbas et al. 2004, Bub, Miyazaki & Iwamoto 2006, Lord 2006, de Martel et al. 2007).  
It is also reported that obesity induced inflammation might be an important link between 
obesity and cancer (van Kruijsdijk, van der Wall & Visseren 2009). Moreover, recently in 
a  matched controlled cohort study by Beddy et al involving 194 patients with oesophageal 
adenocarcinoma, oesophageal squamous cell carcinoma and gastric adenocarcinoma and 
90 controls, showed that proportion of visceral distribution of fat is significantly higher in 
patients with oesophageal or junctional adenocarcinoma compared to the other two groups 
(Beddy et al. 2010). Similarly, studies reported on the association between increased 
visceral fat particularly at oesophago-gastric junction with metaplasia and high grade 
dysplasia (Nelsen et al. 2012). 
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1.2.3 Gastro-oesophageal reflux 
 The relationship between gastro-oesophageal reflux disease and oesophago gastric 
junctional cancer has now been well established (Lagergren et al. 1999, Wu, Tseng & 
Bernstein 2003). The co-relation between gastro-oesophageal reflux and cancer is thought 
to be mediated through Barrett’s metaplasia. Patients with Barrett’s oesophagus have 30 to 
60 times more risk of developing oesophageal adenocarcinoma compared to the general 
population (Cossentino, Wong 2003).  It has also been reported that the risk of oesophageal 
cancer in patients with Barrett’s oesophagus is significantly greater than in patients with 
long standing reflux symptoms in the absence of Barrett’s metaplasia (Solaymani-Dodaran 
et al. 2004).   
1.2.4 Helicobacter pylori 
 The role of Helicobacter pylori in gastric adenocarcinoma has been reported in 
several studies (Danesh 1999). A meta-analysis conducted by Eslick et al showed the 
increased risk of developing gastric adenocarcinoma in patients with H pylori infection 
(Eslick et al. 1999). A study by a Swedish group has reported that, infection by cytotoxin-
associated gene A (cagA) strains of  H pylori was primarily associated with the 
development of the gastric  cancer (Ekstrom et al. 2001). Another meta-analysis by Huang 
and co-workers confirmed the association between H-pylori (in particular the cag A strain) 
and the elevated risk of gastric cancer (Huang et al. 2003). It has been shown however, that 
H pylori was associated with a reduced risk of developing oesophageal adenocarcinoma 
but an elevated risk of oesophageal squamous cancer (Chow et al. 1998a, Ye et al. 2004).   
 The association between H-Pylori infection and gastro-oesophageal junctional 
malignancy however is not clear.  Previously mentioned studies did not show any 
definitive association (Danesh 1999, Eslick et al. 1999, Huang et al. 2003).  But recently 
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some published reports indicated that there might be some association between H pylori 
infection and oesophageal or junctional adenocarcinoma (McColl, Watabe & Derakhshan 
2008, de Martel et al. 2005). It has been reported that, the decrease in H pylori infection is 
associated with increased incidence of oesophageal and junctional adenocarcinoma (Clark 
2003, Ye et al. 2004, Anderson et al. 2008). The plausible mechanism is that, H pylori 
infection may protect the lower oesophageal epithelial layer by inducing atrophic gastritis 
which in turn reduces the gastric acid secretion (McColl, Watabe & Derakhshan 2008).  
1.2.5 Other predisposing conditions  
 A number of conditions have been identified as increased risk factors of developing 
oesophageal and gastric cancer.  Tylosis is rare autosomal dominant skin disorder 
characterized by hyperkeratosis of the palms and soles. Late onset tylosis has been shown 
to be associated with oesophageal squamous cancer (Ellis et al. 1994, Stevens et al. 1996, 
Risk et al. 1999). Achalasia has been shown to increase risk of squmaous carcinoma and 
adenocarcinoma of oesophagus (Ribeiro et al. 1996, Sandler et al. 1995, Brucher et al. 
2001, Ellis et al. 1997). It has also been reported that patients who had surgery for peptic 
ulcer disease had increased risk of developing oesophageal cancer (Lundegardh et al. 
1994) and gastric cancer (Macintyre, O'Brien 1994).  Pernicious anaemia or achlorhydria 
has been shown to be associated with elevated risk of developing gastric cancer as well as 
oesophageal squamous cell cancer (Ye, Nyren 2003). However, it is not clear, if there is 
any elevated risk of developing oesophageal adenocarcinoma associated with pernicious 
anaemia (Mellemkjaer et al. 1996).     
1.3 Clinical presentation of oesophageal and gastric cancer 
Generally, both oesophageal and gastric cancer present late at advanced stage. The 
diagnosis of patients with oesophageal and gastric cancer on basis of clinical features was 
recognised to be difficult, as correlation of symptoms with endoscopic findings were 
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known to be poor (Adang et al. 1996). Symptoms of oesophageal cancer are usually 
insidious.  Dysphagia, weight loss, vomiting or regurgitation, pain, cough or hoarsness are 
the most common presenting symptoms. Gastric cancer, in particular in early stage, lacks 
specific symptoms. Vague epigastric discomfort, indigestion, pain, weight loss, anorexia, 
fatigue or vomiting may be the presenting symptoms for some of the patients. In UK, 
NICE (National Institute for Health and Clinical Excellence) guidance suggested the 
’alarm symptoms’ (such as progressive dysphagia, weight loss, anaemia, persistent 
vomiting and epigastric mass etc) for oesophago-gastric cancer that require urgent referral 
and or investigation (National Institute for Health and Clinical Excellence 2005). However, 
approximately 70% of patients with early gastric cancer have symptoms of uncomplicated 
dyspepsia with no associated anaemia, dysphagia or weight loss (Hallissey et al. 1990). It 
has also been reported recently that localised cancers can be missed if only patients with 
these alarm symptoms have been investigated (Bowrey et al. 2006).   
1.4 Diagnosis of oesophageal and gastric cancer 
 Diagnosis of oesophageal and gastric cancer dependent on clinical features alone is 
unreliable (Meineche-Schmidt, Jorgensen 2002). Two modalities of investigations can be 
performed i.e. contrast swallow (barium swallow or barium meal) and upper GI 
endoscopy. 
 Endoscopy and biopsy remain the investigation of choice for diagnosis in upper GI 
cancer. About 10% malignant lesions are missed on first endoscopy (Bramble, Suvakovic 
& Hungin 2000, Yalamarthi et al. 2004). Lack of adequate biopsy specimen is one of the 
major reasons for the repeat endoscopy. Minimum of eight biopsies from the suspected 
lesions are recommended (The Scottish Intercollegiate Guidelines Network 2006). Barium 
studies are safe, but less sensitive than endoscopy in early cancers (Dooley et al. 1984) and 
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it cannot diagnose precancerous lesions (Arai, Yamada & Maruyama 2002). Therefore, 
barium studies are becoming less routinely carried out nowadays.  
1.5 Clinico-pathological staging of oesophageal and gastric cancer 
 Clinical baseline staging provides useful information for the development of an 
initial therapeutic strategy and is associated with patient outcome. However, pathological 
staging is considered to be the most important prognostic factor in patients with 
oesophageal and gastric cancers. 
 In oesophageal cancer, two major staging systems are commonly used i.e. The 
Japanese Society for Esophageal Diseases (Japanese Society for Esophageal Diseases; In 
2002) and The Tumour Node Metastasis (TNM) Criteria by the American Joint Committee 
on Cancer (AJCC) (Sobin, Wittekind & editors. April 2002) (Table 1-1). The AJCC system 
is most widely used in UK.  In western countries, there are no screening programme for 
early detection of oesophageal cancer because of low incidence, the diagnosis is often 
made late in the disease course. At diagnosis, nearly 50% patients have cancer beyond 
loco-regional level. Moreover fewer than 60% patients with loco-regional disease can 
undergo a curative resection. Approximately 70-80% of resected specimens will have 
metastasis in the regional lymph nodes.  
 Adenocarcinoma of the oesophago-gastric junction has been classified by Sierwert 
et al into three types. This classification is purely based on anatomical location of the 
tumour (Siewert, Stein 1996).  If the epicentre of the tumour or more than 66% of the 
tumour mass is located more than 1 cm above the anatomical oesophago-gastric junction, 
then the tumour is classified as Type I adenocarcinoma of the distal oesophagus.  If the 
epicentre of the tumour or the tumour mass is located within 1cm proximal and 2 cm distal 
to the anatomical oesophago-gastric junction, this tumour is classified as Type II. If the 
epicentre of the tumour or more than 66% of the tumour mass is located more than 2 cm 
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distal to the anatomical oesophago-gastric junction, this tumour is classified as Type III 
(Siewert, Stein 1996). The classification was changed slightly in 2000 by the same group 
(Rudiger Siewert et al. 2000). Type I adenocarcinoma of the distal oesophagus was defined 
as tumour that arises from an area with specialised intestinal metaplasia of the oesophagus 
(i.e., Barrett oesophagus) and may infiltrate the oesophago-gastric junction from above. 
Type II, the true carcinoma of the cardia, arises immediately at the oesophago-gastric 
junction. And Type III or subcardial gastric carcinoma infiltrates the oesophago-gastric 
junction and distal oesophagus from below.  There is no clear consensus about which 
Siewert type of junctional tumour is oesophageal or gastric cancer. In AJCC TNM staging 
system (6
th
 edition), it specifically states that ‘if more than 50% of the tumour involves the 
oesophagus, the tumour is classified as oesophageal cancer, if less than 50% then it is 
classified as gastric cancer’ (Sobin, Wittekind & editors. April 2002).  In the present study, 
Type I and Type II lesions of the gastro-oesophageal junction were designated oesophageal 
cancers and Type III tumours as gastric cancer (Siewert, Stein 1996, Siewert, Stein 1998). 
Indeed this classification has been recognised by the British Society of Gastroenterology 
(Allum et al. 2002) and The Scottish Intercollegiate Guidelines Network for oesophageal 
and gastric cancer (The Scottish Intercollegiate Guidelines Network 2006).  
 In gastric cancer, two major classifications are currently used. The Japanese 
classification is elaborate and is based on anatomical involvement, particularly the lymph 
node stations or echelons (Japanese Gastric Cancer 1998). In western countries, AJCC 
(American Joint Committee on Cancer) and /or UICC (the International Union against 
cancer) staging system is primarily used (Roder et al. 1998) (Table 1-2). Approximately 
50% of patients present in advanced stage of their disease at diagnosis and have poor 
outcome. Nearly 70-80% of all patients have involvement of regional lymphnode. The 
number of positive lymph node has a profound influence on survival (Karpeh et al. 2000). 
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Table 1-1: TNM staging in oesophageal cancer (6th edition) 
 
Primary tumour (T) 
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria 
T3 Tumour invades adventitia 
T4 Tumour invades adjacent structures 
 
Regional lymph nodes (N) 
 
NX Regional lymph node cannot be assessed 
N0 No regional lymph node metastasis 
N1 Regional lymph node metastasis 
 
Distant metastasis (M) 
 
MX Presence of distant metastasis cannot be assessed 
M0 No distant metastasis 
M1 Distant metastasis 
For tumours in the lower thoracic oesophagus: 
M1a Metastasis in ceoliac lymph nodes 
  
M1b  Other distant metastasis    
For tumours in the upper thoracic oesophagus: 
M1a Metastasis in cervical lymph nodes 
M1b Other distant metastasis 
For tumours in the mid thoracic oesophagus: 
M1a Not applicable 
M1b  Non-regional lymph node or other distant metastasis 
 
 
  31 
 
     Stage grouping 
 
0 Tis  N0  M0 
I T1  N0  M0 
 
IIa T2  N0  M0 
IIa T3  N0  M0 
IIb T1  N1  M0 
IIb T2  N1  M0 
 
III T3  N1  M0 
III T4  Any N  M0 
 
IV Any T  Any N  M1 
IVa Any T  Any N  M1a 
IVb Any T  Any N  M1b 
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Table 1-2: TNM staging in gastric cancer (6th edition) 
 
Primary tumour (T) 
   
TX Primary tumour cannot be assessed 
T0 No evidence of primary tumour 
Tis Carcinoma in situ 
T1 Tumour invades lamina propria or submucosa 
T2 Tumour invades muscularis propria or sub-serosa 
T3 Tumour penetrates serosa without invasion of adjacent structures 
T4 Tumour invades adjacent structures 
 
Regional lymph nodes (N) 
 
NX Regional lymph nodes cannot be assessed 
N0 No regional lymph node metastasis 
N1 Metastasis in 1 to 6 regional lymph nodes 
N2 Metastasis in 7 to 15 regional lymph nodes  
N3 Metastasis in more than 15 regional lymph nodes 
 
Distant metastasis (M) 
 
MX Presence of distant metastasis cannot be assessed 
M0 No distant metastasis  
M1 Distant metastasis 
 
 
Note: Involvement of retro-pancreatic, mesenteric and para-aortic lymph nodes, are 
classified as distant metastasis. 
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     Stage grouping 
 
0 Tis  N0  M0 
Ia T1  N0  M0 
Ib T1  N1  M0 
Ib T2  N0  M0 
 
II T1  N2  M0 
II T2  N1  M0 
II T3  N0  M0 
 
IIIa T2  N2  M0 
IIIa T3  N1  M0 
IIIa T4  N0  M0 
IIIb T3  N2  M0 
 
IV T4  N1, 2, 3 M0 
IV T1, 2, 3 N3  M0 
IV Any T  Any N  M 
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1.5.1 Staging modalities  
 The principle imaging modalities for staging oesophageal and gastric cancer are 
multidetector computed tomography (CT), endoscopic ultrasound (EUS), Positron 
emission tomography (PET) integrated with CT (PET-CT) and laparoscopy.  
1.5.1.1 Endoscopy 
For the purpose of proper staging of early (i.e. intra mucosal) oesophageal 
malignancy, endoscopy and endoscopic mucosal resection (EMR) are essential. EMR is 
primarily performed in case of Barrett’s oesophagus with endoscopic evidence of mucosal 
irregularity and dysplasia. The depth of resection involves the submuosal layer. In a 
comparative study, Wani and colleagues reported that, in 88% samples of endoscopic 
mucosal resection had submucosa compared to only 1% samples of endoscopic biopsy, and 
the overall inter-observer agreement for the diagnosis of neoplasia was significantly higher 
for endoscopic mucosal resection specimens than biopsy specimens (Wani et al. 2010). It 
allows assessment not only of depth of penetration but also of degree of differentiation and 
vascular and lymphatic involvement. It is superior to endoscopic ultrasound in staging 
early T1 cancers (Curvers et al. 2008, Mino-Kenudson et al. 2007, Peters et al. 2008).  
1.5.1.2 Computerised Tomography (CT) 
 Computerised Tomography is most commonly used as initial staging investigation 
in patients with oesophageal and gastric cancer. A spiral contrast enhanced scan with thin 
collimation (2.5 to 5 mm) is recommended (Allum et al. 2002).  The study is generally 
performed with intravenous as well as oral contrast. CT scan has been reported to be very 
accurate in detecting distant metastasis. A patient in whom advanced disease has been 
identified with CT scan does not require any further investigation (The Scottish 
Intercollegiate Guidelines Network 2006). CT scan is unable to differentiate between 
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various layers of the oesophagus and therefore it may not be very useful to clarify T1 and 
T2 cancers. Moreover microscopic invasion of T3 tumour is not well visualised on CT 
scan (Saunders, Wolfman & Ott 1997) and therefore there is a risk of under staging of 
oesophageal cancer if it is only relied upon CT scan.  
 In gastric cancer, CT scan has been reported to be accurate in detecting distant 
metastasis but not in assessing the T and N stage (Blackshaw et al. 2003). Similar to 
oesophageal cancer, CT cannot differentiate between T1 and T2 lesions.  About 80-88% 
patients with advanced disease (including T4) can be identified by CT scan (Minami et al. 
1992, Cho et al. 1994, Davies et al. 1997).  
 PET-CT scan has a low detection rate because of the low tracer accumulation in 
diffuse and mucinous tumour type, that are frequent in gastric cancer (Stahl et al. 2003). 
Therefore, it has limited use in staging in patients with gastric cancer (Dassen et al. 2009) 
and requires further evaluation.  PET scan has a significantly lower sensitivity compared to 
CT scan in detecting regional lymph node involvement (56% vs 78%), although it has an 
improved specificity (92% vs 62%) (Chen et al. 2005).  Combined PET-CT imaging has 
been reported to be better than PET scan alone (Dassen et al. 2009, Lim et al. 2006). PET –
CT has a significantly higher accuracy in preoperative staging (68%) than PET (47%) or 
CT (53%) alone (Rosenbaum et al. 2006). Therefore, PET-CT is currently advocated for 
preoperative staging of nodal status as well as distant metastasis particularly in 
oesophageal cancer (Chowdhury, Bradley & Gleeson 2008). 
 
1.5.1.3 Endoscopic Ultrasound (EUS) 
 The ability to identify different layers of the oesophageal and stomach walls by 
EUS makes it superior investigation compared to CT scan in local staging of oesophageal 
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(Ziegler et al. 1991, Tio et al. 1989, Dittler, Siewert 1993a) as well as gastric (Dittler, 
Siewert 1993b, Ziegler et al. 1993) cancer. EUS guided fine needle aspiration cytology for 
potential nodal disease has been shown to improve the accuracy (Vazquez-Sequeiros et al. 
2001). 
 In oesophageal cancer, EUS has very good accuracy in T staging and can 
differentiate mucosal and sub mucosal involvement (Thosani et al. 2012). It has also been 
reported that EUS is very useful in detecting regional lymph node metastasis with a 
sensitivity of 80% (75%-84%) and specificity of 70% (65%-75%) (van Vliet et al. 2008).  
Detection of caeliac lymph node metastasis by EUS has been reported to be better 
compared to abdominal ones. Therefore it has been advocated that, in oesophageal cancer, 
EUS and fine needle aspiration cytology should be used for better T and N staging (Quint, 
Bogot 2008). 
 In gastric cancer, EUS is indicated for assessing the depth of tumour invasion 
(Matsumoto et al. 2000). The accuracy of EUS for gastric cancer T staging ranges from 
82% to 99% and for N staging from 58% to 65%. Sensitivity of detecting T stage in gastric 
cancer is reported to be higher in advanced disease i.e. EUS performs better to exclude T4 
disease than T1 disease (Kwee, Kwee 2008, Puli et al. 2008). On the other hand, the 
accuracy of detecting nodal metastasis was reported to be variable, therefore the role of 
EUS in staging gastric cancer is yet to be defined. 
 Distant lymph node evaluation by EUS has been reported to be less than adequate 
(Tsendsuren, Jun & Mian 2006). Staging for metastatic disease using EUS alone is not 
satisfactory. Moreover EUS examination can be limited by a stricture forming lesion. 
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1.5.1.4 Laparoscopy 
 Laparoscopy is indicated to exclude peritoneal metastasis in oesophago-gastric and 
gastric cancer as CT scan has been reported to be less than adequate (Blackshaw et al. 
2003, Clements, Bowrey & Havard 2004).   De Graaf and colleagues have recently 
reported that additional staging information can be obtained by staging laparoscopy in 
17.1% patients with distal oesophageal cancer, 17.2% patients with oesophago-gastric 
junctional tumour and 28 % patients with gastric cancer (de Graaf et al. 2007).  
Laparoscopic staging may not be necessary in patients with cancer of upper two thirds of 
oesophagus (de Graaf et al. 2007).   
 In gastric cancer, laparoscopic staging can be useful in detecting occult metastasis 
(Sarela et al. 2006). Blackshaw and co-workers have also showed the accuracy of 
laparoscopy in 258 consecutive patients with gastric cancer.  Laparoscopic examination 
detected metastatic disease in 21 patients, in whom CT scanning failed to report the 
metastasis (Blackshaw et al. 2003). Limitations of laparoscopic staging include two 
dimensional evaluation and limited use in identification of hepatic metastasis and peri 
gastric lymph nodes. Indications for laparoscopic staging may vary among different 
institutions. In some, it is performed on patients intended to have curative treatment 
(surgery and or chemotherapy) whereas in some other institutions, laparoscopy is 
performed in patients intended to receive chemotherapy especially if there is consideration 
for addition of radiation.  
 Another potential benefit for staging laparoscopy is to obtain peritoneal fluid for 
cytology. Studies have shown that the peritoneal fluid cytology for malignant cells can 
help to improve staging (Abdalla, Pisters 2004). Positive peritoneal cytology is associated 
with poor prognosis and recurrence in gastric cancer (Bentrem et al. 2005) and oesophago-
gastric junctional adenocarcinoma (Nath et al. 2008). Patients without distant metastasis 
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(M0) with positive peritoneal fluid cytology in gastric cancer are unlikely to benefit from 
resection alone (Burke et al. 1998). Moreover, a recent report suggested that clearing 
cytology positive gastric cancer with chemotherapy resulted in improved survival (Mezhir 
et al. 2010). Clearly, positive peritoneal fluid cytology has a role in staging gastric cancer 
and should be considered as M1, even in absence of visible peritoneal implants. 
1.5.1.5 Bronchoscopy 
 Oesophageal cancer at or above the level of carina may invade the tracheo-
bronchial tree and bronchoscopy may have a role in detecting this as well as obtaining 
biopsy. EUS may be adequate to detect tumour extension to the airway, but any uncertainty 
should warrant bronchoscopic examination (Omloo et al. 2008). 
1.5.2 Pathological Stage and outcome 
 Patient outcome may be associated with the initial clinical stage, but the best 
correlation with survival is associated with pathological tumour stage (pTNM) following 
resection for gastro-oesophageal cancer (Lerut et al. 2004, Barchielli et al. 2001).  
Although the pathological T category has been shown to be independently associated with 
survival, within the TNM system, the presence of metastatic tumour in lymph nodes has 
been shown to be of primary importance (Karpeh et al. 2000).  Moreover, the ratio of 
positive lymph nodes, to the resected lymph nodes has been demonstrated as a better 
measurement of extent of lymph node involvement and has been shown to have  
independent prognostic significance in oesophageal cancer (Mariette et al. 2008, Liu et al. 
2009) and gastric cancer (Deng et al. 2009, Fukuda et al. 2009, Marchet et al. 2007). 
 In gastric cancer, there is no universally accepted guidance on the minimum 
number of lymph nodes necessary for accurate staging. But resection of at least 15 lymph 
nodes is recommended to reduce stage migration. Better survival in patients at any stage of 
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gastric cancer was reported to be related to the number of lymph nodes examined (Smith, 
Schwarz & Schwarz 2005). 
1.6 Treatment of oesophageal and gastric cancer 
 The treatment strategy for patients with gastro-oesophageal cancer is dependent on 
TNM stage, presence of co-morbid conditions and patient choice.  Patients can be 
classified using the above criteria into curative and palliative groups. 
1.6.1 Curative treatments of oesophageal and gastric cancer 
1.6.1.1 Endoscopic treatments 
 Endoscopic therapy has now become an essential part of the treatment of early 
oesophageal and gastric cancer. There are few treatment modalities available to treat 
dysplasia and early cancer such as endoscopic mucosal resection (EMR), endoscopic 
submucosal dissection (ESD) and ablation techniques such as photo dynamic therapy 
(PDT), argon plasma coagulation (APC), laser (photo thermal) and radio frequency 
ablation (RFA). All patients who receive endoscopic treatment must have repeat 
surveillance endoscopy. 
 EMR is increasingly used for treatment of pre-cancerous lesions and early 
oesophageal cancer i.e. high grade dysplasia, T1cancer involving mucosa only (ASGE 
TECHNOLOGY COMMITTEE et al. 2008) as an alternative to surgery. Following 
resection of early Barrett’s cancer and high grade dysplasia, mucosal ablation of the 
residual Barrett’s tissue is required to decrease the risk of subsequent cancer development  
(Pech et al. 2008, Larghi et al. 2007, Seewald et al. 2003, Lopes et al. 2007, Ganz et al. 
2008). 
  40 
 Endoscopic mucosal resection (EMR) and endoscopic submucosal dissection 
(ESD) have also been used in early gastric cancer as an alternative to gastrectomy. The 
criteria for endoscopic mucosal resection (EMR) are Tis or T1 differentiated tumours 
limited to mucosa ≤ 2 cm and not ulcerated (Soetikno et al. 2005, Ono et al. 2001) (Okines 
et al. 2010). Use of this technique is limited in western countries as the incidence of early 
gastric cancer is low. In some reported studies endoscopic submucosal dissection has been 
shown to be more effective than EMR in early gastric cancer (Oda et al. 2006) (Yahagi et 
al.). However, there are no randomised studies that compare these endoscopic techniques 
in treatment of gastric cancer and further evaluation is required.  
1.6.1.2 Surgical resection 
Oesophageal cancer:  
 Surgery is regarded as standard treatment in selected patients who have  localised 
oesophageal tumour. Patients who are medically fit (i.e. medically able to tolerate major 
abdominal and/or thoracic surgery) and have  TNM stage I to III disease are generally 
selected for surgery.  T4 oesophageal tumours with involvement of heart, great vessels, 
trachea, distant non regional lymph node metastasis or metastasis to other solid organs are 
considered non resectable although advanced oesophageal tumours may be converted to 
potentially operable cancer following neo-adjuvant chemo-radiotherapy (Slater et al. 
2001). There are various surgical approaches for oesophagectomy such as, Transhiatal, 
Transthoracic and Minimally invasive oesophagectomy (Ng, Vezeridis 2010). The optimal 
operative approach is determined by type, location of the tumour as well as patient factors 
and surgeon’s experience. In a recent large population based study, it was reported that, 
there was no difference in long term survival between transhiatal and transthoracic 
oesophagectomy (Chang et al. 2008). There is no well designed randomised controlled trial 
to compare the long term outcome of minimally invasive oesophagectomy and open 
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resection. Lymph node resection should be performed in a standard extended (en-bloc) 
technique which will help in minimising staging error and reduce the chance of loco-
regional recurrence. Number of lymph nodes removed has been reported to be an 
independent predictor of survival (Rizk et al. 2010) as is the ratio of the positive lymph 
node (Roder et al. 1994). 
Gastric cancer:  
 Surgery is the principle treatment option for early gastric cancer. Complete 
resection with adequate margin (4 cm or greater) is advisable although the type of surgery 
(total versus subtotal gastrectomy) and the extent of lymphadenectomy remains a subject 
of controversy. Subtotal gastrectomy is suitable for distal gastric cancers and has a similar 
surgical outcome with fewer post operative complications compared to total gastrectomy 
(Bozzetti et al. 1999). Proximal gastrectomy or total gastrectomy is indicated for 
proximal/mid body gastric cancer. It is recommended that the distal, subtotal or total 
gastrectomy for T1 to T3 tumours. T4 tumours require enbloc resection with involved 
structures. A carcinoma is considered unresectable if there is evidence of peritoneal 
involvement, distant metastasis or locally advanced disease such as invasion or encasement 
of major blood vessels.  
 The role of laparoscopic approach in gastrectomies is still being investigated. It 
may have important advantages such as less blood loss, accelerated post operative 
recovery, less post operative pain, early return of normal bowel function when compared to 
open surgery (Reyes et al. 2001). Although a recent metaanalysis demonstrated that 
laparoscopic surgery was associated with longer operating time and reduced nodal harvest 
compared with open surgery (Memon et al. 2008). Clearly the role of laparoscopic 
approach needs to be further evaluated.  
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 In gastric cancer, perigastric lymph nodes along the greater and lesser curvatures 
are grouped as N1. The nodes along the left gastric artery, common hepatic artery, coeliac 
artery and the splenic artery are grouped together as N2. Metastasis to more distant nodes 
such as para aortic group of lymph nodes (N3 and N4) is regarded as distant metastasis. D0 
resection refers to incomplete resection of N1 lymphnodes. D1 resection includes N1group 
of lymph nodes completely. In D2 resection, the omental bursa along with the front leaf of 
the transverse mesocolon is removed along with N2 group of lymph nodes. For proximal 
gastric cancer, D2 dissection involves splenectomy. Reports have suggested that the more 
extensive lymph node dissection has influence on survival in patients with advanced 
gastric cancer (Schwarz, Smith 2007). However, various reports comparing D1 and D2 
resection for gastric cancer have shown no survival benefit with extended lymph node 
dissection in gastric cancer (Bonenkamp et al. 1999, Cuschieri et al. 1999, Hartgrink et al. 
2004, McCulloch et al. 2004). It has been argued that if the complication rate after D2 
resection could be decreased then there might be a noticeable benefit in selected group of 
gastric cancer patients. A modified D2 lymphadenectomy without pancreatectomy and 
splenectomy has been suggested (Jansen et al. 2005) (Khatri, Douglass 2004) (Douglass et 
al. 2007). Indeed, D2 lymphadenectomy has shown survival benefit in various European 
studies (Degiuli et al. 2004a) (Degiuli et al. 2004b) (Sierra et al. 2003) (Edwards et al. 
2004). Modified D2 lymphadenectomy (without pancreatectomy or splenectomy) is 
associated  with low morbidity and mortality and therefore recommended (Schwarz, Smith 
2007, Songun et al. 2010). So currently in UK, D2 lymphnode dissection is regarded as a 
standard procedure in specialised centres with appropriate surgical expertise and 
postoperative care, for patients considered medically fit for surgery . Resection of the 
spleen and pancreas is only indicated if there is direct invasion. Splenectomy is indicated 
for tumours of the proximal greater curve and gastric fundus; principally to remove splenic 
hilar nodes. Resection of adjacent organs is indicated when there is definite or suspected 
transmural invasion and the patient is fit  for  radical surgery (Okines et al. 2010).  
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1.6.2 Neo adjuvant, peri-operative and adjuvant therapy 
Oesophageal cancer:  
 A recent meta-analysis on pre operative radiotherapy for patients with potentially 
resectable oesophageal cancer showed only a modest increase in overall survival (about 3-
4% only). Therefore preoperative radiotherapy is not recommended for operable 
oesophageal cancer (Arnott et al. 2005). On the contrary, pre operative chemoradiation 
followed by surgery has been reported to offer survival benefit compared to surgery alone 
(Gebski et al. 2007). A large randomised controlled trial conducted by medical research 
council UK on pre-operative chemotherapy for patients with oesophageal cancer involving 
802 patients. There was significant improval in survival in patients who received 
preoperative chemotherapy compared to surgery alone (Medical Research Council 
Oesophageal Cancer Working Group 2002, Allum et al. 2009) and is now considered as 
the gold standard in potentially curative oesophageal cancer patients. Post operative 
chemo-radiation in oesophageal cancer has been reported to have beneficial effect on 
survival (Bedard et al. 2001, Rice et al. 2003, Adelstein et al. 2009). However, a 
randomised controlled trial has failed to show any significant survival benefit of 
radiotherapy following oesophageal cancer resection (Teniere et al. 1991). Similarly  in  a 
recently published meta-analysis on adjuvant chemotherapy after oesophageal cancer 
surgery  has not shown any improved outcome (Zhang et al. 2008). 
 The role of definitive chemoradiation has been reported in some studies particularly 
in oesophageal squamous cell carcinoma. Some European studies have reported at least 
equivalent survival in patient who received definitive chemoradiation compared to surgery 
(Stahl et al. 2005, Bedenne et al. 2007).   
Gastric and oesophago gastric junctional cancer:  
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 A UK MRC randomised trial (MAGIC trial) with three cycles of preoperative and 
post operative chemotherapy (i.e. peri-operative chemotherapy) with three cycles of 
epirubicin (E) 50 mg/m2, cisplatin (C) 60 mg/m2 and continuous intravenous infusion of 
5-fluorouracil (F) 200 mg/m2/day (ECF) significantly improved 5-year survival from 
23.0% with surgery alone to 36.3% (Cunningham et al. 2006). This perioperative 
chemotherapy regimen is most widely accepted in UK.  
 A landmark intergroup North American randomised trial demonstrated that, post 
operative chemoradiation with 5 fluorouracil/leucovorin before, during and after 
radiotherapy in 556 patients resulted in improved five year survival rate in gastric and 
oesophago gastric junctional adenocarcinoma (Macdonald et al. 2001). Therefore this 
treatment option has been widely accepted in the USA particularly for those patients who 
didn’t receive preoperative chemotherapy. Moreover, another large non-randomized 
observational study suggested a potential clinical benefit from postoperative 
chemoradiation after optimal D2 dissection for gastric cancer (Kim et al. 2005).  
 In a metaanalysis post operative adjuvant chemotherapy in gastric cancer has 
demonstrated a small survival benefit (Liu et al. 2008). A large randomised phase III trial 
in Japan in 1059 patients evaluated the efficacy of oral fluoropyrimidine S-1 in stage II and 
stage III gastric cancer patients who underwent D2 resection (Sakuramoto et al. 2007). 
Overall survival was better in the S-1 group. There are no data available with oral 
fluoropyrimidine in the western population.  
 In patients with gastro-oesophageal junctional adenocarcinoma and tumour of 
gastric cardia, preoperative chemoradiation  has shown some benefit in terms of complete 
pathological response and survival (Walsh et al. 1996) (Stahl et al. 2009). For localised 
adenocarcinoma of gastro-oesophageal junction or gastric cardia preoperative 
chemoradiation is the preferred approach in USA.  However the role of neoadjuvant 
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chemoradiation in adenocarcinoma of gastro-oesophageal junction needs to be evaluated 
further  preferably through large prospective randomised controlled trials.   
 In gastric cancer, although neoadjuvant chemoradiation has shown some benefit in 
terms of complete pathological response and better chance of radical surgery (Ajani et al. 
2006), it remains experimental and its value has not been confirmed in a comparative 
study. 
 In summary, pre-operative chemotherapy is recognised as a standard of care for 
patients with mid and distal oesophageal cancer and also for oesophago-gastric junctional 
cancer. For localised squamous cell cancer of oesophagus definitive chemoradiation is 
advocated. Peri-operative chemotherapy for gastric cancer and oesophago-gastric 
junctional tumour (type I and type II adenocarcinoma) is now most widely used in UK. 
1.6.3 Palliative treatment 
 Majority of oesophageal and gastric cancer present in the advanced stage and 
therefore require palliative treatment. Palliative chemotherapy has been shown to be 
benefitial compared to  the best supportive care in advanced gastric cancer (Wagner et al. 
2010, Cunningham et al. 2008, Pyrhonen et al. 1995, Murad et al. 1993, Glimelius et al. 
1997). Similar findings were noted in inoperable oesophageal and oesophago-gastric 
junctional tumours as well (Shah, Schwartz 2004).  
 Until recently, the combination of chemotherapeutic regimen of ECF has been 
preferred in oesophageal, gastric and junctional cancer (Webb et al. 1997). Newer 
regimens containing capecitabine or oxaliplatin are reported to be equally effective 
(Cunningham et al. 2008). External beam radiotherapy can help in relieving symptoms of 
dysphagia in oesophageal cancer (Caspers et al. 1988, Cwikiel, Cwikiel & Albertsson 
1996). 
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 In gastric cancer,external beam radiotherapy (45-50.4 Gy) as a single modality has 
minimal effect in patients who  has  locally unresectable gastric cancer and does not have 
any effect on survival (Hazard, O'Connor & Scaife 2006).  However, concurrent use of 
chemotherapeutic agents such as 5 fluorouracil along with radiotherapy in patients with 
locally unresectable gastric cancer has resulted in better survival (Moertel et al. 1969). A 
combination of chemotherapy is more effective than 5 fluorouracil alone (Wagner et al. 
2010).  Two drug regimen incorporating a platinum agent (i.e. cisplatin) and a 
fluoropyrimidine (i.e. 5 fluorouracil) is generally used. Adding an anthracycline can have 
significant benefit as a triple drug regimen. ECF (epirubicin, cisplatin and protracted 
infusion of 5 fluorouracil) among the most active and well tolerated regimen.  Docetaxel is 
also considered as a first line drug in combination with cisplatin and 5 fluorouracil(as 
DCF) (Van Cutsem et al. 2006). Irinotecan incombination with5- fluorouracil/leucovorin 
has similar efficacy to 5-fluorouracil/cisplatin and therefore can be considered in a selected 
group of patients (Dank et al. 2008). 
 The over expression of vascular endothelial growth factor receptor (VEGFR), 
epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 
(HER 2) has been associated with poor prognosis in patients with oesophageal and gastric 
cancer(Wagner, Moehler 2009, Gravalos, Jimeno 2008).  In a recent randomised 
prospective trial, it has been demonstrated that the addition of trastuzumab with standared 
chemotherapy has improved overall survival in advanced gastric and gastro-oesophageal 
adenocarcinoma (Bang et al. 2010). All patients should have HER-2 status tested and 
Trastuzumab should be added to the standard chemotherapy agents in patients with HER-2 
positive tumours. The use of bevacizumab (anti VEGFR antibody) and cetuximab (anti 
EGFR antibody) have been explored in clinical trials but remains experimental (Pinto et al. 
2007, Pinto et al. 2009). 
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 Palliative gastric resection should not be done unless patient is symptomatic and in 
that case lymph node resection is not required. A systematic review compared distal 
gastric/duodenal stent with gastro jejunostomy and has reported that there was no 
difference in technical success, late major complications and persisting symptoms. 
However patients with stents were reported to have better initial improvement of clinical 
symptoms and had less frequent early minor complications. Recurrent obstructive 
symptoms were more common after stent placement. Mean survival was higher with gastro 
jejunostomy.  Therefore, gastric bypass with gastrojejunostomy to the proximal stomach 
(in case of distal obstructing tumour) instead of self expanding metal stent placement is a 
preferred method in symptomatic patients if surgery is feasible (Jeurnink et al. 2007). 
 Other palliative treatments options for oesophageal and gastric cancer include 
oesophageal intubation, stenting, dilatation, brachytherapy, laser therapy, photo dynamic 
therapy, argon plasma coagulation, injection therapy with ethanol with a variable success 
(Allum et al. 2002). 
1.7 Determinants of short term outcome of oesophageal and gastric cancer 
following surgery 
 Early detection and surgery confers the greatest chance of long-term cure in 
oesophageal and gastric cancer.  However, upper GI cancer surgery is associated with 
considerable morbidity and mortality.  Postoperative mortality following gastro-
oesophageal cancer resection is significant and has been reported as varying from 1%–23% 
(Koshy et al. 2004, Jamieson et al. 2004).  Therefore preoperative surgical risk assessment 
is a vital part of modern surgical practice. This will allow a surgeon to anticipate the 
adverse events following the surgery; facilitate the informed consent process and surgical 
decision making.  Nevertheless, the impact of the quality of surgery and post-operative 
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care in patients undergoing gastro-oesophageal resection, in particular for cancer, remains 
unclear due to variations in case mix. 
 Various surgical risk prediction models have been developed to objectively 
quantify the postoperative morbidity and mortality. Some of the common risk prediction 
models in surgery are APACHE III ( Acute Physiology and Chronic Health Evaluation) 
(Knaus et al. 1991), POSSUM (Physiological and Operative Severity Score for the 
enUmeration of Mortality and Morbidity) (Copeland, Jones & Walters 1991) and ASA 
(The American Society of Anesthesiologist’) physical status classification (Owens, Felts & 
Spitznagel 1978, Haynes, Lawler 1995). The ASA score is easy to use but it is not very 
precise and it does not consider surgical insult in predicting post operative outcome. The 
APACHE scoring system is quite complex and time consuming. Moreover all the 
parameters are not always easily obtainable, particularly outside that of the intensive care 
setting. Therefore, missing values in the data is a potential source of error in APACHE 
scoring system (Chandra, Mangam & Marzouk 2009). POSSUM scoring system was 
particularly developed as an audit tool to compare post operative outcome in general 
surgery as well as in various sub specialities. POSSUM and its other modifications are 
most widely used in UK due its reasonable ability to predict post operative outcome 
(Chandra, Mangam & Marzouk 2009). 
 
1.7.1 Role of POSSUM and its related models as predictors of post-operative 
outcome in gastro-oesophageal cancer  
 In order to assess the impact of treatment in multidisciplinary teams and institutions  
reliable tools are required  to assess the morbidity and mortality risks including the severity 
of the surgical insult.  The POSSUM (Physiological and Operative Severity Score for the 
enUmeration
 
of Mortality and Morbidity) model for predicting post-operative mortality 
  49 
was developed by Copeland and co-workers (Copeland, Jones & Walters 1991) using 
cohorts of general surgical patients.  This was subsequently revised to P-POSSUM by 
Whitelay and coworkers who reported that POSSUM over predicted post-operative 
mortality particularly in those who were at low risk (Whiteley et al. 1996).  P-POSSUM 
used the same set of variables as POSSUM but had a different logistic regression equation.  
Attempts have been made to modify the POSSUM scoring system for specific surgical 
procedures.  For example, V-POSSUM (Prytherch DR. Ridler BM. Beard JD. Earnshaw JJ. 
Audit and Research Committee,The Vascular Surgical Society of Great Britian and Ireland 
2001) for vascular, RAAA-POSSUM (Prytherch, Sutton & Boyle 2001) for ruptured 
abdominal aortic aneurysm and CR-POSSUM (Tekkis et al. 2004b) for colorectal surgery.  
These risk assessment tools have been used to allow comparative audit of surgical 
mortality although they fail to address prediction of morbidity and mortality in individual 
patients.   
 POSSUM has been reported to be superior to the Acute Physiology And Chronic 
Health Evaluation (APACHE) II tool, for the prediction of postoperative death in patients 
undergoing major surgery in a high-dependency unit (Jones, Copeland & de Cossart 1992).  
More recently, this model has been adapted to a specialised model for the prediction of 
risk-adjusted postoperative mortality in oesophageal and upper gastrointestinal surgery (O-
POSSUM) (Tekkis et al. 2004a).  Both POSSUM and P-POSSUM scoring systems use a 
12 factor physiological score and a 6 factor operative severity score.  In O-POSSUM, the 
operative severity score is modified to exclude operative blood loss, number of procedures 
and peritoneal soiling.  Age was regressed independently from POSSUM (Table 1-3).   
 It is therefore interesting to examine the use of POSSUM and its related models as 
predictors of post-operative mortality and morbidity in patients undergoing surgery for 
gastro-oesophageal cancer.  
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An online database search in Pubmed, Cochrane Database of Systematic Reviews, 
Database of abstracts of reviews, Cochrane Controlled Trials Register, EMBASE (the 
Excerpta Medica Database), was carried out from 1991 (year of the original POSSUM 
scoring system; Copeland, Jones & Walters 1991) to 2008.  Key words used in search were 
as detailed in Table 1-4.  Articles that examined POSSUM scoring (POSSUM/ P-
POSSUM/ O-POSSUM) prospectively or retrospectively in gastro-oesophageal cancer 
surgery were examined as well as relevant references to obtain useful information. 
  In the studies examined, the predictive value (the observed: expected ratio 
(O/E) in each POSSUM model and the p-value for goodness-of-fit) and the discriminatory 
power (area under the curve from receiver operator characteristic curve) were recorded 
where given.  The weighted O/E ratio was calculated and plotted using SPSS software 
(Statistical Package for the Social Sciences version 15·0, SPSS Inc., Chicago, IL, USA).  
 A total of 22 articles were identified.  On close inspection 12 papers did not provide 
useful data (three papers had data published in other articles, four articles included 
colorectal and general surgical patients as well as gastro-oesophageal cancer patients, three 
articles incorporated only physiological components of POSSUM and two articles were not 
in English).  This left 10 original studies to be included in the present review. 
 There were five studies of POSSUM on post-operative mortality in patients 
undergoing resection for gastro-oesophageal cancer (Zafirellis et al. 2002b, Bollschweiler 
et al. 2005, Lai et al. 2007, Otsuka et al. 2007, Lamb et al. 2008) (Table 1-5).  Two studies 
were on oesophageal and three studies were on gastric cancer.  In the individual studies 
POSSUM appeared to have poor predictive accuracy and showed significant lack of 
goodness of fit.  In the pooled data of these studies the observed: expected ratio in 
oesophageal cancer resections varied from 0.37 to 0.66 and from 0.08 to 0.17 in gastric 
cancer. The weighted observed to expected ratio for 1189 patients was 0.37 (Figure 1-1).  
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 There were six studies of P-POSSUM on post-operative mortality in patients 
undergoing resection for gastro-oesophageal cancer (Tekkis et al. 2004a, Lai et al. 2007, 
Lamb et al. 2008, Gocmen et al. 2004, Nagabhushan et al. 2007, Internullo et al. 2008) 
(Table 1-6).  In the individual studies P-POSSUM appeared to have good predictive 
accuracy and showed significant goodness of fit in oesophageal cancer resections.  In 
contrast P-POSSUM appeared to have poor predictive accuracy in gastric cancer. In the 
pooled data of these studies the observed: expected ratio in oesophageal cancer resections 
varied from 1.03 to 1.17, from 0.21 to 0.7 in gastric cancer and from 0.83 to 0.89 in gastro-
oesophageal cancer.  The weighted observed to expected ratio for 2314 patients was 0.83 
(Figure 1-1). 
 There were five studies of O-POSSUM on post-operative mortality in patients 
undergoing resection for gastro-oesophageal cancer (Lai et al. 2007, Gocmen et al. 2004, 
Nagabhushan et al. 2007, Internullo et al. 2008, Lagarde et al. 2007) (Table 1-7).  In a 
single study O-POSSUM appeared to have good predictive accuracy and showed 
significant goodness of fit in gastric cancer. In contrast, in three oesophageal studies as 
well as in one gastro-oesophageal study, O-POSSUM appeared to have poor predictive 
accuracy and showed significant lack of goodness of fit.  In the pooled data of these studies 
the observed: expected ratio in oesophageal cancer resections varied from 0.29 to 0.51, 
0.90 in gastric cancer and 0.65 in gastro-oesophageal cancer.  The weighted observed to 
expected ratio for 1755 patients was 0.51 (Figure 1-1). 
 There were five studies of POSSUM on post-operative morbidity in patients 
undergoing resection for gastro-oesophageal cancer (Zafirellis et al. 2002b, Bollschweiler 
et al. 2005, Otsuka et al. 2007, Lamb et al. 2008, Sah et al. 2008a) (Table 1-8).  In the 
individual studies POSSUM appeared to have good predictive accuracy and showed 
significant goodness of fit. In the pooled data of these studies the observed: expected ratio 
  52 
in oesophageal cancer resections was 0.86 and from 0.40 to 0.99 in gastric cancer.  The 
weighted observed to expected ratio for 1038 patients was 0.86. 
 In the present systematic review the POSSUM model of post-operative mortality 
prediction has clear limitations in patients undergoing surgery for gastro-oesophageal 
cancer. POSSUM significantly over predicted mortality in gastro-oesophageal cancer and 
more so in gastric compared with oesophageal resections.  The poor predictive value of 
POSSUM in these patients may be due to the fact that the model was originally developed 
from data in general surgical patients.  In patients with gastro-oesophageal cancer, surgery 
has a high operative severity score and therefore results in a higher risk prediction.  In 
contrast, O-POSSUM was developed specifically for gastro-oesophageal surgery and 
appears to be good in predicting mortality following gastric cancer surgery but less so in 
oesophageal resections (however, this was based on only one gastric cancer study).  Higher 
prediction of mortality in older patients (as age is included twice in this model) and 
exclusion of operative variables like blood loss may have played a role in the over 
prediction of the mortality.  Lastly, P-POSSUM appeared to be the most useful risk 
prediction model in oesophageal resections but substantially over predicted the risk in 
gastric resections.  Despite the varying degree of over prediction of mortality of the 
different POSSUM models all maintained good discriminatory power in gastro-
oesophageal cancer.  Therefore, the present systematic review confirms that subsequent 
revisions of POSSUM such as P-POSSUM and O-POSSUM have improved the reliability 
of the prediction of post-operative mortality in patients with gastro-oesophageal cancer. 
 The aim of the present study was to undertake a systematic review of the use 
POSSUM and its related models as predictors of post-operative mortality and morbidity in 
patients undergoing surgery for gastro-oesophageal cancer.  However, a number of studies 
identified and included in the present review had gastric cancer patients alone.  Also, these 
gastric cancer studies were heterogeneous in case mix.  Therefore, inclusion of these 
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studies may be considered to be a confounding factor in the present systematic review.  
Nevertheless, there were also a number of studies identified and included in the present 
review that had oesophageal cancer patients alone and these were also considered 
separately and together with the gastric cancer studies.  Therefore, the approach used in the 
present systematic review we believe was even handed and consistent with its aim. 
 It has long been recognised that a risk prediction model that could determine an 
individual patient’s risk in a specific surgical operation would be very useful in 
preoperative assessment and consent process.  This need has driven the development 
POSSUM and its related models.  Nevertheless POSSUM and its related models have been 
used as an audit tool in different fields of surgery.  In the present study all three POSSUM 
models over predicted post operative mortality in gastro-oesophageal cancer.  This may be 
due to improvements in surgery and peri-operative care as part of an increasingly 
specialised and centralised upper gastrointestinal cancer service since  each of the 
POSSUM models was originally developed.   
 It is of interest that although the POSSUM was introduced in 1991 the application 
of POSSUM , P-POSSUM and O-POSSUM  in gastro-oesophageal cancer has only been 
reported in the last decade. Nevertheless, over this period it would appear that the 
POSSUM models increasingly overestimate mortality. A possible reason for this is the 
increasing use of minimally invasive operative techniques and better peri-operative care.  
 With the continuing reduction in mortality following gastro-oesophageal cancer 
resection there is now a need to accurately predict morbidity in these patients.  It was of 
interest therefore that, compared with mortality, POSSUM appeared to better predict post 
operative morbidity.  Indeed, attempts have been made to modify the POSSUM scoring 
system for predicting morbidity in upper gastrointestinal surgery (Otsuka et al. 2007).  
However, a deficiency in the current POSSUM models is that they are not based on a good 
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understanding of the patho-physiological process that results in morbidity and mortality 
following cancer surgery.  Recently it has become clear that the systemic inflammatory 
response, as evidenced by an inflammation based prognostic score (Glasgow Prognostic 
Score, GPS), is strongly associated with long term survival of both inoperable (McMillan 
2008) and operable (McMillan 2009) cancer patients.  Given that the physiological 
component of POSSUM also predicts long-term survival following potentially curative 
colorectal (Brosens et al. 2006, Jenkins, O'Neill & Morran 2007) and pancreatic (de Castro 
et al. 2009) cancer it may be that the systemic inflammatory response will also be useful in 
post-operative morbidity and mortality.  Indeed, Moyes and co-workers (Moyes et al. 
2009) have recently shown that the GPS independently predicts post operative infective 
complications in these patients.  Given that the GPS is much simpler (two factors) 
compared with physiological POSSUM (12 factors) further work is required to compare its 
value in predicting morbidity and mortality following cancer surgery.  
 In summary, the present systematic review shows that POSSUM, P-POSSUM and 
O-POSSUM over-estimate mortality in gastro-oesophageal cancer. Furthermore P-
POSSUM appears to be the most useful of the POSSUM scoring systems in predicting 
post-operative mortality in patients undergoing surgery for gastro-oesophageal cancer.  It is 
not clear which POSSUM scoring system best predicts post-operative morbidity in these 
patients. 
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Figure 1-1: The weighted observed to expected mortality ratio (O:E Ratio) for POSSUM 
(n= 1189), P-POSSUM (n= 2314) and O-POSSUM (n=1755 ) from a systematic review of 
patients undergoing surgery for gastro-oesophageal cancer. 
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Table 1-3: Variables used in POSSUM, P-POSSUM and O-POSSUM equations. 
Physiological Scores:  
Score 1 2 4 8 
Age (years)
* ≤60 61-70 ≥71 - 
Cardiac Signs Normal Cardiac 
drugs/steroid 
Oedema; 
warfarin. 
Borderline 
cardiomegaly on 
CXR 
JVP 
Cardiomegaly 
on CXR 
Respiratory 
signs 
Normal SOB on 
Exertion 
Mild COPD on 
CXR 
SOB stairs 
Mod COPD on 
CXR 
SOB rest 
fibrosis or 
consolidation on 
CXR 
Systolic BP, 
mm Hg 
110-130 131-170 
100-109 
≥171 
90-99 
≤89 
Pulse, beats/min 50-80 81-100 
40-49 
101-120 ≥121 
≤39 
Glasgow Coma 
score 
15 12-14 9-11 ≤8 
Urea nitrogen, 
mmol/L 
<7.5 7.6-10 10.1-15 ≥15.1 
Na mEq/L >136 131-135 126-130 ≤125 
K mEq/L 3.5-5 3.2-3.4 
5.1-5.3 
2.9-3.1 
5.4-5.9 
≤2.8 
≥6 
Hb g/dl 13-16 11.5-12.9 
16.1-17 
10-11.4 
17.1-18 
≤9.9 
≥18.1 
WCC x1012/L 4-10 10.1-20 
3.1-3.9 
≥20.1 
≤3 
- 
ECG Normal  AF (60-90) Any other 
changes 
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Operative Severity scores:  
Score 1 2 4 8 
Operative 
severity          
Minor Intermediate Major Major + 
No. of 
procedures       
over 30 days† 
1 2 >2  
Blood loss per 
operation, mL† 
<100 101-500 501-999 >1000 
Peritoneal 
contamination† 
No Serous blood (< 
250 ml) 
Local pus Free Bowel 
content, pus or 
blood 
Presence of 
malignancy 
No Primary only Nodal 
metastases 
Distant 
metastases 
Mode of Surgery Elective  Emergency 
resuscitation 
Possible. 
operation <24 h 
Emergency, 
immediate 
operation <2 h 
 
POSSUM equation (R1for mortality and R2 for morbidity):  
LogeR1/(1−R1) = −7.04 + (0.13 x Physiological Score) + (0.16 x Operative Severity 
Score). 
LogeR2/(1−R2)= −5.91 + (0.16 x Physiological Score) + (0.19 x Operative Severity 
Score). 
 
P-POSSUM equation for mortality: 
LogeR/(1-R) = -9.065 + (0.1692 x Physiological Score) + (0.1550 x Operative Severity 
Score) 
 
O-POSSUM calculation:  
*Age was regressed independently from the Physiological and Operative Severity Score 
for the enUmeration of Mortality and morbidity (POSSUM). 
 †Risk factors not used in scoring system specific for upper gastrointestinal surgery (O-
POSSUM). 
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Table 1-4: Search terms and methods. 
 
1     exp esophageal neoplasms/ or exp stomach neoplasms/  
2     exp surgical procedures, operative/  
3     1 and 2  
4     exp esophageal neoplasms/su or exp stomach neoplasms/su  
5     ((oesophag$ or esophag$ or gastric$ or gastro$ or stomach) adj (cancer$ or 
tumour$ or tumor$ or carcin$ or malignan$ or neoplas$ or oncolog$)).ti,ab.  
6     (oesophagect$ or esophagect$ or surg$ or gastrect$ or resect$ or 
esophagogastrect$ or oesphagogastrect$).ti.  
7     6 and 5  
8     4 or 3 or 7  
9     possum.ti,ab 
10     8 and 9 
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Table 1-5: Studies of POSSUM on post-operative mortality in patients undergoing resection for gastro-oesophageal cancer 
 
Study Year (Country) Patients (n) Tumour type 
POSSUM 
Predicted  
mortality (%) 
POSSUM 
Observed  
mortality (%) 
O:E 
mortality 
ratio 
Comments 
Zafirellis et al 2002 (UK) 204 Oesophageal 19.12 12.75 
 
 
0.66 
Overestimates risk 
p=0.002 
AUC=0.62 
Bollschweiler et al 2005 (Germany) 137 Gastric 21.17 3.65 
 
 
0.17 
 
 
Overestimates risk 
Lai et al
a
 2007 (China) 545 Oesophageal 15 5.5 
 
 
0.37 
Overestimates risk 
p<0.001 
AUC=0.776 
 
Otsuka et al
a 
2007 (Japan) 123 Gastric 14.1 1.6 
 
0.11 
 
Overestimates risk 
Lamb et al
 
2008 (UK) 180 Gastric 21.4 1.7 
 
 
0.08 
 
Overestimates risk 
p<0.001 
 
Weighted O/E ratio for 1189 patients was 0.37. 
Peri-operative mortality = Deaths within 30 days of surgery. AUC = area under ROC curve. 
a 
in hospital mortality described. O:E is Observed to Expected ratio 
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Table 1-6: Studies of P-POSSUM on post-operative mortality in patients undergoing resection for gastro-oesophageal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted O/E ratio for 2314 patients was 0.83. 
Peri-operative mortality = Deaths within 30 days of surgery. AUC = area under ROC curve. 
a 
in hospital mortality described. O:E is Observed to Expected ratio 
Study Year (Country) Patients (n) Tumour type 
P-POSSUM 
Predicted  
mortality (%) 
P-POSSUM 
Observed  
mortality (%) 
O:E 
mortality 
ratio 
Comments 
Gocmen et al 2004(Turkey) 126 Gastric 15.87 11.1 
 
0.7 
Overestimates risk 
p=0.002 
AUC=0.703 
Tekkis et al 2004(UK) 1042 Gastro- oesophageal 14.5 12 
 
0.83 
Overestimates risk 
p=0.001 
AUC=0.743 
Nagabhushan et al 2007 (UK) 313 Gastro- oesophageal 11.5 10.2 
 
0.89 
Overestimates risk 
p=0.019 
AUC=0.68 
Lai et al 2007 (China) 545 Oesophageal 4.7 5.5 
 
 
1.17 
 
p=0.814  
AUC=0.776 
Internullo et al
a 
2008 (Belgium) 108 Oesophageal 7.2 7.4 
 
1.03 
 
Lamb et al 2008 (UK) 180 Gastric 7.8 1.7 
 
0.21 
Overestimates risk 
p=0.006 
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Table 1-7: Studies of O-POSSUM on post-operative mortality in patients undergoing resection for gastro-oesophageal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted O/E ratio for 1755 patients was 0.51. 
Peri-operative mortality = Deaths within 30 days of surgery. AUC = area under ROC curve. 
a 
in hospital mortality described. O:E is Observed to Expected ratio 
Study Year (Country) Patients (n) Tumour type 
O-POSSUM 
Predicted  
mortality (%) 
O-POSSUM 
Observed  
mortality (%) 
O:E 
mortality 
ratio 
Comments 
Gocmen et al 2004 (Turkey) 126 Gastric 11.9 11.1 
 
0.9 
 
p=0.13 
AUC=0.880 
Nagabhushan et al 2007(UK) 313 Gastro- oesophageal  15.65 10.2 
 
0.65 
Overestimates risk 
p=0.011 
AUC=0.61 
Lagarde et al
a 
2007 (Netherlands) 663 Oesophageal 12.4 3.6 
 
0.29 
Overestimates risk 
p<0.001 
AUC= 0.60 
Lai et al 2007 (China) 545 Oesophageal 10.9 5.5 
 
0.51 
 
p=0.002 
AUC=0.676 
Internullo et al
a 
2008 (Belgium) 108 Oesophageal 15.1 7.4 
 
0.49 
 
Overestimates risk 
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Table 1-8: Studies of POSSUM on post-operative morbidity in patients undergoing resection for gastro-oesophageal cancer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Weighted O/E ratio for 1038 patients was 0.86. 
Peri-operative morbidity = Complication within 30 days of surgery. AUC = area under ROC curve. O:E is Observed to Expected ratio 
 
Study Year (Country) Patients (n) Tumour type 
POSSUM 
Predicted  
morbidity (%) 
POSSUM 
Observed  
morbidity (%) 
 
O:E 
morbidity 
ratio 
 
 
 
Comments 
Zafirellis KD 2002 (UK) 204 Oesophageal 62.3 53.4 
 
0.86 
 
p<0.001 
AUC=0.55 
 
Bollschweiler E 2005 (Germany) 137 Gastric 65.7 34.3 
 
0.52 
 
Otsuka Y 2007 (Japan) 123 Gastric 47.9 39.8 
 
0.83 
 
Sah BK 2008 (China) 394 Gastric 45.5 45.2 
 
0.99 
 
p = 0.962 
Lamb P 2008 (UK) 180 Gastric 67.2 26.6 
 
0.40 
 
p <0.0001 
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1.7.2 Role of systemic inflammatory response 
 There has been a lot of improvement in surgery and peri-operative care in last 
couple of decades resulting in reduced mortality following oesophageal and gastric cancer 
resection. But post-operative morbidity remains a clinically significant problem (Zafirellis 
et al. 2002b, Sah et al. 2008b) and have been reported to vary between 40-80% (Hulscher 
et al. 2001, Lagarde et al. 2008, Sah et al. 2010). It has now become clear that post-
operative infectious complications, in particular anastomotic leak, also compromise long 
term outcome in patients with colorectal cancer (McArdle, McMillan & Hole 2005, Marra 
et al. 2009, Jung et al. 2008, Law et al. 2007).  Rizk et al have examined the impact of post 
operative complication on long term outcome following gastro-oesophageal cancer in 510 
consecutive patients.  Post operative complication was associated with increased length of 
stay, increased mortality and poorer overall survival (Rizk et al. 2004).  Recently, similar 
results have also been reported by Tsujimoto et al in 1332 patients with gastric cancer. 
Patients with post operative infective complication had significant unfavourable outcome 
and poorer long term survival in patients who underwent resection for gastric cancer 
(Tsujimoto et al. 2009).  Post-operative anastomotic leak contributes to significant 
proportion of post operative mortality in oesophageal cancer (Alanezi, Urschel 2004). 
Therefore, infectious complications, in particular the anastomotic leak, can be catastrophic 
for the patient, both in terms of long and short term outcomes. So, it is clear that early 
detection of post operative infectious complications may be of considerable clinical 
benefit.  
 Recently, it has been reported that biochemical markers of the systemic 
inflammatory response, in particular C reactive protein, provide an early indication of post 
operative infectious complications following gastrointestinal cancer surgery (Welsch et al. 
2007, Welsch et al. 2008, Korner et al. 2009). Moreover Moyes et al have reported that pre 
operative Glasgow Prognostic Score (systemic inflammatory marker based scoring) is 
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useful in predicting post operative infectious complications in colorectal cancer (Moyes et 
al. 2009). There are very limited studies available to show the relationship between pre or 
post operative systemic inflammatory markers and post operative infectious complications. 
Deitmar and colleagues have reported that elevated post operative C reactive protein may 
predict anastomotic leak following oesophagectomy (Deitmar et al. 2009).  But it is not 
clear what threshold concentration of C-reactive protein is a good predictor of post 
operative infectious complications following resection of oesophago-gastric cancer.   
1.8 Tumour related determinants of long term survival following oesophageal and 
gastric cancer resection 
1.8.1 Established pathological determinants 
 Pathological TNM staging by American Joint Committee on Cancer (AJCC) is the 
most important prognostic stratification of oesophageal and gastric cancer (Sobin, 
Wittekind & editors. April 2002) (Siewert et al. 2001, Siewert et al. 1998) as discussed 
above in chapter 1.5.2.  Moreover, presence of lymph node metastasis (in particular the 
ratio of involved nodes to the total number of nodes removed and identified), positive 
resection margins (R1 resection) and poorly differentiated tumours are associated with 
poorer survival (Roder et al. 1994, Zafirellis et al. 2002a) (Bilici et al. 2010).  However 
variable outcome following resection for oesophageal and gastric cancer in same stage 
demonstrates a need for other prognostic parameters (Khan et al. 2004). Therefore 
identification of alternative prognostic markers in oesophageal and gastric cancer may help 
to develop a precise prognostic classification.  
1.8.2 Tumour proliferation 
 One of the hallmarks of cancer is its potential for uncontrolled proliferation. 
Immuno-histochemical assessment Ki67 protein is the most common method of assessing 
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tumour cell proliferation.  Ki67 is a large protein, which is associated with dense fibrillary 
component of the nucleolus (Verheijen et al. 1989) in the cell . This protein undergoes 
changes during cell cycle, in particular during mitosis and certainly plays a very important 
role in cell proliferation (Brown, Gatter 2002).  Although the exact role of Ki67 still to be 
defined, it has been examined as a prognostic indicator of various tumours (Brown, Gatter 
2002). 
 Role of Ki67 has been extensively investigated in breast cancer. Number of studies 
has reported that the high proliferative activity i.e. high Ki67 expression was associated 
with poorer survival in breast cancer (Yerushalmi et al. 2010, Beck et al. 1995).  Ki67 has 
also been reported to have a prognostic value in soft tissue tumour (Rohr et al. 1998, 
Stefanou et al. 1998), lung cancer (Scagliotti et al. 1993, Harpole et al. 1995), brain tumour 
(Enestrom et al. 1998, Wakimoto et al. 1996), cervical cancer (Garzetti et al. 1995, Ho, 
Hsu & Chiang 2000) and in colorectal cancer (Palmqvist et al. 1999, Kimura et al. 2000). 
 The role of Ki67 has been recognized in the process of carcinogenesis in 
oesophageal cancer (Jin, Zhang & Liu 2001) . There was a strong association of high Ki67 
expression with dysplasia and neoplasia in barretts oesophagus (Polkowski et al. 1995, Xu 
et al. 2002, Kerkhof et al. 2008). On the other hand Chao et al reported that Ki67 might not 
play an important role in development of adenocarcinoma of oesophagus from barrett’s 
metaplasia (Chao et al. 2008).  Qi et al showed in tissue micro array made from paraffin 
embedded oesophageal squamous cell cancer tissues,  Ki67 index was associated with high 
risk tumour features such as higher tumour grade (Qi et al. 2006). Oesophageal tumours 
with overexpression of Ki67 were reported to have better response following chemo-
radiotherapy (Ressiot et al. 2008, Okuno et al. 1999, Takeuchi et al. 2003). Higher 
expression of intra tumoral Ki67 has been correlated with poorer survival in oesophageal 
cancer  (Youssef et al. 1995, Imdahl et al. 2000).On the contrary Serbia et al have reported 
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in 150 oesophageal squamous cell cancer patients that Ki67 proliferation index does not 
provide any prognostic  information (Sarbia et al. 1996).  
 In gastric cancer, high Ki67 expression was associated with aggressive tumour 
behaviour as well as poorer survival (Tzanakis et al. 2009, Chen et al. 2008). On the 
contrary, Ki67 was not associated with survival in a study conducted by Al-Moundhri et al 
in 121 patients with gastric cancer (Al-Moundhri et al. 2005) as well as by Muller et al in 
418 patients with gastric cancer (Muller et al. 1996).  
1.8.3 Tumour necrosis 
 Presence of intra tumoral necrosis has been reported as a marker of poor prognosis 
in various solid tumours. The role of tumour necrosis has extensively been studied in renal 
or transitional cell carcinoma and majority of them reported that the presence of tumour 
necrosis as a poor prognostic marker in respect to overall survival (Amtrup, Hansen & 
Thybo 1974, Roosen et al. 1994, Sabo et al. 2001) and cancer specific survival (Cheville et 
al. 2003, Frank et al. 2002) (Sengupta et al. 2005). It has also been implicated to enhanced 
risk of metastasis and disease recurrence (Brinker et al. 2000, Leibovich et al. 2003, Frank 
et al. 2003). Tumour necrosis has been associated with other aggressive tumour 
characteristics such as size, grade, pathological stage, higher tumour proliferation index 
(Ki-67), vascular invasion (Sengupta et al. 2005, Lam et al. 2005, Lee et al. 2006, Klatte et 
al. 2009). Tumour micro vessel density was inversely associated with intra tumoral 
necrosis in localised renal cell carcinoma (Sabo et al. 2001).  The relationship between 
clinical parameter and the tumour necrosis has also been examined such as poor 
performance status (Lam et al. 2005), anaemia and body mass index (Sengupta et al. 2005). 
Sengupta et al also reported the co-relation between tumour necrosis and markers of 
inflammatory response i.e. elevated white cell count and erythrocyte sedimentation rate 
(Sengupta et al. 2005).  Similar correlation has been reported in breast cancer.  Tumour 
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necrosis was associated with tumour size, local extension and grade (Fisher et al. 1978), 
tumour recurrence (Gilchrist et al. 1993) and survival (Gilchrist et al. 1993, Marques et al. 
1990, Shek, Godolphin 1988). Several other studies in breast cancer failed to associate 
between tumour necrosis and survival (Rilke et al. 1991, Kato et al. 1997, Leek et al. 1999, 
Lee et al. 2006). Leek et al examined the correlation between tumour necrosis, macrophage 
infiltration and microvessel density in 109 consecutive invasive breast cancer patients.  
The degree of tumour necrosis was correlated with macrophage infiltration and 
angiogenesis as well as other features of aggressive tumour behaviour i.e. high grade, 
larger size and low oestrogen receptor status (Leek et al. 1999). Therefore, they have 
suggested that the aggressive tumours outgrow their blood supply leading to intra tumoral 
hypoxia and subsequent necrosis. This in turn may attract macrophages which initiate the 
angiogenic process in the tumour.  Carlomagno et al noted the association between peri-
tumoral inflammatory cell infiltrate and tumour necrosis in 1457 patients with infiltrating 
ductal carcinoma of breast (Carlomagno et al. 1995). On the other hand, Lee AH el al has 
reported that there was no obvious correlation between tumour inflammatory infiltrate and 
tumour necrosis in invasive breast cancer (Lee et al. 2006). The role of tumour necrosis 
and a poor predictor of survival has been shown in other tumours such as in lung cancer 
(Eerola et al. 1999, Kessler et al. 1996, Swinson et al. 2002), colorectal cancer (Pollheimer 
et al. 2010, Gao et al. 2005, Svennevig et al. 1984) and other solid organ tumours 
(Llombart-Bosch et al. 1986, Muro-Cacho, Cantor & Morgan 2000, Hiraoka et al. 2010). 
Preoperative neo adjuvant radio therapy in rectal cancer has shown to increase the rumour 
necrosis (Knutsen, Adell & Sun 2006) but was not associated with survival.  
 It is now apparent that tumour necrosis has a definitive role to play in tumour 
biology and behaviour. Moreover it has been strongly associated with other aggressive 
tumour characteristics. To date, there is no published report on tumour necrosis in 
  68 
oesophageal and gastric cancer, in particular as a prognostic marker or the interrelationship 
between inflammatory response and necrosis.  
1.8.4 Microvessel density (CD34+) 
 Angiogenesis is a process by which new capillaries are formed from the endothelial 
cells. Intra tumoral angiogenesis is one of the key mechanisms by which the tumour 
maintains its growth and metastatic potential (Hasan, Byers & Jayson 2002, Sasano, 
Suzuki 2005). Several studies have reported a correlation between intra tumoral 
microvessel density and tumour angiogenesis (Hasan, Byers & Jayson 2002). Numerous 
methods are available for a quantitative assessment of intra tumoural microvessel density. 
Among these, anti CD34 monoclonal antibody which is an immune-histochemical 
endothelial marker, has been most frequently used because of its good sensitivity and 
reproducibility (Vieira et al. 2004) (da Silva et al. 2009).  
 Increased intra tumoral microvascular density was associated with long term 
survival in breast cancer (Hansen et al. 2000) (Heimann et al. 1996), non small cell lung 
cancer (Fontanini et al. 1997), malignant mesothelioma (Edwards et al. 2001), endometrial 
cancer (Guset et al. 2010) and in rectal cancer (Svagzdys et al. 2009).  
 Elpek el al has reported in 53 patients with oesophageal squamous cell cancer that, 
increased microvessel density in the tumour specimen was associated with poorer survival 
(Elpek et al. 2001). Whereas Nomiya and colleagues reported that high microvessel density 
was associated with aggressive tumour behaviour such as higher tumour proliferation 
(Ki67 index) and tumour infiltration in oesophageal cancer (Nomiya et al. 2004). In gastric 
cancer, Chen et al reported in 86 patients that, CD34 positive microvessel was associated 
with poorer survival as well as aggressive tumour behaviour (Chen et al. 2008).  On the 
other hand some published reports have shown that there are poor association between 
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microvessel density and survival but it was related to the aggressive tumour behaviour in 
gastric cancer. Mao et al showed in 92 patients with gastric cancer using tissue micro 
array, that increased CD34 positive microvessel density was associated with poor 
histological types and metastasis (Mao et al. 2007). Similarly, increased microvessel 
density was significantly associated with lymph node metastasis and TNM stage but not 
survival (Da et al. 2008). Iordache et al also reported the association between the 
aggressive tumour behaviour and increased microvessel density (Iordache et al. 2010). 
Ohno et al reported the lack of prognostic significance of the CD34+ microvessel density 
in gastric cancer (Ohno et al. 2005).  
1.9 Host related determinants of long term survival following oesophageal and 
gastric cancer resection 
 The key role of host related factors have long been identified in disease progression 
and outcome following resection of oesophageal and gastric cancer along with tumour 
related factors. Therefore a careful selection of patients for resection not only depends on 
tumour related factors (i.e. TNM stage etc) but also patient related factors such as co-
morbidity and performance status. Poor performance status, co-morbidity or organ 
dysfunction have been reported to have a prognostic significance in oesophageal and 
gastric cancer (McCulloch et al. 2003, Bartels, Stein & Siewert 1998) (Chau et al. 2004). 
There is a lack of consensus in assessing pre operative co-morbidity prior to oesophago-
gastric cancer resection. The assessment of performance status is however subjective in 
most of the cases.  It has been reported that there is a significant difference in the 
assessment of performance status between oncologists, nurses and patients (Ando et al. 
2001).  Therefore it is imperative to develop objective and reproducible prognostic score 
that can reliably reflect post operative outcome following resection of oesophageal and 
gastric cancer. 
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1.9.1 Host immune response 
 The function of immune response is to protect from infection and or tissue 
destruction.  There are two broad categories of immune response: innate and adaptive 
immune response.  The innate immune system or native immunity is non-specific defence 
against microbes or antigen or foreign body. Whereas adaptive immunity, also called 
specific immunity, is stimulated by microbes or antigens.  By convention, the term 
‘immune response’ refers to adaptive immunity. The main components of the innate 
immune system are phagocytic cells, such as neutrophils, natural killer cells and 
macrophages, myeloid derived suppressor cells, dendritic cells and the complement 
proteins.  Antigen stimulates the acute inflammatory response, with mobilisation of 
initially neutrophils, and subsequently macrophages, to engulf and destroy the microbes or 
antigen. The adaptive immune system can also be of two different kinds; cell mediated 
immunity and humoral immunity.  Cell mediated immunity is responsible for defence 
against intracellular microbes and is controlled by CD4+ and CD8+ T lymphocytes from 
the thymus.  Humoral immunity, in contrast, is responsible for defence against 
extracellular pathogens and is controlled by B lymphocytes, from bone marrow. This 
adaptive immunity is slower to evolve but characterised by long term memory. 
 Hanahan and Weinberg listed six alterations essential for malignant growth: self-
sufficiency in growth signals, insensitivity to antigrowth signals, limitless replicative 
potential, ability to evade apoptosis, sustained angiogenesis, and ability to invade the 
tissues and metastasise (Hanahan, Weinberg 2000). An increasing body of research in the 
following years has suggested that host immune response against the tumour cells, in 
particular by T and B lymphocytes, macrophages, and natural killer cells might have a 
major role to play in tumour growth and metastasis. Indeed Colotta et al and colleagues 
have recently suggested the cancer-related inflammation as the seventh hallmark of cancer 
(Colotta et al. 2009). There is substantial evidence that indicates that the immune system 
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may contribute to both in tumour progression and inhibition (Dougan, Dranoff 2009). This 
dual role of the immune system in cancer pathogenesis indicates a complex interplay of 
innate and adaptive immune response in the tumour microenvironment. It is believed that 
the adaptive immune response helps to specifically detect and target the infectious agents, 
whereas innate immune system helps in wound healing and clearing the debris. This task 
of tissue housecleaning is carried out by macrophages and neutrophils. These cells are also 
believed to promote tumour progression (DeNardo, Andreu & Coussens 2010, Biswas, 
Mantovani 2010, Egeblad, Nakasone & Werb 2010). 
1.9.2 Systemic inflammatory response 
 Inflammation as described above is a reaction in response to cellular injury or 
damage. Initiation, maintenance and termination of inflammatory process are highly 
complex. It can be initiated by trauma, infection, allergic reaction or malignancy. There are 
numerous cellular and humoral mediators that play key roles in inflammation process. It 
has also been recognised that there is a systemic component of inflammatory response 
apart from local inflammation which thought to be mediated by cytokines (Heinrich, 
Castell & Andus 1990, Kushner 1993). The systemic changes involving various organ 
system in the body is referred as “acute phase response” (Kushner 1993) (Table 1-9). 
Moreover, there are number of plasma proteins which undergo changes in their 
concentration during inflammatory process, termed as “acute phase proteins” (Gabay, 
Kushner 1999). However, it has been shown that a persistent response is seen in many 
patients, including those with malignant disease.  It has therefore been suggested that the 
term “systemic inflammatory response” is used to reflect the sometimes chronic nature of 
the systemic response to inflammation. 
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 Table 1-9: Systemic changes associated with the acute phase response. 
 
Neuroendocrine changes 
 
Fever, somnolence, and anorexia 
Increased secretion of corticotropin-releasing hormone, 
Decreased production of insulin-like growth factor I 
Increased adrenal secretion of catecholamines 
Hematopoietic changes 
 
Anemia of chronic disease 
Leukocytosis 
Thrombocytosis 
Metabolic changes 
 
Loss of muscle and negative nitrogen balance 
Decreased gluconeogenesis 
Increased hepatic lipogenesis 
Increased lipolysis in adipose tissue 
Decraesed lipoprotein lipase activity in muscle and adipose 
tissue 
Cachexia 
Hepatic changes 
 
Increased metallothionein, inducible nitric oxide synthase, 
tissue inhibitor of metalloproteinase-1 
decreased phosphopyruvate carboxykinase activity 
Changes in non protein 
plasma constituents 
 
hypozincemia, hypoferremia, and hypercupremia 
increased plasma retinol and glutathione concentrations 
 
1.9.2.1 Acute phase proteins 
 Acute phase protein as mentioned above has been defined as plasma proteins whose 
concentration in serum changes either way (increase or decrease) by at least 25 percent 
during any inflammatory process (Morley, Kushner 1982) (Table 1-10). The magnitude of 
the change of concentration varies significantly as well as the timing. For example there 
might be as much as 1000 fold increase of some acute phase proteins such as C reactive 
protein and serum amyloid A (Figure 1-2). Complement proteins or fibrinogen or 
haptoglobin exhibit a sustained but slow response to the inflammation. Amongst the acute 
phase proteins, C-reactive protein and albumin are the two most commonly measured in 
routine clinical practice, due to their well standardised assays and sensitivity. 
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Table 1-10: The major acute-phase proteins 
 
Protein Types Increased Decreased 
Complement system C3,C4,C9, Factor B, C1 
inhibitor, C4b binding 
protein, Mannose 
binding lectin 
 
Coagulation system Fibrinogen, 
plasminogen, Tissue 
plasminogen activator, 
Urokinase, Protein S, 
Vitronectin, 
Plasminogen activator 
inhibitor 1 
Factor XII 
Antiproteases α 1 protease inhibitor,  α 
1 antichymotrypsin, 
trypsin inhibitors,  
 
Transport proteins Ceruloplasmin, 
Haptglobin, Hemopexin 
Transferrin, Thyroxine 
binding globulin,  
Participants in 
inflammatory response 
Phospholipase A2, 
Lipopolysaccaride 
binding protein, 
Interleukin 1 receptor 
antagonist, Granulocyte 
colonystimulating factor 
 
Other C- reactiveprotein, 
Serum amyloid A, α 1 
acid glycoprotein, 
Fibronectin, ferritin, 
Angiotensinogen 
Albumin, Alpha 
fetoprotein, Insulin like 
growth facctor 1 
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Figure 1-2: Characteristic patterns of change in plasma concentrations of some acute phase 
proteins after a moderate inflammatory stimulus (Gabay, Kushner 1999). 
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1.9.2.1.1 C- reactive protein 
 C-reactive protein is a non-specific, acute phase protein that was first described in 
1930. It was named as C reactive protein because of its ability to bind to the C-
polysaccharide in the pneumococcal cell wall (Tillett, Francis 1930). C reactive protein is 
produced in liver in response to a variety of inflammatory cytokines (i.e. interleukin 1, 
interleukin 6 or tumour necrosis factor alpha) (Du Clos 2000). C reactive protein works as 
a key component of the innate immune system in the body. It binds to phosphocholine and 
thus helps to identify some of the foreign pathogens as well as damaged cells (Volanakis 
JE 1997). It has been shown to activate the complement cascade, bind to phagocytic cells 
and act as an opsonin for various pathogens (Volanakis JE 1997). It also helps to produce 
inflammatory cytokines and other tissue factors by activating monocytes (Ballou, Lozanski 
1992) (Du Clos 2000, Cermak et al. 1993). The synthesis of C reactive protein in 
hepatocytes starts rapidly (approximately within six hours ) following a inflammation and  
reaches its peak concentrations at about 48 hours, with a doubling rate at every 8 hours 
(Kushner, Broder & Karp 1978) (Pepys, Hirschfield 2003). The level of C reactive protein 
rise is usually proportional to the tissue damage.  Concentrations of C reactive protein can 
come down to normal level within 2-3 days of cessation of the inflammatory process 
(Kolb-Bachofen 1991).  Due to its fast kinetics C reactive protein can provide adequate 
and useful information about the inflammatory process and therefore it has been a very 
useful marker in the monitoring of patients with inflammatory diseases (Werner et al. 
2003, van Leeuwen, van Rijswijk 1994). The normal concentration of C reactive protein in 
human subjects may vary from less than 2 mg per litre to 10mg per litre. Therefore it has 
been suggestion that clinically significant rise of C reactive protein should be considered if 
the level is more than 10 mg per litre. (Morley, Kushner 1982).  
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1.9.2.1.2 Albumin 
 Albumin is a multigene family of protein and is the most abundant protein in the 
circulatory system. It is produced in the liver and has many physiological functions such as 
maintenance of colloid osmotic pressure, transporting various molecules in blood, free 
radical scavenging, platelet function inhibition and antithrombotic effect etc (He, Carter 
1992). It has also been recognised that serum albumin behaves as a negative acute phase 
protein, as its concentration in serum decreases in inflammation (Don, Kaysen 2004). 
Hypoalbuminaemia also reflect a poor nutritional status (Don, Kaysen 2004, McMillan et 
al. 2001). Albumin has a long plasma half-life of around twenty days, compared with 19 
hours for C-reactive protein.  Changes in serum albumin concentration are easily 
detectable and it is routinely measured in clinical practice.   
1.9.2.2 Cellular immunity 
 One of the main components of the adaptive immunity is cellular reaction involving 
circulating cells i.e. neutrophils, monocytes, eosinophils, lymphocytes, basophils and 
platelets. Leukocytosis is a common feature of inflammation and primarily because of 
accelerated release of cells from bone marrow mediated by cytokines, i.e interleukin 1 (IL 
1) and tumour necrosis factor etc. These inflammatory mediators stimulate bone marrow 
stromal cells and T cells to produce colony stimulating factors (CSFs), which in turn 
stimulates proliferation and differentiation of bone marrow precursors of granulocytes 
(Kumar V, Abbas A K & Fausto N 2004).   
1.9.2.3 Systemic inflammation and cancer survival 
 It has now been recognised that survival of patients with cancer not only depends 
on tumour related characteristics but also on host related factors.  It is now known that 
cancer can induce inflammatory microenvironment (Colotta et al. 2009, Balkwill, 
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Mantovani 2001, Mantovani et al. 2008, Coussens, Werb 2002, Vakkila, Lotze 2004).  The 
mechanism by which tumour initiates systemic  inflammatory response is complex. One 
possible hypothesis is the tumour hypoxia and necrosis may initiate inflammatory process 
as apoptosis is a relatively clean form of programmed cell death and does not elicit 
inflammatory process (Thompson 1995) (Vakkila, Lotze 2004). Moreover, tumour cells 
can instigate the production of pro inflammatory cytokines, which in turn stimulates the 
production of acute phase proteins including C reactive proteins (Barber et al. 2000, 
Tisdale 1999).   
 An elevated systemic inflammatory response (as evidenced by an increased C-
reactive protein concentration in blood as well as leucocytosis) has been found to be 
associated with a poor survival in patients with a variety of cancers independent of tumour 
stage. It has been reported that the elevated C reactive protein is a prognostic indicator in 
patients with colorectal (McMillan 2008), gastro-oesophageal (Crumley et al. 2006), 
pancreatic (Jamieson et al. 2005), renal (Karakiewicz et al. 2007), urinary bladder (Hilmy 
et al. 2005) and non small cell lung (Hara et al. 2007) cancer.  
 Nozoe et al reported in 262 patients with oesophagectomy for oesophageal cancer 
that, those who had elevated serum level of C reactive protein (>5 mg/l) had poorer 
survival in 1, 3 and 5 year follow up (Nozoe, Saeki & Sugimachi 2001). Similar findings 
were noted by Ikeda et al, who reported in 356 patients with oesophageal cancer that, 
elevated C reactive protein (>5mg/l) is a independent prognostic factor of survival (Ikeda 
et al. 2003). A different cut off value of C reactive protein (10 mg/l) was used by Shimada 
et al in patients with oesophageal squamous cell cancer and it was shown to be an 
independent factor  of poor survival (Shimada et al. 2003). In case of gastric cancer, raised 
pre operative C reactive protein was reported to have independent prognostic value as well 
(Wang, Sun 2009) 
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 Pre operative low serum albumin level has been reported to have independent 
prognostic value in colorectal cancer (Heys et al. 1998) (Cengiz et al. 2006, Longo et al. 
1998) and breast cancer (Lis et al. 2003) (Al Murri et al. 2007). Lien et al looked at the role 
of pre operative hypoalbuminaemia in gastric cancer and its relationship with survival. It 
was found that pre operative low serum albumin (<35 g/dl) was associated with poorer 
survival in operable gastric cancer (Lien et al. 2004).  
 It is also of interest that in cancer related inflammation, as serum C reactive protein 
level rises, albumin level falls and this phenomenon is consistent in various types of 
tumour (McMillan 2008). Therefore a new inflammation based scoring system for cancer 
was devised and was called Glasgow Prognostic Score, which has subsequently been 
modifiedand called Modified Glasgow Prognostic Score (mGPS) (McMillan 2008). 
Patients with an elevated C-reactive protein (>10 mg/l) were assigned a modified GPS 
score (mGPS) of 1 or 2 depending on the absence or presence of hypo-albuminaemia (<35 
g/l). Patients in whom neither of these abnormalities was present were allocated a score of 
0. In a recent review, it has been reported that the Glasgow Prognostic Score has an 
independent prognostic value in breast, colorectal, gastro-oesophageal, renal, pancreatic 
and non small cell lung cancer (McMillan 2009). Glasgow Prognostic score prior to neo-
adjuvant therapy has been reported to predict survival of oesophageal cancer (Kobayashi et 
al. 2008).  
It has been reported that there are strong direct associations between obesity, 
cardiovascular co-morbidity and the magnitude of the systemic inflammatory response e.g 
elevated C-reactive protein concentrations in North American and European population 
(Choi, Joseph & Pilote 2013, Tzotzas, Evangelou & Kiortsis 2011, Kao, Shiesh & Wu 
2006).  With reference to the mGPS and its thresholds (C-reactive protein >10mg/l and 
albumin <35) factors such as obesity and co-morbidity have a relatively small effect with 
the exception of anaemia (Richards et al. 2010, Roxburgh et al. 2010).  In contrast, tumour 
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necrosis is recognised to be associated with changes in the mGPS (Richards et al. 2012).  
Therefore, it is not likely that obesity and comorbidity per se confounded the interpretation 
of the results in the present thesis.   
 The role of elevated leucocytes and platelets as a marker of systemic inflammatory 
response and its prognostic significance in cancer is less clear. It has been reported that 
Neutrophil Lymphocyte Ratio (NLR) has independent prognostic value in non small cell 
lung cancer (Sarraf et al. 2009), colorectal cancer (Walsh et al. 2005) (Malik et al. 2007) 
(Kishi et al. 2009) (Halazun et al. 2008), hepatocellular cancer (Gomez et al. 2008a), 
cholangiocarcinoma (Gomez et al. 2008b) and ovarian cancer (Cho et al. 2009). Moreover 
high neutrophil count (>6x10
9
) preoperatively has been shown to be of poor prognostic 
indicator in colorectal cancer (Neal et al. 2009).  
 Pre operative elevated platelet count (>400x10
9 
) was associated with poorer 
survival in non small cell lung cancer (Tomita et al. 2008), colorectal cancer (Kandemir et 
al. 2005), pancreatic cancer (Suzuki et al. 2004), hepatocellular cancer (Hashimoto et al. 
2005), breast cancer (Taucher et al. 2003), ovarian cancer (Menczer et al. 1998) (Li et al. 
2004) (Gungor et al. 2009) and renal cell cancer (Jacobsen et al. 2002, Inoue et al. 2004, 
Gogus et al. 2004). Platelet lymphocyte ratio (PLR) was also recognised as a prognostic 
marker in resectable pancreatic cancer (Smith et al. 2009).  
 Similarly pre operative lymphocyte count and monocyte count were also been 
shown to have a role in predicting survival in colorectal cancer (Tartter 1987)(Sasaki et al. 
2007). 
 The relationship between blood leucocyte and platelet count and survival resection 
of oesophageal and gastric cancer is rather sparse. Shimada et al reported in 374 patients 
with oesophageal squamous cell cancer that pre operative thrombocytosis (>293x10
9
) was 
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an independent predictor of survival as well as associated with poor tumour characteristics 
(Shimada et al. 2004).  Similarly Ikeda et al looked into 369 consecutive patients with 
gastric cancer and found that preoperative elevated platelet count (>400x10
9
) was 
associated with poorer survival (Ikeda et al. 2002).  
1.9.3 Tumour associated macrophages 
 The most frequently found immune cells within the tumour microenvironment are 
tumour-associated macrophages (TAMs) and T cells. It is believed that the tumour-
associated macrophage (TAM, CD68+) plays the most important role in the tumour related 
inflammatory response. However, also mast cells, neutrophils and even effectors of the 
adaptive immunity (especially in the form of antibodies) may activate inflammatory 
reactions that promote cancer progression (de Visser, Eichten & Coussens 2006, Galli, 
Grimbaldeston & Tsai 2008). In most studies, accumulation of TAM has been associated 
with the angiogenesis and poor prognosis (Mantovani et al. 2008, Balkwill, Charles & 
Mantovani 2005, Bingle, Brown & Lewis 2002, Pollard 2004). Pro tumourogenic property 
of TAM might be mediated by releasing cytokines, growth factors and matrix-degrading 
enzymes (Wyckoff et al. 2007, Mantovani et al. 2006, Condeelis, Pollard 2006) and 
various angiogenic factors (e.g. vascular endothelial growth factor (VEGF), platelet-
derived growth factor and fibroblast growth factor) (Balkwill, Mantovani 2001, Mantovani 
et al. 2006, Lewis, Pollard 2006, Murdoch et al. 2008). It has also been reported that TAM 
accumulates in the hypoxic areas of tumour and hypoxia triggers a proangiogenic program 
in these cells (Murdoch et al. 2008). However increased macrophage infiltration in tumour 
also been reported as good prognostic indicator (Kim et al. 2008, Pupa et al. 1996, Shimura 
et al. 2000). This anti tumour immunity mediated by TAMs may be through presenting 
tumor antigens to T-cells and by tumourocidal activity (Mantovani 1994). Tumouricidal 
activity by the activated macrophages is exerted either by direct or indirect cytotoxicity. 
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Various toxic factors, such as TNFα, serine proteases, and reactive nitrogen intermediates 
are involved in this process (Bingle, Brown & Lewis 2002, Lewis, Pollard 2006). 
 Previous  studies have reported that the increased TAMs in the tumour tissues in 
oesophageal squamous cell cancer are associated with tumour progression and poorer 
survival (Guo et al. 2007, Koide et al. 2002). Although, in another published report on 
oesophageal squamous cell carcinoma CD68+ macrophage in the tumour tissue was not 
associated with survival (Ishibashi et al. 2006) 
 In gastric cancer, Ishigami et al. reported that increased TAMs infiltration in 
tumour had more aggressive clinico-pathological characteristics and poorer prognosis 
(Ishigami et al. 2003). Similarly, Kawahara et al have also reported the poor prognostic 
value of tumour associated macrophages (CD68+) and also its association with 
microvessel density (Kawahara et al. 2010). But in contrast, Ohno et al has reported that 
the higher infiltration of the CD68+ macrophages in the tumour nests had a beneficial 
effect in terms of survival in gastric cancer (Ohno et al. 2003). Moreover they have also 
reported the close association between CD68+ macrophages and CD8+ T lymphocytes in 
gastric cancer (Ohno et al. 2003) and also with the microvessel density (Ohno et al. 2005). 
In another study involving tissue microarray in gastric cancer, CD68+ macrophages were 
not associated with survival (Haas et al. 2009).  
 The role of the tumour associated macrophages in oesophageal and gastric cancer 
needs to be investigated further.  
1.9.4 Tumour infiltrating lymphocyte 
 The role of T lymphocyte in cancer immunity has long been recognised (DeNardo, 
Andreu & Coussens 2010). Mature T cells are divided into two major groups based on the 
T cell receptors (TCRs) they express: γδ and αβ. αβ  T cells are further classified according 
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to their effector functions as CD8+ cytotoxic T cells (CTLs) and CD4+ helper T (Th) cells, 
which include Th1, Th2, Th17 and T regulatory (Treg) cells as well as natural killer T 
(NKT) cells. T lymphocyte can have tumour promoting as well as tumour suppressing 
effects (Smyth, Dunn & Schreiber 2006, DeNardo et al. 2009). Most tumour infiltrating 
lymphocytes (TILs) are cytotoxic T lymphocytes (CTLs), which are related to tumour 
specific immunity (Boon et al. 1994).  
 CD8+ T lymphocytes infiltration in tumour micro environment was correlated with 
better survival in colorectal cancer (Ohtani 2007, Galon et al. 2006, Pages et al. 2009), 
pancreatic cancer (Fukunaga et al. 2004), hepato cellular cancer (Gao et al. 2007), ovarian 
cancer (Sato et al. 2005, Zhang et al. 2003), cervical cancer (Piersma et al. 2007), renal 
cancer (Nakano et al. 2001), urothelial cancer (Sharma et al. 2007) and lung cancer (Kawai 
et al. 2008). It has been reported that, in melanoma, dense intratumoral, not peritumoral T 
cell infiltrates were correlated with improved survival (Clark et al. 1989, Clemente et al. 
1996). Similar findings were reported in colorectal cancer as well (Naito et al. 1998). 
 In oesophageal squamous cell cancer higher CD8+ lymphocytes associated with 
better overall survival (Cho et al. 2003, Schumacher et al. 2001). Moreover, Schumacher et 
al reported that the intra tumoral CD8+ T lymphocyte infiltration is a good predictor of 
outcome than peri-tumoral infiltration (Schumacher et al. 2001).  Also following chemo-
radiotherapy in oesophageal squamous cell cancer, CD8+ T lymphocytes were predictive 
of long term outcome (Ashida et al. 2006). But in another study involving one hundred and 
thirty patients with oesophageal adenocarcinoma, CD8+ lymphocyte was not associated 
with survival (Zingg et al. 2010). 
 In gastric cancer tumour infiltrating lymphocytes have been reported to be 
associated with survival (Davessar et al. 1990, Ma et al. 1994, Songun et al. 1996). 
However Fukuda et al reported no association between TILs and survival in T3 gastric 
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cancer (Fukuda et al. 2002). More specifically, CD8+ T-lymphocytes have been reported 
to provide prognostic information in gastric cancer using tissue microarray (Lee et al. 
2008). Similar findings were reported by Milasiene et al (Milasiene, Stratilatovas & 
Norkiene 2007). Moreover, the number of CD8+ T lymphocytes in cancer cell nests were 
predictive of survival (Ohno et al. 2002). In contrast, other reported studies in gastric 
cancer, CD8+ T lymphocyte was not associated with survival (Haas et al. 2009, Chiaravalli 
et al. 2006, Shen et al. 2010). 
1.10 The role of Tissue Micro Array (TMA) in research of molecular markers 
 The tissue microarray (TMA) technology makes it possible to simultaneously 
analyse hundreds of tissue specimens for numerous molecular markers. It has also been 
shown that the TMA samples were quite useful to link up molecular changes in the tissue 
with the clinical endpoints (Torhorst et al. 2001, Kallioniemi et al. 2001).  
 Tissue Micro array has been used to assess tumour infiltrating lymphocytes in 
various other studies involving Hodgkin’s lymphoma (Alvaro-Naranjo et al. 2005), 
prostrate (Karja et al. 2005), colorectal cancer (Pages et al. 2005, Zlobec et al. 2008a, 
Zlobec et al. 2008b), ovarian cancer (Callahan et al. 2008) and breast cancer (Bates et al. 
2006). 
 Micro vessel density (CD34+) has also been assessed in TMA in various cancers 
such as breast, lung and hepato-cellular (Xu et al. 2008, Donnem et al. 2007, Chebib et al. 
2007) and gastric cancers (Mao et al. 2007, Zheng et al. 2006). Similarly Ki-67 
proliferation index was assessed in TMA in various cancers such as bladder cancer (Burger 
et al. 2007), breast cancer (Cheang et al. 2009, Park et al. 2005, Sapino et al. 2006), 
prostrate cancer, colorectal cancer (Hashimoto et al. 2006, Okon et al. 2006) and gastric 
cancer  (Zheng et al. 2006). 
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1.11 Aims 
 The overall aim of the thesis was to examine the inter-relationships between patient 
physiology and systemic inflammatory response as well as local inflammatory response 
and outcome (both short term and long term), in patients undergoing resection for 
oesophageal and gastric cancer.   
More specifically the aims of the thesis are:  
To compare patients’ pre operative physiological status (POSSUM scoring system) 
and systemic inflammatory response (modified Glasgow prognostic scoring model) in the 
prediction of post-operative outcome, both short term and long term, in patients 
undergoing resection of oesophago-gastric cancer. Also to examine the value of serial daily 
post-operative markers of systemic inflammatory response like white cell count, albumin 
and C-reactive protein concentrations in the prediction of post-operative complications in 
these patients. 
 To compare the prognostic value of selected markers of the systemic inflammatory 
response in patients undergoing potentially curative resection for oesophageal and gastric 
cancer. 
 To examine the relationship between local and systemic inflammatory responses 
and outcome in patients undergoing potentially curative resection for oesophageal and 
gastric cancer. 
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2 Chapter II: A comparison of POSSUM and GPS models in the 
prediction of post operative outcome in patients undergoing 
oesophago-gastric cancer resection. 
2.1 Introduction 
 Despite improvements in surgery and peri-operative care resulting in reduced 
mortality for oesophago-gastric cancer resections, post-operative morbidity remains a 
clinically significant problem (Zafirellis et al. 2002b, Sah et al. 2008b) and have been 
reported to vary between 40-80% (Hulscher et al. 2001, Lagarde et al. 2008, Sah et al. 
2010). 
 To objectively assess the impact of the patients’ physiological condition on 
outcome following surgery Copeland and co-workers developed the Physiological and 
Operative Severity Score for the enUmeration of Mortality and morbidity (POSSUM) 
(Copeland, Jones & Walters 1991) using cohorts of general surgical patients. This was 
subsequently revised to P-POSSUM (Portsmouth POSSUM) by Whitelay and co-workers 
who reported that POSSUM over predicted post-operative mortality, particularly in those 
who were at low risk (Whiteley et al. 1996).  P-POSSUM used the same set of variables as 
POSSUM but had a different logistic regression equation.  More recently, this model has 
been adapted to a specialised model for the prediction of risk-adjusted postoperative 
mortality in oesophageal and upper gastrointestinal surgery (O-POSSUM) (Tekkis et al. 
2004a).  Both POSSUM and P-POSSUM scoring systems use a 12 factor physiological 
score and a 6 factor operative severity score.  In O-POSSUM, the operative severity score 
was modified to exclude operative blood loss, number of procedures and peritoneal soiling.  
Age was regressed independently from POSSUM. (Table 2-1).  In terms of outcome 
following surgery for oesophago-gastric cancer various POSSUM models have been used 
with variable accuracy (Chapter 1).    
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 Recently, it has become clear that the presence of a systemic inflammatory 
response underlies the recognised relationship between poor nutritional status and poor 
outcome in patients with oesophago-gastric cancer (Deans et al. 2009, Crumley et al. 
2010b). Indeed, an elevated C-reactive protein has been shown to be related to increased 
incidence of peri-operative blood transfusion and general complication in oesophago-
gastric cancer patients (Gockel et al. 2006).  This has recently been refined to include the 
combination of C-reactive protein and albumin, termed the modified Glasgow prognostic 
score (mGPS) (McMillan 2009).   Therefore, it is of interest that the mGPS has been 
shown to be associated with post-operative complications (Moyes et al. 2009) and long 
term survival (Ishizuka et al. 2007, McMillan et al. 2007) in patients undergoing 
potentially curative resection for colorectal cancer.  Furthermore, both POSSUM and 
mGPS are significantly associated with long term survival in these patients (Brosens et al. 
2006, Jenkins, O'Neill & Morran 2007, Richards et al. 2010).   
 With reference to oesophago-gastric cancer several studies have reported that the 
development of a post-operative complication after major surgery contributes not only to 
adverse short term outcome, but also to reduced long term survival (Rizk et al. 2004, 
Tsujimoto et al. 2009, Lagarde et al. 2008).  Therefore, it may be that post-operative 
complications are simply a surrogate marker for underlying pre-operative host-related 
factors, and it is these that are the true determinants of survival.  However, the relationship 
between pre-operative patient physiology, systemic inflammatory response, postoperative 
complications and survival has not been examined.    
 The aim of the present study, therefore, was to compare POSSUM and mGPS 
models in the prediction of post-operative outcome, both short term and long term, in 
patients undergoing resection of oesophago-gastric cancer. 
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2.2 Patients and Methods 
 All patients who underwent oesophago-gastric cancer resections in Glasgow Royal 
infirmary from January 2005 to May 2009 and had data for POSSUM, P-POSSUM and O-
POSSUM and the mGPS models to be scored were included in the study.  Data on 
patients’ demographics, deprivation score, preoperative physiological score, ASA risks, 
operative details, and post-operative outcomes were collected from a comprehensive 
review of patient records.  
 The tumours were staged according to the tumour node metastasis (TNM) Criteria 
from the 6
th
 edition of the International Union Against Cancer (UICC) Classification of the 
Malignant Tumours (Sobin, Wittekind & editors. April 2002).  Tumours of the oesophago-
gastric junction were further subdivided according to site, using the Siewert classification; 
Type I and II lesions of the oesophago-gastric junction were designated, as cancers of the 
oesophagus. Type III tumours of the cardia were designated gastric cancers (Siewert, Stein 
1996).  
 POSSUM physiological score and operative severity score were calculated 
according to Copeland and co-workers (Copeland, Jones & Walters 1991).  P-POSSUM 
and O-POSSUM were calculated as described by Whitelay and coworkers (Whiteley et al. 
1996) and Tekkis et al (Tekkis et al. 2004a) respectively (2-1).  Missing data (3%) was 
limited to “operative blood loss” and “evidence of peritoneal soiling” with missing values 
allocated a score of ‘1’ (representing a normal result) as suggested by previous studies (Lai 
et al. 2007, Nagabhushan et al. 2007) . 
 The mGPS was constructed as previously described (McMillan 2008). An elevated 
C-reactive protein (>10 mg/l) were assigned a modified GPS score (mGPS) of 1 or 2 
depending on the absence or presence of hypo-albuminaemia (<35g/l).  Patients in whom 
neither of these abnormalities was present were allocated a score of 0.  
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 The extent of deprivation was defined using the Carstairs deprivation index 
(Carstairs, Morris 1990). This is composed of four indicators of deprivation (car 
ownership, overcrowded housing, Registrar General social class and male unemployment) 
and has been validated for use within central Scotland (Hole, McArdle 2002).  Deprivation 
scores were based on the postcode of the patients’ residence at the time of surgery 
(www.isdscotland.org). For illustrative purposes, the results are presented by 
amalgamating the seven categories into three groups: affluent (categories 1 and 2), 
intermediate (categories 3–5) and deprived (categories 6 and 7).  Furthermore, patients 
who drink more than permissive limits of alcohol (21 units and 14 units of alcohol per 
week for male and female respectively) have been categorised as alcohol excess (Morgan 
MY, Ritson B 2003).  Patients were assigned to POSSUM physiology groups (score 11 – 
14, 15 – 20, 21 – 30, > 30) and POSSUM operative groups (score ≤15 and > 15) according 
to previously published thresholds (Tekkis et al. 2004a, Richards et al. 2010). Patients 
were also categorised according to The American Society of Anesthesiologist’ (ASA) 
physical status classification ( 1:A normally healthy patient; 2:A patient with mild systemic 
disease; 3: A patient with severe systemic disease that is not incapacitating; 4: A patient 
with an incapacitating systemic disease that is a constant threat to life) (Owens, Felts & 
Spitznagel 1978, Haynes, Lawler 1995) 
 Postoperative morbidity and mortality was defined as any complication or death 
occurring within 30 days of surgery as this metric was used in various risk adjusted 
predictive models (Internullo et al. 2008, Steyerberg et al. 2006, Daley et al. 1997).  Data 
were collected from the case notes review and regional cancer death registry office.  All 
cases of postoperative mortality were excluded from the subsequent survival analysis.  
 The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary. 
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2.2.1 Statistical analysis  
 The risks were calculated for POSSUM and P-POSSUM on a calculation sheet 
(website: http://www.sfar.org).  The O-POSSUM was obtained by introducing preoperative 
physiological variables and the surgical variables on the spreadsheet (website: 
http://www.risk prediction.org.uk).  Post-operative morbidity was assessed over the first 30 
days of surgery.  Morbidity was documented on the basis of the definition by Copeland et 
al (Copeland, Jones & Walters 1991).  However, only whether or not the patient had a 
complication (and not the number of complications that each patient had) was used in the 
analysis. Non-symptomatic or minor urinary tract infection was not recorded and therefore 
only included if complicated by sepsis.  Similarly, post-operative mortality was defined as 
death during first 30 days of surgery, regardless of cause was recorded.  The observed 
numbers of events (morbidity and mortality) were compared with expected/predicted 
numbers by all three scoring systems.  Comparison of categorical variables was performed 
using binary logistic regression; variables significant on univariate analysis were 
progressed to a multivariate model. 
 Survival analysis was performed using Cox proportional hazards regression; 
variables significant on univariate analysis were progressed to a multivariate model.  
Deaths, excluding post-operative mortality, up to the end of August 2010 were included in 
the analysis.  The results of the statistical tests were given, where appropriate, with the 
95% confidence interval.  The discriminatory power of the three scoring systems was 
examined by receiver–operator characteristic (ROC) curve analysis, using the area under 
the curve (AUC).  Statistical analysis was performed using SPSS software (version 15.0 
SPSS Inc, Chicago, USA). 
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2.3 Results 
 The clinico-pathological characteristics of the 121 patients have been summarised 
in Table 2-2.  The majority of patients were over the age of 60 years (64%), male (72%), 
had an ASA of 1 or 2 (84%), were non smokers (66%), did not consume excess alcohol 
(65%), were not deprived (62%) and had mGPS of 0 (75%).  The majority patients had 
physiology scores were less than 20 (75%) and had high operative scores (78%).  The 
majority of patients had TNM stage I or II disease (64%). Similar numbers of patients 
underwent resection for oesophageal and gastric cancer and had neo-adjuvant therapy.   
 Overall fifty nine patients (49%) had post operative complications and five patients 
(4%) died within 30 days of surgery.  Details of the complications are shown in Table 2-3. 
Complications were categorised into six grades according to the modified Clavien-Dindo 
classification (Dindo, Demartines & Clavien 2004). Briefly, these grades are as follows: no 
complications (grade 0); deviation from normal hospital course, but no need for medication 
or intervention e.g. minute anastomotic leakage, wound infections opened bedside, vocal 
cord paralysis, social/placement problems etc (grade 1); complications requiring drugs or 
blood transfusion e.g. pneumonia requiring antibiotics, atrial fibrillation requiring 
medication, blood transfusion (any: pre-, per-, or post-OP), wound infection requiring 
antibiotics, anastomotic leakage requiring somatostatin etc (grade 2); complications 
requiring interventional treatment e.g. pleural effusion requiring drainage, pneumothorax 
requiring drainage, chest drain for empyema, bronchoscopic lavage, endoscopic dilatation, 
electric reconversion atrial fibrillation or any surgical reintervention etc (grade 3); life 
threatening complications requiring ICU admittance e.g. single or muli organ failure (grade 
4); and postoperative mortality (grade 5).  
Post operative infection was the most common cause of morbidity in our study 
group and multiple complications in one case.  In terms of complications, respiratory 
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complication (25%) and anastomotic leak (12%) were most common.  The distribution of 
complications according to Cavien-Dindo classification was grade 1: 6 patients (5%), 
grade 2: 24 patients (20%), grade 3: 12 patients (10%), grade 4: 17 patients (14%) and 
grade 5: 5 patients (4%) (Table 2-3).  
 Predicted and observed morbidity in POSSUM risk categories are shown in Table 
2-4.  There were predicted complications in 72 patients (60%) giving an overall 
standardised morbidity ratio of 0.82 and ROC analysis for the POSSUM morbidity 
equation was (AUC 0.639, 95% CI 0.541 to 0.737, p=0.008) relatively poor discriminatory 
power.  In particular, in the high risk group the standardised morbidity ratio was 0.73, the 
POSSUM morbidity equation substantially over predicted post-operative complications.  
 The relationship between clinico-pathological characteristics and development of 
post-operative complication is shown in Table 2-5.  On univariate analysis, increased age 
(p<0.05), male sex (p<0.05), higher ASA score (p<0.01), current smoking (p<0.10), 
alcohol excess (p<0.10), elevated mGPS (p<0.10) and higher POSSUM physiological 
score (p<0.01) were associated with development of post operative complication.  On 
multivariate analysis of these significant factors, male sex (HR 3.61, 95% CI 1.38-9.46, 
p=0.009) and POSSUM physiology score (HR 2.13, 95% CI 1.11-4.08, p=0.023) were 
independently associated with post operative morbidity.  
 The post-operative mortality rates predicted by the POSSUM, P-POSSUM and O-
POSSUM equations compared to the observed mortality rate are shown in Table 2-6.  The 
post-operative mortality rates predicted by POSSUM, P-POSSUM and O-POSSUM were 
16.5, 5.8 and 9.9 per cent respectively giving a standardised mortality ratio of 0.25, 0.71 
and 0.42.  POSSUM and O-POSSUM over predicted mortality in all risk groups, whereas 
P-POSSUM over predicted mortality in low risk groups. ROC analysis for the P-POSSUM 
mortality equation was AUC 0.808, 95% CI 0.55 to 1.06, p=0.020.  This showed relatively 
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good discriminatory power in predicting post operative mortality compared with POSSUM 
(AUC 0.759, 95% CI 0.48 to 1.04, p=0.051), and O-POSSUM (AUC 0.715, 95% CI 0.46 
to 0.97, p=0.105). 
 The relationships between pre-operative clinico-pathological characteristics, post-
operative complications and cancer specific survival are shown in Table 2-7.  The median 
follow up for survivors was 31 months (range 15-65).  During this period, 39 patients died 
from oesophago-gastric cancer and 5 patients died from other causes.   On univariate 
survival analysis, male sex (p<0.05), elevated mGPS (p<0.05), POSSUM operative score 
(p<0.05) and increased TNM stage (p<0.001) were significantly associated with cancer 
specific survival.  On multivariate survival analysis, mGPS (HR 1.96, 95% CI 1.09–3.54, 
p=0.025) and TNM stage (HR 2.21, 95% CI 1.44–3.38, p<0.001) remained independently 
associated with cancer specific survival (Table 2-7).  
2.4 Discussion 
 In the present study, male sex and the POSSUM physiological score were 
independent predictors of post-operative complications in patients undergoing potentially 
curative resection of oesophago-gastric cancer resection.  In contrast, the POSSUM 
operative score was not significantly associated with the development of post-operative 
complications.  Moreover, the pre-operative systemic inflammatory response and 
hypoalbuminaemia, as evidenced by the mGPS, but not the patient physiology or the post-
operative complications were independently associated with poorer cancer specific 
survival.  Taken together, the results of the present study suggest that pre-operative host 
related factors are important in determining both short and long term outcome following 
potentially curative resection of oesophago-gastric cancer.  
 To date, there has been very little data on the role of systemic inflammatory 
markers in post-operative complications in patients undergoing potentially curative 
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resection for gastrointestinal cancer.  Previously, Gockel and coworkers (2006) reported 
that an elevated C-reactive protein was associated with increased post-operative 
complications in patients undergoing surgery for oesophago-gastric cancer (Gockel et al. 
2006).  More recently, Moyes and coworkers reported that an elevated mGPS was 
associated with increased post-operative complications in patients undergoing surgery for 
colorectal cancer (Moyes et al. 2009).  In the present study, compared with the POSSUM 
morbidity equation, the mGPS was weakly and not independently associated with the 
development of post-operative complications.  Therefore, the results of the present study 
would suggest that patient physiology, compared with the systemic inflammatory response, 
is the major factor in determining post-operative complications. 
In the present study, male sex was also associated with development of post 
operative complications. It might be due to the fact that majority (81%) of patients were 
male. Therefore it will be interesting to examine patients’ physiological status and its 
relationship with development of post operative complications in a larger cohort. Indeed in 
a recent study in 1017 patients with gastric cancer it has been reported that, pre operative 
patients co morbidity is related to development of post operative complication not GPS 
(Kubota et al. 2012).      
 Clearly, a risk adjusted model with accurate prediction of post-operative morbidity 
and mortality is important in surgical audit.  In the present study although the POSSUM 
morbidity equation appeared to predict post-operative complications well in low risk 
group, it appeared to overestimate post-operative complication in the high risk group.  
Nevertheless, the overall observed to expected ratio was 0.82, surprisingly good given that 
the morbidity equation was developed approximately 20 years ago and in a general 
surgical population.  Indeed, the POSSUM physiology score performed better than ASA 
score in predicting post-operative complications in these patients.  Furthermore, the results 
suggest that the physiology component of the POSSUM score, compared with the 
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operative component, has the strongest influence on the development of post-operative 
complications.  However, given the fact that all patients had oesophago-gastric cancer 
resections and had similar operative severity score, predictive value of the POSSUM 
operative score may have been underestimated.  Therefore, since post-operative morbidity 
is now much more common than post-operative mortality future work may be directed at 
optimising the POSSUM morbidity score.  
  In the present study although the POSSUM physiology score predicted post-
operative complications, it was not significantly associated with cancer specific survival.  
These results are not consistent with previous studies in patients undergoing surgery for 
colorectal cancer reporting long term prognostic value (Brosens et al. 2006, Jenkins, 
O'Neill & Morran 2007).  However, when recently, the prognostic value of the POSSUM 
physiology score and the mGPS in predicting cancer survival were compared in colorectal 
cancer it was clear that the mGPS had superior value (Richards et al. 2010).  Therefore, the 
results of the present study suggest that the systemic inflammatory response, compared 
with patient physiology, is a major factor in determining long term survival.  
 The impact of neo-adjuvant therapy on the systemic inflammatory response 
is not clear.  However, it has been previously reported that, elevated C reactive protein was 
an independent predictor of overall as well as disease free survival in patients with 
oesophageal cancer following neo-adjuvant therapy (Guillem, Triboulet 2005, Zingg et al. 
2010).  Further longitudinal studies are required to demonstrate effect of systemic 
chemotherapy in inflammatory response in particular with C reactive protein. 
The routine clinical use of the mGPS has yet to be established.  However, from the 
present and recent studies (Vashist et al. 2011) its potential role in the risk stratification of 
patients undergoing surgery for oesophageal cancer is clear since this procedure has a high 
potential for morbidity and mortality and recovery to pre-resectional functional status, if 
  95 
 95 
ever reached, can take a year or more.  Therefore, it can be concluded that ‘Preoperative 
evaluation of the GPS may help to stratify oesophageal cancer patients to different risk 
profiles, which is essential in the era of customized therapy’ (Vashist et al. 2011).  
Furthermore, with the increasing use of neoadjuvant therapy in oesophageal cancer prior to 
surgery and the consequent reduction in the value of pathological findings (as it may down 
stage the tumour), the value of the mGPS in clinical staging and predicting outcome may 
be of increasing importance in these patients.  Clearly, further work is required to establish 
the role of the mGPS in patients undergoing surgery for gastric cancer. 
 There is now increasing evidence of the role of the systemic inflammatory response 
in predicting cancer survival in lung, gastrointestinal and renal cancers, independent of 
tumour stage (McMillan 2009, Roxburgh, McMillan 2010). More recently, in a study of 
almost 10,000 cancer patients, this has been extended to other tumour types (Proctor et al. 
2011).  Whilst the mGPS is predictive of cancer survival, TNM stage remains a 
significantly more powerful predictor oesophago-gastric cancer since on multivariate 
analysis the HR for mGPS is 1.96 compared with HR of 2.21 for TNM stage.  Therefore, 
the results of the present study suggest an important role for mGPS (and therefore 
inflammation and hypoalbuminemia) in predicting cancer survival that can be considered 
in addition to TNM stage.  
To date, following oesophago-gastric cancer resection, few studies have compared 
the different POSSUM models in predicting mortality (Lai et al. 2007, Luna et al. 2009).  
In the present study all three POSSUM models examined over predicted the post operative 
mortality rate.  POSSUM and O-POSSUM over predicted in all risk groups.  In contrast, P-
POSSUM had the least over predicted mortality particularly in high risk group and showed 
a good discriminatory power.  The relatively poor performance of the POSSUM and O-
POSSUM models, compared with P-POSSUM, in the present study may have been due to 
small sample size. Nevertheless, the results of the present study are consistent with the 
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large majority of the literature in oesophago-gastric cancer (Chapter 1).  In the present 
study the basis of the overestimation of post-operative mortality following oesophago-
gastric cancer resection by all three models, although not certain, was likely to be due to 
improved post-operative care and centralisation of upper gastrointestinal cancer service 
since the prediction models were devised.  Therefore, given that post-operative mortality 
following oesophago-gastric surgery is now considerably lower, it would be of interest to 
up-date and refine the existing POSSUM models to recapture its role as an effective audit 
tool in this surgical speciality.  
 In summary, the results of the present study show that, in patients undergoing 
surgery for oesophago-gastric cancer, the POSSUM physiology score, was useful in 
predicting the development of post-operative complications.  Also, our results suggest that 
the mGPS was useful in predicting cancer specific survival.  In contrast, post-operative 
complications were not independently associated with poorer cancer specific survival.  
Clearly, in the present study the relatively small numbers of patients and outcome events, 
especially mortality, limit the strength of these conclusions.  Nevertheless, the results of 
the present study would suggest that pre-operative host related factors are important in 
determining both short and long term outcome following potentially curative resection of 
oesophago-gastric cancer. 
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Table 2-1: Variables used in POSSUM, P-POSSUM and O-POSSUM equations. 
 
Physiological Score 1 2 4 8 
Age (years)
* ≤60 61-70 ≥71 - 
Cardiac Signs Normal Cardiac 
drugs/steroid 
Oedema; warfarin. 
Borderline 
cardiomegaly on 
CXR 
JVP 
Cardiomegaly on 
CXR 
Respiratory signs Normal SOB on Exertion 
Mild COPD on 
CXR 
SOB stairs 
Mod COPD on 
CXR 
SOB rest 
fibrosis or 
consolidation on 
CXR 
Systolic BP, 
mm Hg 
110-130 131-170 
100-109 
≥171 
90-99 
≤89 
Pulse, beats/min 50-80 81-100 
40-49 
101-120 ≥121 
≤39 
Glasgow Coma score 15 12-14 9-11 ≤8 
Urea nitrogen, 
mmol/L 
<7.5 7.6-10 10.1-15 ≥15.1 
Na mEq/L >136 131-135 126-130 ≤125 
K mEq/L 3.5-5 3.2-3.4 
5.1-5.3 
2.9-3.1 
5.4-5.9 
≤2.8 
≥6 
Hb g/dl 13-16 11.5-12.9 
16.1-17 
10-11.4 
17.1-18 
≤9.9 
≥18.1 
WCC x1012/L 4-10 10.1-20 
3.1-3.9 
≥20.1 
≤3 
- 
ECG Normal  AF (60-90) Any other changes 
 
Operative Score 1 2 4 8 
Operative severity          Minor Intermediate Major Major + 
No. of 
procedures       over 30 
days† 
1 2 >2  
Blood loss per 
operation, mL† 
<100 101-500 501-999 >1000 
Peritoneal 
contamination† 
No Serous blood (< 
250 ml) 
Local pus Free Bowel 
content, pus or 
blood 
Presence of 
Malignancy 
No Primary only Nodal metastases Distant metastases 
Mode of Surgery Elective  Emergency 
resuscitation 
Possible. operation 
<24 h 
Emergency, 
immediate 
operation <2 h 
 
POSSUM equation (R1for mortality and R2 for morbidity):  
LogeR1/(1−R1) = −7.04 + (0.13 x Physiological Score) + (0.16 x Operative Severity Score). 
LogeR2/(1−R2)= −5.91 + (0.16 x Physiological Score) + (0.19 x Operative Severity Score). 
 
P-POSSUM equation for mortality: 
LogeR/(1-R) = -9.065 + (0.1692 x Physiological Score) + (0.1550 x Operative Severity Score) 
 
O-POSSUM calculation:  
*Age was regressed independently from the Physiological and Operative Severity Score for the enUmeration 
of Mortality and morbidity (POSSUM). 
 †Risk factors not used in scoring system specific for upper gastrointestinal surgery (O-POSSUM). 
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Table 2-2: The clinico-pathological and operative characteristics of patients who underwent 
potentially curative resection of oesophago-gastric cancer 
 
Variables  Patients (n=121 (%)) 
Age  ≤60 44 (36) 
 61-70 48 (40) 
 ≥71 29 (24) 
Sex  Female 34 (28) 
 Male 87 (72) 
ASA  1 20 (16) 
 2 82 (68) 
 3 18 (15) 
 4 1 (1) 
Smoking status Non 80 (66) 
 Ex or current 41 (34) 
Alcohol excess No 78 (65) 
 Yes 43 (35) 
Deprivation 
 
1-2 18 (15) 
 3-5 57 (47) 
 6-7 46 (38) 
mGPS 0 99 (82) 
 1 16 (13) 
 2 6 (5) 
POSSUM physiology score 11-14 27 (22) 
 
15-20 64 (53) 
 21-30 30 (25) 
POSSUM operative score ≤15 26 (22) 
 >15 95 (78) 
POSSUM morbidity category Low risk 64 (53) 
 High risk 57 (47) 
POSSUM mortality category Low risk 87 (72) 
 Medium risk 24 (20) 
 High risk 10 (8) 
P-POSSUM mortality category Low risk 116 (96) 
 Medium risk 5 (4) 
O-POSSUM mortality category Low risk 107 (88) 
 Medium risk 14 (12) 
   
TNM Stage I 48 (40) 
 Stage II 29 (24) 
 Stage III 44 (36) 
Tumour site Oesophageal 61 (50) 
 Gastric 60 (50) 
Neoadjuvant therapy No 54 (45) 
 Yes 67 (55) 
Adjuvant therapy No 102 (85) 
 Yes 19 (15) 
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 Table 2-3: List of complications in patients underwent resection for oesophago-gastric 
cancer (n=59). 
 
Complication types Number of 
patients 
Anastomotic leak 14 
Other serious infections 9 
Respiratory (pneumonia, insufficiency etc) 30 
Cardiac complications, Liver and renal failure 14 
Other complications (wound infection, urinary, ileus, post op 
confusion etc) 
14 
Post operative deaths (in hospital) 5 
Clavien-Dindo classification
* 
Grade 1 
Grade 2 
Grade 3 
Grade 4 
Grade 5 
 
6 
24 
12 
17 
5 
 
 
Values do not equal to 100% as several patients had more than one post operative 
complications. 
*Clavien-Dindo classification (Dindo, Demartines & Clavien 2004) 
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Table 2-4: Predicted and Observed morbidity in POSSUM risk categories in patients who 
underwent potentially curative resection of oesophago-gastric cancer (n= 121). 
 
 Predicted 
Risk (%) 
Number of 
patients 
Predicted 
morbidity 
Observed 
morbidity 
O:E 
Low risk ≤30 9 2 1  
 31-40 16 6 5  
 41-50 21 10 10  
 51-60 18 10 11  
Total ≤60 64 28 27 0.96 
High risk 61-70 22 14 10  
 71-80 18 14 11  
 81-90 11 10 7  
 91-100 6 6 4  
Total >60 57 44 32 0.73 
Overall 0-100 121 72 59 0.82 
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Table 2-5: The relationship between clinico-pathological characteristics and the development 
of post-operative complications; binary logistic regression analysis 
 
Variables Complications 
n=59 (%) 
Univariate 
OR (95% CI) 
P value Multivariate 
OR (95% CI) 
P value 
Age  ≤60 yrs 13 (22)     
         61-70 30 (51)     
         ≥71 16 (27) 1.82 (1.12-2.95) 0.016  0.237 
Sex  Female 11 (19)     
        Male 48 (81) 2.57 (1.12-5.92) 0.026 3.61 (1.38-9.46) 0.009 
ASA  1 6 (10)     
          2 39 (66)     
          3 13 (22)     
          4 1 (2) 2.54 (1.28-5.04) 0.008  0.106 
Smoking status 
  Non 
34 (58)     
  Ex or current 25 (42) 2.11 (0.98-4.56) 0.056  0.270 
Alcohol excess 
  No 
33 (56)     
  Yes 26 (44) 2.09 (0.98-4.45) 0.058  0.051 
Deprivation  1-2 8 (14)     
                     3-5 25 (42)     
                     6-7 26 (44) 1.36 (0.80-2.29) 0.253   
mGPS  0 44 (75)     
             1 11 (19)     
             2 4 (7) 1.97 (0.94-4.14) 0.074  0.078 
PPS  11-14 8 (14)     
         15-20 31 (52)     
         21-30 20(34) 2.18 (1.24-3.81) 0.006 2.13 (1.11-4.08) 0.023 
POS  ≤15 10 (17)     
          >15 49 (83) 1.70 (0.70-4.14) 0.239   
      
TNM  Stage I 23 (39)     
           Stage II 18 (30)     
           Stage III 18 (30) 0.88 (0.58-1.32) 0.525   
Tumour site  
  Oesophageal 
 
33 (56) 
    
  Gastric 26 (44) 0.65 (0.32-1.33) 0.237   
Neoadjuvant  No 23 (39)     
                      Yes 36 (61) 1.57 (0.76-3.22) 0.224   
      
PPS  POSSUM physiology score, POS  POSSUM operative score 
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Table 2-6: Predicted and Observed mortality in risk categories as defined by POSSUM, P-POSSUM and O-POSSUM mortality equations 
 
 POSSUM P-POSSUM O-POSSUM 
 Predicted 
Risk (%) 
Patients 
(n) 
Predicted 
mortality 
Observed 
mortality 
O:E Patients 
(n) 
Predicted 
Mortality 
Observed 
mortality 
O:E Patients 
(n) 
Predicted 
mortality 
Observed 
mortality 
O:E 
Low risk 0-10 43 3 1  107 4 2  75 4 1  
 10-20 44 6 0  9 1 1  32 5 2  
 ≤20 87 9 1 0.11 116 5 3 0.6 107 9 3 0.33 
Medium risk 21-40 24 6 2 0.33 5 2 2 1.0 14 3 2 0.67 
High risk >40 10 5 2 0.40 0 0 0  0 0 0  
Total 0-100 121 20 5 0.25 121 7 5 0.71 121 12 5 0.42 
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Table 2-7: The relationship between clinicopathological characteristics, post-operative 
complications and cancer-specific survival; Cox regression analysis (post-operative mortality 
excluded). 
 
TNM stage (I/ II/ III) 2.43 (1.61-3.69) <0.001 2.21 (1.44-3.38) <0.001 
Tumour site 
(oesophageal/ gastric) 
 
0.54 (0.29-1.04) 
 
0.065 
 
 
 
0.551 
Neo-adjuvant (No/ yes) 0.60 (0.32-1.13) 0.116   
Adjuvant therapy (No/yes) 1.60 (0.73-3.48) 0.240   
 
 
 
Variable Univariate Multivariate 
HR (95% C.I.) P-value HR (95% C.I.) P-value 
Age (<60/ 61-70/ >70 yrs) 0.96 (0.63-1.44) 0.827   
Sex (female/ male) 2.45 (1.03-5.85) 0.044  0.377 
ASA (1/ 2/ 3/ 4) 1.04 (0.59-1.81) 0.902   
Smoking status 
(Non/ Ex or current) 
 
0.61 (0.30-1.26) 
 
0.181 
  
Alcohol excess (No/ yes) 1.11 (0.58-2.13) 0.757   
Deprivation (1-2/ 3-5/ 6-7) 0.98 (0.62-1.57) 0.937   
mGPS (0/ 1/ 2) 1.70 (1.01-2.86) 0.045 1.96 (1.09-3.54) 0.025 
POSSUM physiology score 
(11-14/ 15-20/ 21-30) 
 
1.04 (0.64-1.70) 
 
0.881 
  
POSSUM operative score 
(<15/ >15) 
 
2.97 (1.05-8.31) 
0.039 
 
 
0.111 
Post –operative 
Complication (No/ yes) 
 
1.39 (0.74-2.61) 
 
0.304 
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3 Chapter III: Persistent elevation of C-reactive protein following 
oesophago-gastric cancer resection as a predictor of post operative 
surgical site infectious complications 
3.1 Introduction 
 Despite improvements in surgery and peri-operative care resulting in reduced 
mortality for oesophago-gastric cancer resections, post operative morbidity remains a 
clinically significant problem (Zafirellis et al. 2002b, Sah et al. 2008b).  In particular, post 
operative infectious complications remain a significant clinical problem and are the most 
common cause of peri-operative morbidity (Sah et al. 2010).   
 Such complications are in the main surgical site-specific infections (SSI) or remote 
site infections (RI) and have been reported to vary between 40-80% (Hulscher et al. 2001, 
Lagarde et al. 2008, Sah et al. 2010).  An anastomotic leakage is the most serious SSI and 
has been reported to vary from 3-25% (Sah et al. 2010, Lorentz, Fok & Wong 1989, 
Hankins et al. 1989, Urschel 1995, Isguder et al. 2005, Lo et al. 2002, Lerut et al. 2002), 
and accounts for approximately 30-40% post operative deaths (Whooley et al. 2001, 
Griffin et al. 2001).  
 It has now become clear that post-operative infectious complications, in particular 
anastomotic leak, also compromise long term outcome in patients with colorectal cancer 
(McArdle, McMillan & Hole 2005, Marra et al. 2009, Jung et al. 2008).  Recently, similar 
results have also been reported following both oesophageal (Lagarde et al. 2008) and 
gastric (Tsujimoto et al. 2009) resections.  Therefore, infectious complications, in 
particular the anastomotic leak, can be catastrophic for the patient, both in terms of long 
and short term outcomes. 
 Currently, in patients who have undergone oesophago-gastric surgery an 
anastomotic leak is usually detected symptomatically or radiologically prior to re-
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instituting normal feeding (approximately 8 days) and often when the patient has become 
critically ill (Griffin et al. 2001).  Similarly, other infectious complications are only 
detected when the patient develops clinical symptoms.  Clearly, when such infectious 
complications are detected at a late symptomatic stage they are likely to require major 
clinical intervention such as re-operation and or admission to intensive care.  From the 
above, it is clear that early detection of post operative infectious complications may be of 
considerable clinical benefit.  
 Recently, it has been reported that biochemical markers of the systemic 
inflammatory response, in particular C reactive protein, provide an early indication of post 
operative infectious complications following gastrointestinal cancer surgery.  Welsch and 
coworkers (2007), in 48 patients with infectious complications matched with 48 patient 
with no infectious complications undergoing surgery for rectal cancer, reported that 
increased C-reactive protein concentrations on postoperative day 3 were associated with 
infectious complications and the optimal threshold value was 140mg/l (Welsch et al. 
2007).  The same group reported, in 688 patients undergoing surgery for pancreatic 
disease, that increased C-reactive protein concentrations on postoperative day 4 were 
associated with infectious and the optimal threshold value was 140mg/l (Welsch et al. 
2008).  Korner and co-workers (2009) reported, in 231 patients undergoing surgery for 
colorectal cancer, that increased C-reactive protein concentrations on postoperative day 3 
were associated with intra-abdominal infections with the threshold value being 190mg/l 
(Korner et al. 2009). 
 More recently Woeste and colleagues (2010), in 342 patients undergoing surgery 
for colorectal cancer, reported that a prolonged elevation in the C-reactive protein 
concentration with no subsequent decrease precedes the occurrence of anastomotic leakage 
(Woeste et al. 2010).  Ortega-Deballon et al (2010), in 133 patients undergoing elective 
colorectal surgery, reported that high C-reactive protein levels on post operative day 4 
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were associated with anastomotic leaks and the optimal threshold value was 125mg/l 
(Ortega-Deballon et al. 2010).  Mackay and co-workers (2010) reported that, in 160 
patients undergoing surgery for colorectal cancer, increased C-reactive protein 
concentrations on postoperative day 4 were associated with infectious complications and 
the optimal threshold value was 145mg/l (Mackay, Molloy & O'Dwyer 2010).   
 To date there is little information on the diagnostic value of post-operative C 
reactive protein concentrations in predicting post operative complications in patients 
undergoing oesophago-gastric cancer surgery.  Deitmar and colleagues (2009) reported 
that, in 50 patients who developed an anastomotic leakage matched with 50 patient with no 
leak undergoing oesophagectomy, increased C-reactive protein concentrations on 
postoperative day 2 were associated with anastomotic leak and the optimal threshold value 
was 135mg/l (Deitmar et al. 2009).   
 Therefore, it is not clear what threshold concentration of C-reactive protein or what 
post-operative day is optimal for the detection of infectious complication in patients who 
have undergone surgery for oesophago-gastric cancer.  The aim of the present study was to 
examine the value of serial daily post-operative markers of systemic inflammatory 
response like white cell count, albumin and C-reactive protein concentrations in the 
prediction of post-operative infectious complications in these patients. 
3.2 Patients and Methods  
3.2.1 Patients 
 Patients who underwent oesophago-gastric cancer resections in the Royal 
Infirmary, Glasgow, UK from January 2005 to August 2009 were included in the study.  
Patient characteristics were collected in a prospective surgical database.  All patients were 
operated on electively with exception of three patients who underwent an emergency 
 
 107 
 107 
procedure.  The tumours were staged according to the tumour node metastasis (TNM) 
Criteria from the 6
th
 edition of the International Union Against Cancer (UICC) 
Classification of the Malignant Tumours (Sobin, Wittekind & editors. April 2002).  
Tumours of the gastro-oesophageal junction were further subdivided according to site, 
using the Siewert classification; Type I and II lesions of the gastro-oesophageal junction 
were designated, as cancers of the oesophagus. Type III tumours of the cardia were 
designated gastric cancers (Siewert, Stein 1996).   
 Prior to surgery patients were assessed to establish their respiratory status.  Normal 
respiratory status was considered as those patients without having shortness of breath on 
exertion or having no signs on chest X-ray.  Pre-operatively the patients received DVT 
(deep venous thrombosis) prophylaxis and antibiotic prophylaxis.  Patients with 
oesophageal cancer under went trans-hiatal or Ivor-lewis oesophagectomy and for gastric 
cancer partial or total gastrectomy. Patients with oesophago-gastric junctional tumour had 
Ivor-lewis oesophagectomy. All patients underwent potentially curative en-bloc resection 
with D2 lymph-adenectomy.  Serial daily blood samples were taken for routine laboratory 
analysis of white cell count, albumin and C-reactive protein in the pre and post-operative 
period (days 1-7).  Measurement of pre operative C-reactive protein was carried out in the 
few days prior to surgery as part of their routine work up, irrespective of whether or not 
they had received neoadjuvant chemotherapy. In the post-operative period patients had a 
daily clinical assessment and additional investigations were carried out as clinically 
indicated.  All patients had anastomotic drains post-operatively which were left in position 
until radiological evidence of anastomotic integrity was confirmed.   
 Post-operative complications were recorded according to the recognised POSSUM 
definitions (Copeland, Jones & Walters 1991).  Infectious complications were classified as 
surgical site infections (SSI) and remote infections (RI).  For example, a surgical site 
infection included wound infection, anastomotic leak or intra-abdominal collection that 
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occurred following surgery and was associated specifically with the surgical procedure.  
An anastomotic leak was confirmed by radiology (i.e., contrast enhanced multi-detector 
CT scan or conventional radiology with water soluble contrast), endoscopy, or during 
surgical exploration.  With reference to remote infections, an example would be 
pneumonia that occurred at sites not directly associated with the surgical procedure. Non-
symptomatic or minor urinary tract infection were not recorded and therefore only 
recorded if complicated by sepsis.  
 The extent of deprivation was defined using the Carstairs deprivation index 
(Carstairs, Morris 1990). This is an area-based measure derived from the 1991 census, 
using the postcode of residence at diagnosis, which divides the score into a seven-point 
index. For illustrative purposes, the results are presented by amalgamating the seven 
categories into three groups: affluent (categories 1 and 2), intermediate (categories 3–5) 
and deprived (categories 6 and 7). The Carstairs deprivation index has been extensively 
utilised in cancer patients and is particularly appropriate for use in the central belt of 
Scotland (Hole, McArdle 2002). 
The study was approved by the Research Ethics Committee, Royal Infirmary, Glasgow. 
3.2.2 Methods 
 The white cell count (WCC) (reference range 4–10×109/L) was analyzed using a 
hematological blood analyzer (Advia 120, Bayer, or CellDyn, Abbott).  Serum 
concentrations of albumin (normal range 35-50 g/L) and C-reactive protein (normal range 
0-10 mg/L) were measured by a BCG dye-binding method and turbidometric assay, 
respectively, using an auto-analyser (Abbott Diagnostics, Abbott Park, IL).  The 
coefficient of variation for these methods, over the range of measurement, was less than 
10% as established by routine quality control procedures. 
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3.2.3 Statistics 
 Data are presented as median and range. Data from different time periods were 
tested for statistical significance using the Friedman test and where appropriate 
comparisons of data from different time periods were carried out using the Wilcoxon 
signed rank test.  The diagnostic accuracy of white cell count, C-reactive protein and 
albumin was assessed by ROC (Receiver Operator Curve) curve analysis (Robertson, 
Zweig 1981, Zweig, Campbell 1993, Soreide 2009).  The area under the ROC curve 
(AUC) is a direct measure of the diagnostic accuracy of the test.  An AUC value greater 
than >0.50 indicates the ability of a test to significantly discriminate between positive and 
negative cases with regard to the classification variable (e.g., presence or absence of 
disease).  A test with an AUC greater than 0.80 was considered as having a high diagnostic 
accuracy and indicates that at least 80% of the patients with the disease were classified 
correctly.  A P value <0.05 (two-sided tests) was considered significant.  Statistical 
analysis was performed using SPSS version 15.0 for Windows (SPSS Inc, Chicago, IL). 
3.3 Results 
 One hundred and thirty six patients underwent oesophago-gastric cancer resection 
during the study period.  The relationship between patient characteristics and the 
development of post operative infectious and non-infectious complications is shown in 
Table 3-1.  The majority of patients were under the age of 65 years (51%), were male 
(73%), had an ASA of 1 or 2 (85%), normal respiratory status (84%), normal heart rate 
(70%) and were not deprived (64%).  The majority of patients had a pre-operative white 
cell count (94%), albumin (86%) and C-reactive protein concentration (82%) within the 
normal range.  
 Similar numbers of patients underwent resection for oesophageal and gastric 
cancer.  Of the 136 patients studied 54 (40%) developed infectious complications and 13 
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(10%) developed non-infectious complications in post operative period.  Of the thirteen 
non-infectious complications; there were four patients who developed cardio-vascular 
complications, three developed respiratory failure without infection and six developed 
other complications (Table 3-1).  In those patients who developed complications they were 
more likely to be male (p<0.05), had a higher ASA score (p<0.05) and had abnormal 
respiratory status pre-operatively (p<0.05).  The development of post-operative 
complications was also related with the type of the operation (p<0.05).  
 The relationship between circulating white cell count, albumin and C reactive 
protein concentrations and infectious and non-infectious complications in the first seven 
post operative days are shown in 3- 2.  Compared with those patients who did not develop 
complications the white cell count was significantly higher on post-operative day 4 
(p<0.05), day 5 (p<0.01), day 6 (p<0.01), and day 7 (p<0.05) in those patients who 
developed infectious and non-infectious complications.  Similarly, albumin was 
significantly lower on post-operative day 5 (p<0.01), day 6 (p<0.01), and day 7 (p<0.01) in 
those patients who developed infectious and non-infectious complications.  In contrast C 
reactive protein was significantly higher on post-operative day 1 (p<0.05), day 3 (p<0.01) 
day 4 (p<0.01), day 5 (p<0.01), day 6 (p<0.01), and day 7 (p<0.01) in those patients who 
developed infectious and non-infectious complications. 
 Of the 54 infectious complications 28 were surgical site infections and 26 were 
remote site infections.  Of the 28 surgical site infections seventeen patients developed an 
anastomotic leak by the median post op day 6 (range 2-13).  A further five patients 
developed wound infection and six patients developed a deep infection (intra abdominal or 
intra thoracic) or collection.  Of the 26 remote site infections twenty-one developed a chest 
infection, three developed septicaemia, one developed urinary tract infection and one 
developed clostridium difficile diarrhoea  
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 The relationship between circulating white cell count, albumin and C reactive 
protein concentrations and surgical site and remote infectious complications in the first 
seven post operative days are shown in Table 3-3.  Compared with those patients who did 
not develop complications the white cell count was significantly higher on post operative 
day 5 (p<0.01), day 6 (p<0.01), and day 7 (p<0.001) in those patients who developed 
surgical site infectious complications.  Similarly, the white cell count was significantly 
higher on post-operative day 4 (p<0.05), day 5 (p<0.001), day 6 (p<0.001), and day 7 
(p<0.01) in those patients who developed remote site infectious complications (Figure 3-
1). 
 Compared with those patients who did not develop complications albumin was 
significantly lower on post operative day 3 (p<0.05), day 4 (p<0.01), day 5 (p<0.001), day 
6 (p<0.001), and day 7 (p<0.001) in those patients who developed surgical site infectious 
complications.  Similarly, albumin was significantly lower on post-operative day 2 
(p<0.05), day 3 (p<0.05) day 4 (p<0.05), day 5 (p<0.01), day 6 (p<0.001), and day 7 
(p<0.001) in those patients who developed remote site infectious complications (Figure 3-
2). 
 Compared with those patients who did not develop complications C-reactive 
protein was significantly higher on post operative day 1 (p<0.01), day 2 (p<0.01), day 3 
(p<0.001), day 4 (p<0.001), day 5 (p<0.001), day 6 (p<0.001), and day 7 (p<0.001) in 
those patients who developed surgical site infectious complications.  Similarly, C-reactive 
protein was significantly higher on post-operative day 5 (p<0.01), day 6 (p<0.001), and 
day 7 (p<0.001) in those patients who developed remote site infectious complications 
(Figure 3-3).  
 Compared with those patients who did not develop anastomotic leaks (n=119), 
white cell count was not significantly different to those who developed anastomotic leak 
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(n=17, Figure 3-4). In contrast, C-reactive protein was significantly higher from post 
operative day 3 onwards in those patients who developed anastomotic leaks (Figure 3-5).   
 When the relationship between peri-operative concentration of C-reactive protein 
and the development of the post-operative complications were examined only in those 
patients who underwent a thoracotomy (n=57), day 3 and day 4 C-reactive protein 
concentrations were associated with the development of post-operative infectious 
complications (p=0.072 and p=0.012 respectively). 
 In order to establish a threshold for the relationship between C reactive protein and 
the development of infectious complications following surgery for oesophago-gastric 
cancer Receiver Operator Curves (ROC) were plotted for post operative days 3 and 4 
(Figure 3-6 and 3-7).    On post operative day 3 a threshold of 180 mg/l was associated 
with the development of a SSI, providing a sensitivity of 71%, specificity of 65%, and a 
diagnostic accuracy of 0.736 (95% CI, 0.623–0.848; p <0.001).  For remote site infections 
the diagnostic accuracy of a C reactive protein threshold of 180 mg/l on post op day 3 was 
0.463 (95% CI, 0.350–0.577; p =0.567).  
 On post operative day 4 a threshold of 180 mg/l was associated with the 
development of a SSI, providing a sensitivity of 61%, specificity of 86%, and a diagnostic 
accuracy of 0.788 (95% CI, 0.680–0.895; p <0.001).  For remote site infections the 
diagnostic accuracy of a C reactive protein threshold of 180 mg/l on post op day 4 was 
0.502 (95% CI, 0.375–0.629; p=0.977). 
 On post operative day 3, a threshold of 180 mg/l was associated with the 
development of an anastomotic leak, providing a sensitivity of 82%, specificity of 63%, 
and a diagnostic accuracy of 0.808 (95% CI, 0.683–0.933; P<0.001).  On post operative 
day 4, a threshold of 180 mg/l was associated with the development of an anastomotic 
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leak, providing a sensitivity of 71%, specificity of 83%, and a diagnostic accuracy of 0.857 
(95% CI, 0.751–0.963; P<0.001).  
3.4 Discussion 
 The results of the present study show that the magnitude of the systemic 
inflammatory response, in particular C reactive protein, following resection for oesophago-
gastric cancer is associated with the development of post operative complications, in 
particular surgical site infections and anastomotic leakage.  Furthermore, a C reactive 
protein threshold of 180mg/l on post operative days 3 and 4 was shown to predict SSI and 
anastomotic leak with good and very good diagnostic accuracy respectively.  When those 
patients who underwent a thoracotomy alone were examined day 3 and day 4 C-reactive 
protein predicted the development of infectious complications. 
 In the present study the pre-operative C-reactive concentrations was not 
significantly associated with the development of the post-operative complications 
(p=0.186). This is in contrast to previous studies in patients undergoing resection for 
colorectal cancers (Moyes et al. 2009).  However, they examined the pre-operative mGPS 
(modified Glasgow Prognostic Score) (McMillan 2008), a combination of C-reactive 
protein and albumin, in 455 patients. In the present study in 136 patients undergoing 
resection for oesophago-gastric cancer the pre operative mGPS was more strongly  
associated with the development of the post-operative complication (p=0.106). Therefore, 
the present study may have been underpowered to detect an association between the pre-
operative systemic inflammatory response and the development of the post operative 
complications.   
 The results of the present study are consistent with previous studies which have 
highlighted the superiority of post operative concentration of C reactive protein, compared 
with white cell count in predicting the development of the infectious complications.  
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However these studies have suggested a variety of C reactive protein thresholds in 
different post operative days to predict the likelihood of developing a surgical site 
infectious complications (Welsch et al. 2007, Welsch et al. 2008, Korner et al. 2009, 
Deitmar et al. 2009, Ortega-Deballon et al. 2010, Mackay, Molloy & O'Dwyer 2010).  
When these threshold values (including the present study) in different post operative days 
were applied to the data of the present study (Table 3-4), on day 3 there was variation in 
the sensitivity between 64% and 89% and specificity between 38% to 67% in predicting 
surgical site infection.  Also, on day 4 there was variation in the sensitivity predicting 
surgical site infection between 61% and 79% and specificity between 55% to 86%.  
Therefore depending on the threshold value of the C reactive protein used and the post 
operative day chosen there is a considerable variation in the predictive value of the C 
reactive protein.   
 Nevertheless, it was of interest that the sensitivity and the specificity of the C 
reactive protein thresholds established in previous studies both on day 3 and day 4 were 
similar to that in the present study.  Furthermore, that the sensitivity and specificity of the 
C reactive protein threshold were consistently better on day 4.  These results have a 
number of important implications.  Firstly, that clinical monitoring of daily C reactive 
protein concentrations provides some prior warning of the development of a surgical site 
infectious complication, in particular an anastomotic leak.  We would suggest that a C 
reactive protein concentration between 170mg/l and 190mg/l on post operative day 3 and 4 
is indicative of the development of a surgical site infectious complication following 
oesophago-gastric cancer resection.  Given that, both in the present and previous studies, 
the average time for the development of an anastomotic leak is between post operative day 
6 and 8, daily monitoring of C reactive protein concentrations may substantially improve 
the early detection of an anastomotic leak and perhaps its subsequent treatment.  Clearly, if 
this was proven to be the case then this would be the major contribution to reducing the 
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post operative morbidity and mortality associated with resection of oesophago-gastric 
cancer.   
 It was of interest that the post-operative changes of C-reactive protein were 
significantly associated with the development of infectious complications, in particular 
anastomotic leaks, whereas changes of white cell count were not.  The reasons for the 
discrepancy in their relative prognostic value is not clear.  Usually, a rise in circulating C-
reactive protein concentrations considered as a result, rather than a cause, of an infectious 
complication.  However, it may be that C-reactive protein is more sensitive to the presence 
of infection.  Indeed, C-reactive protein has an important role in innate immunity as an 
early defence against infection, assisting complement-binding to foreign and damaged cells 
and enhancing phagocytosis by macrophages.  More recently, through activation of 
complement and interaction with Fcgamma receptors, C-reactive protein has been shown 
to provide a link between the innate and adaptive immune systems (Peisajovich et al. 2008, 
Coventry et al. 2009, Du Clos, Mold 2004, Sander et al. 2010). Furthermore, With 
increasing concentrations of C-reactive protein there is a depression of T-lymphocyte 
function (Fietta et al. 2009, Wichmann et al. 2005).  Also, with increasing C-reactive 
protein there is an increase in the stress response and the degree of hyperglycaemia 
(Motoyama et al. 2010) and that post-operative hyperglycaemia has recently been shown to 
be an important factor associated with the promotion of bacterial growth and the 
development of post-operative infectious complications (Ramos et al. 2008, Ambiru et al. 
2008). Therefore, in addition to giving advance notice of a clinical infection, it may also 
play an important direct role in modulating the post-operative immune function of patients 
with oesophago-gastric cancer. 
In present study, although the non-infectious complications were 4 times less 
common than the infectious complications, it was of interest that there were elevated post 
operative C reactive protein concentrations in patients with non infectious complications as 
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well.  Therefore, this should be considered when the specificity of C reactive protein for 
infectious complications and anastomotic leakage is interpreted. 
 In summary, early identification of post-operative infectious complications in 
patients undergoing oesophageal or gastric resection for cancer is crucial in order to 
provide adequate therapeutic interventions. The present study shows that post-operative 
CRP measurements on days 3 and 4 predicts surgical site infectious complications, in 
particular an anastomotic leak, following resection for oesophago-gastric cancer. 
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Table 3-1: Characteristics of oesophago-gastric cancer patients with and without 
postoperative complications 
 
a
Individual deprivation categories were used in the statistical analysis 
 No 
Complications 
(n=69) 
Infectious 
Complications 
(n=54) 
Non-infectious 
Complications 
(n=13) 
P 
value 
Age (<65/ 65-74/ ≥75 years) 37/25/7 26/21/7 6/6/1 0.597 
Sex (Male/ Female) 44/25 45/9 10/3 0.046 
ASA (1/2/3/4) 14/49/6/0 5/37/11/1 1/9/3/0 0.014 
Respiratory status (Normal/ 
Abnormal) 
61/8 43/11 8/5 0.019 
Heart rate (50-80/ >80 or <50) 49/20 38/16 8/5 0.595 
Deprivation (1-2/3-5/6-7)
a 
11/37/21 5/27/22 3/4/6 0.411 
Tumour site (Oesophageal/ 
Gastric) 
30/39 32/22 8/5 0.164 
Type of operations 
Partial gastrectomy/ Total 
gastrectomy/ Trans-hiatal 
oesophagectomy/ Ivor-lewis 
oesophagectomy 
16/20/12/21 7/11/6/30 2/1/4/6 0.016 
Operative blood loss (101-500/ 
501-999/ ≥1000 ml) 
29/20/20 6/30/18 5/5/3 0.213 
TNM stage (1/2/3/4) 27/14/27/1 18/22/12/2 6/3/3/1 0.621 
Neoadjuvant therapy 
(Yes/No) 
 
36/33 
 
36/18 
 
8/5 
 
0.261 
Pre-operative white cell count 
(<8.5/ 8.5–11/>11x109/l) 
57/ 9/ 3 44/ 6/ 4 10/ 2/ 1 0.541 
Pre-operative albumin (≥35/ <35 
g/l) 
60/ 9 48/ 6 9/ 4 0.291 
Pre-operative C-reactive protein 
(≤10/ >10 mg/l) 
60/ 9 42/ 12 10/ 3 0.186 
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Table 3-2:The relationship between serial post-operative values of white cell count, albumin 
and C-reactive protein and the development of infectious and non-infectious complications. 
 
 No 
complications 
(n=69) 
Infectious 
complications 
(n=54) 
P value
a
 
 
Non-infectious 
complications 
(n=13) 
P value
a
 
      
Pre op WCC 6.2 (1.6-15.6) 7.0 (2.2-17.9) 0.283 5.5 (2.2-11.5) 0.485 
WCC day 1 10.2 (4.3-17.9) 11.3 (5.6-25.9) 0.103 11.3 (5.4-14.9) 0.969 
WCC day 2 10.9 (6.4-20.9) 11.7 (2.2-32.7) 0.326 11.9 (7-18.7) 0.172 
WCC day 3 9.1 (4.5-18.4) 9.6 (1.9-22.6) 0.293 12.0 (5.5-20.2) 0.137 
WCC day 4 7.6 (3.8-17.5) 9.2 (2.6-18.5) 0.022 9.7 (3.8-15.8) 0.045 
WCC day 5 6.7 (3.9-16) 10.3 (3.5-19.6) <0.001 9.2 (4.8-17.1) 0.003 
WCC day 6 7.4 (4.4-15) 11.5 (5.3-21.7) <0.001 9.7 (5.9-21.7) 0.008 
WCC day 7 8.1 (3.9-16.6) 12.9 (3.5-34.9) <0.001 10.7 (5.7-20.7) 0.015 
      
Pre op Alb 40 (20-47) 39 (22-49) 0.630 39 (15-32) 0.844 
Alb day 1 23 (15-32) 23 (13-31) 0.265 26 (19-33) 0.579 
Alb day 2 25 (16-33) 23 (15-29) 0.033 22 (18-31) 0.265 
Alb day 3 24 (16-33) 22 (14-29) 0.008 23 (16-31) 0.214 
Alb day 4 25 (16-37) 22 (13-30) <0.001 23 (15-29) 0.077 
Alb day 5 26 (18-37) 21 (11-34) <0.001 21 (16-31) 0.004 
Alb day 6 27 (18-40) 22 (10-33) <0.001 22 (13-34) 0.002 
Alb day 7 28 (17-38) 21 (10-34) <0.001 22 (11-36) 0.001 
      
Pre op CRP 4.5 (1-77) 3.6 (1-85) 0.515 6 (1-31) 0.361 
CRP day 1 114 (10-214) 140.5 (25-306) 0.010 160 (65-332) 0.038 
CRP day 2 196.5 (53-328) 216 (95-350) 0.077 268 (90-366) 0.008 
CRP day 3 152.5 (42-298) 183.5 (61-392) 0.006 295 (46-369) 0.001 
CRP day 4 108 (37-226) 163.5 (40-393) <0.001 229 (20-300) 0.002 
CRP day 5 80.5 (18-293) 196.5 (25-321) <0.001 167 (14-341) 0.006 
CRP day 6 66 (16-312) 181 (16-395) <0.001 144 (11-316) 0.003 
CRP day 7 55 (13-293) 179.5 (12-429) <0.001 140 (19-344) 0.004 
 
Median (range), WCC white cell count, Alb albumin, CRP C reactive protein.  
a
 compared with no complications. 
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Table 3-3:The relationship between serial post-operative values of white cell count, albumin 
and C-reactive protein and the development of surgical site and remote infectious 
complication 
 
 Infectious complication (n=54) 
 No  
complications  
(n=69) 
Surgical site 
infection  
(n=28) 
P value
a 
Remote 
infection  
(n=26) 
P value
a 
      
Pre op WCC 6.2 (1.6-15.6) 6.2 (2.2-17.9) 0.729 7 (2.6-13.7) 0.164 
WCC day 1 10.2 (4.3-17.9) 11.8 (7-25.9) 0.016 10.8 (5.6-19.1) 0.874 
WCC day 2 10.9 (6.4-20.9) 11.8 (6.5-32.7) 0.208 11.2 (2.2-20.5) 0.761 
WCC day 3 9.1 (4.5-18.4) 9.4 (4.4-22.6) 0.363 10.2 (1.9-16.9) 0.441 
WCC day 4 7.6 (3.8-17.5) 8.7 (4.1-18.5) 0.183 9.9 (2.6-16.4) 0.017 
WCC day 5 6.7 (3.9-16) 9.0 (3.5-17.9) 0.007 12.0 (4.7-19.6) <0.001 
WCC day 6 7.4 (4.4-15) 9.7 (5.3-21.7) 0.006 12.4 (6.6-20.5) <0.001 
WCC day 7 8.1 (3.9-16.6) 12.9 (6.8-34.9) <0.001 13.5 (3.5-32.7) 0.002 
      
Pre op Alb 40 (20-47) 39 (34-47) 0.925 40 (22-49) 0.373 
Alb day 1 23 (15-32) 24 (13-31) 0.740 23 (14-28) 0.139 
Alb day 2 25 (16-33) 24 (16-29) 0.225 23 (15-26) 0.027 
Alb day 3 24 (16-33) 22 (16-29) 0.028 22 (14-29) 0.044 
Alb day 4 25 (16-37) 21 (15-29) 0.002 22 (13-30) 0.012 
Alb day 5 26 (18-37) 21 (14-30) <0.001 21 (11-34) 0.001 
Alb day 6 27 (18-40) 22 (13-31) <0.001 22 (10-33) <0.001 
Alb day 7 28 (17-38) 23 (11-33) <0.001 21 (10-34) <0.001 
      
Pre op CRP 4.5 (1-77) 3.7 (1-85) 0.346 3.2 (1-71) 0.936 
CRP day 1 114 (10-214) 146 (25-306) 0.007 139 (25-241) 0.153 
CRP day 2 196.5 (53-328) 221 (95-350) 0.007 196 (106-310) 0.930 
CRP day 3 152.5 (42-298) 219 (61-392) <0.001 160 (69-316) 0.562 
CRP day 4 108 (37-226) 212 (42-393) <0.001 143 (40-328) 0.171 
CRP day 5 80.5 (18-293) 217 (33-321) <0.001 133 (25-313) 0.008 
CRP day 6 66 (16-312) 189 (27-333) <0.001 126 (16-395) <0.001 
CRP day 7 55 (13-293) 196 (18-378) <0.001 139 (12-429) <0.001 
 
Median (range) 
WCC white cell count, Alb albumin, CRP C reactive protein.  
a
 compared with no complications. 
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Table 3-4: Comparison of different threshold values of C- reactive protein in predicting various infective complications in the study cohort. 
OG: Oesophago-gastric; O: oesophageal; CR: colorectal; R: rectal and panc: pancreatic. POD: post operative day; CRP C reactive protein.  
      Analysis of CRP threshold in the present study (n=136) 
Study Type Patients 
(n) 
POD CRP 
Threshold 
 Infectious complications Surgical site infection Anastomotic leakage 
      Sensitivity 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Sensitivity 
(%) 
Specificity 
(%) 
Deitmar S et al O 50 2 135  89 13 93 17 100 17 
Kørner H et al CR 231 3 190  46 65 64 67 77 66 
Welsch T et al R 48 3 140  78 39 89 38 94 36 
This study OG 136 3 180  52 64 71 65 82 63 
            
MacKay G et al CR 160 4 145  61 71 75 66 88 66 
Welsch T et al Panc 688 4 140  63 67 75 62 88 61 
Ortega-Deballon et al CR 133 4 125  65 57 79 55 88 53 
This study OG 136 4 180  43 90 61 86 71 83 
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Figure 3-1: The perioperative changes in white cell count (10
9
/ l) in patients with surgical site infection (SSI), remote site infection (RI) and no complication 
(NC). 
NC 
SSI 
RI 
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Figure 3-2: The peri-operative changes in albumin in patients with surgical site infection (SSI), remote site infection (RI) and no complication (NC). 
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Figure 3-3: The peri-operative changes in C-reactive protein in patients with surgical site infection (SSI), remote site infection (RI) and no complication (NC). 
NC 
SSI 
RI 
  124 
 124 
 
 
Figure 3-4: The peri-operative changes in white cell count (10
9
/ l) in patients with anastomotic leaks versus patients with out anastomotic leak. 
AL 
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Figure 3-5: The peri-operative changes in C-reactive protein patients with anastomotic leaks versus patients with out anastomotic leak. 
AL 
  126 
 126 
 
 
 
Figure 3-6: Diagnostic accuracy of CRP with regard to surgical site infections after oesophago-gastric cancer resection. Comparison of ROC curves for post 
operative day (POD) 3 and 4 with respective AUC values of 0.736 and 0.788. 
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Figure 3-7: Diagnostic accuracy of CRP with regard to development of the anastomotic leaks after oesophago-gastric cancer resection. Comparison of ROC 
curves for post operative day (POD) 3 and 4 with respective AUC values of 0.808 and 0.857. 
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4 Chapter IV: Comparison of the prognostic value of tumour and 
patient related factors in patients undergoing potentially curative 
resection of oesophageal cancer 
4.1 Introduction 
 Following curative resection for oesophageal cancer, pathological analysis for 
tumour related factors guides’ prognosis. A variety of high risk features including tumour 
stage, resection margin, nodal status, the ratio of metastatic to examined lymph nodes are 
considered to be important (Liu et al. 2009, Roder et al. 1994, Hsu et al. 2009, Saha et al. 
2009).  
 It is now increasingly recognised that the outcome for patients with cancer is not 
only determined by tumour related factors but also by host related factors, in particular the 
systemic inflammatory response (McMillan 2009, Roxburgh, McMillan 2010).  With 
reference to oesophageal cancer an elevated C-reactive protein concentration prior to 
surgery has been reported to have independent prognostic value predicting poor survival 
(Nozoe, Saeki & Sugimachi 2001, Ikeda et al. 2003, Shimada et al. 2003, Gockel et al. 
2006, Crumley et al. 2006).  An elevated platelet count has also been shown to have a 
similar independent prognostic value (Shimada et al. 2004) in oesophageal cancer patients.   
 From such work a number of systemic inflammation based prognostic scores have 
been proposed to simplify and standardise the measurement of the systemic inflammatory 
response in routine clinical practice.  These include the modified Glasgow Prognostic 
Score (mGPS), the Neutrophil Lymphocyte Ratio (NLR) and the Platelet Lymphocyte 
Ratio (PLR) all of which have been reported to be independent predictors of survival in 
gastrointestinal cancer (McMillan 2009).  Recently, Crumley and co-workers (Crumley et 
al. 2010a) reported that the mGPS improved the pre treatment clinical staging of patients 
who presented with gastro-oesophageal cancer thus aiding clinical decision making in 
these difficult to treat patients.  In terms of pathological staging in patients who have 
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undergone potentially curative surgery the relative prognostic value of the mGPS, NLR 
and PLR is not clear.  More specifically, it is not clear which of these scores best predicts 
survival in oesophageal cancer. 
 Therefore, the aim of the present study was to compare the prognostic value of 
selected markers of the systemic inflammatory response in patients undergoing potentially 
curative resection for oesophageal cancer. 
4.2 Patients and Methods 
 One hundred and twelve patients undergoing potentially curative resection for 
oesophageal carcinoma (including type I and II tumours of the gastro-oesophageal junction 
(Siewert, Stein 1996) in the upper GI surgical unit, Glasgow Royal Infirmary, between 
1996 and 2008 were included in the study.   Patients had laboratory measurement of white 
cell, neutrophil, lymphocyte and platelet counts, albumin and C-reactive protein in the few 
days prior to surgery as part of their routine work up, irrespective of whether or not they 
had received neoadjuvant chemotherapy.  Clinical staging was performed primarily by 
radiological investigation using CT scan in the period 1996- 2006, using CT scan with 
endoscopic ultrasound in the period 2006-2007 and using CT scan with endoscopic 
ultrasound and PET scan in the period 2007 to present.  From the period of 2005 to present 
all patients also underwent staging laparoscopy.  
 The tumours were staged according to the tumour node metastasis (TNM) Criteria 
from the 6
th
 edition of the International Union Against Cancer (UICC) Classification of the 
Malignant Tumours (Sobin, Wittekind & editors. April 2002).  Tumours of the gastro-
oesophageal junction were further subdivided according to site, using the Siewert 
classification; Type I and II lesions of the gastro-oesophageal junction were designated, as 
cancers of the oesophagus. Type III tumours of the cardia were designated gastric cancers 
(Siewert, Stein 1996) and were therefore excluded from the study.  
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 All patients underwent potentially curative en-bloc resection with lymph-
adenectomy (median 18, range 6–44 nodes resected) and survived at least 30 days 
following surgery. Thirty four patients received neo-adjuvant chemotherapy, mostly in last 
two years of the study period.  Oesophageal cancer patients and Type I gastro-oesophageal 
junctional tumour received 2 cycles of pre operative cisplatin and 5-flurouracil as in the 
MRC OE-O2 study (Medical Research Council Oesophageal Cancer Working Group 
2002).  Type II gastro-oesophageal junctional tumour was treated with 3 cycles of ECF 
(Epirubicin, Cisplatin and 5-Flurouracil).   
 Patients who had clinical evidence of infection or other inflammatory condition 
(e.g. vasculitis, connective tissue disorders, rheumatological conditions) were excluded 
from the study. 
 The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary. 
 
 The coefficient of variation for the routine laboratory measurements of absolute 
white cell, neutrophil, lymphocyte, and platelet counts, albumin and C-reactive protein, 
over the range of measurement, was less than 10% as established by routine quality control 
procedures. The limit of detection of the assay was a C-reactive protein concentration 
lower than 6mg/l.  A C-reactive protein concentration of greater than 10mg/l was 
considered to indicate the presence of a systemic inflammatory response (McMillan et al. 
2001) 
 The mGPS was constructed as previously described (McMillan 2008). An elevated 
C-reactive protein (>10 mg/l) were assigned a modified GPS score (mGPS) of 1 or 2 
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depending on the absence or presence of hypo-albuminaemia (<35g/l). Patients in whom 
neither of these abnormalities was present were allocated a score of 0. 
4.2.1 Statistics 
 The laboratory variables were grouped using standard thresholds (Ikeda et al. 2002, 
McMillan et al. 2001a, Maltoni et al. 2005, Yamanaka et al. 2007). Survival analysis of the 
group variables was performed using the Cox proportional hazard model.  Deaths up to the 
end of February 2010 were included in the analysis.  Multivariate survival analysis, 
including all significant covariates (P≤ 0.05 to account for multiple comparisons) was 
performed using a stepwise backward procedure to derive a final model of the variables 
that had a significant independent relationship with survival.  To remove a variable from 
the model, the corresponding P-value had to be greater than 0.05.  The relationships 
between the mGPS and other variables were analysed using the Mantel–Haenszel (X2) test 
for trend as appropriate.  Analysis was performed using SPSS software (SPSS Inc., 
Chicago IL, USA). 
4.3 Results 
  The relationship between clinico-pathological characteristics, systemic 
inflammatory response and survival in patients with oesophageal cancer is shown in Table 
4-1.  Overall, the majority of patients were less than the age of 65years old (61%), male 
(76%) and had adenocarcinoma (78%).  The majority of patients had TNM stage II or III 
(81%) disease.  The majority of patients had white cell (93%), neutrophil (89%), 
lymphocyte (91%), and platelet (96%) counts in the normal range.  Of the 112 patients 
who underwent a curative resection for oesophageal cancer, only 13 (12%) patients had a 
mGPS of 1 (Table 4-1).   
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 Majority of patients had curative surgery (n=111) except for one patient who had 
pathological T4 disease.  The median follow up of the survivors was 55 months and the 
minimum was 15 months.  During this period 52 (46%) patients died of their cancer and 7 
(6%) patients died of non-cancer causes.  On univariate analysis only TNM stage 
(p=0.001), Tumour differentiation (p=0.001), positive to total lymph node ratio (LNR) 
(p<0.001), adjuvant therapy (p=0.012) and mGPS (p=0.001) were significantly associated 
with cancer specific survival (Table 4-1).  On multivariate analysis, LNR (HR 2.87, 95% 
CI 1.99 - 4.15, p<0.001, Figure 4-1) and mGPS (HR 4.31, 95% CI 2.20 - 8.45, p<0.001, 
Figure 4-2) retained independent significance (Table 4-1). When the lymph node ratio was 
removed from the model TNM stage (HR 2.18, 95% CI 1.40-3.39, p=0.001) retained 
independent prognostic value. In our study only 25 patients had squamous cell carcinoma 
and 87 patients had adenocarcinoma. Only 5 patients had positive mGPS score in 
squamous cell carcinoma group and 8 patients had positive mGPS in adenocarcinoma 
group (Table 4-2).  When patients with adenocarcinomas (n=87, 8 patients with a mGPS of 
1) underwent multivariate survival analysis, only LNR (HR 3.01, 95% CI 1.98-4.57; 
p<0.001) and mGPS (HR 3.72, 95% CI 1.67-8.31; p = 0.001) were independently 
associated with cancer specific survival.   
 The relationship between the mGPS and clinicopathological characteristics in 
oesophageal cancer patients is shown in Table 4-2.  An increase in the mGPS was 
associated with high white cell count (p<0.05).  Patients with mGPS 0 had mean survival 
of 83 months and patients with mGPS 1/ 2 had mean survival of 31 months (p=0.001).  
4.4 Discussion 
 In the present study a comparison of the relationship of a number of cellular 
components of the systemic inflammatory response and cancer specific survival was 
examined in patients undergoing potentially curative resection for oesophageal cancer.  Of 
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the inflammation based prognostic scores, the mGPS, NLR and PLR, only mGPS was 
significantly associated with cancer specific survival and had prognostic value independent 
of pathological TNM stage.   
 These results are consistent with the recent report of Rashid and co-workers (2010) 
that, in 294 patients undergoing oesophageal cancer resection, the pre operative neutrophil 
lymphocyte ratio did not offer useful prognostic value (Rashid et al. 2010).  Moreover 
these results are consistent with previous work that compared the prognostic value of the 
mGPS and NLR in patients undergoing potentially curative resection for colorectal cancer 
(Leitch et al. 2007).  Therefore, it would appear that the systemic inflammation-based 
prognostic scores based on the acute-phase proteins, C-reactive protein and albumin, are 
superior to those based on the cellular components of the white cell count, specifically 
neutrophils, lymphocyte and platelets.  Taken together this would suggest that mGPS has 
superior prognostic value in gastrointestinal cancer and should be used in preference to 
cellular markers of the systemic inflammatory response.   
 The basis of the relationship between the systemic inflammatory response and 
poorer cancer survival in patients with oesophageal cancer is not clear.  However, the 
components of the mGPS are recognised to be associated with cancer cachexia (McMillan 
2008, Morley, Thomas & Wilson 2006, Fearon et al. 2006), compromised cell-mediated 
immunity (Du Clos, Mold 2004, Canna et al. 2005) and upregulation of growth factors and 
angiogenesis (de Jong et al. 2004, Krzystek-Korpacka et al. 2008).  Therefore, the 
mechanisms underlying the relationship between systemic inflammatory responses and 
cancer specific survival are likely to be complex.  These include extrinsic pathways such as 
nutritional and functional decline, immune dysfunction and tumour angiogenesis, growth 
and dissemination. More specifically, recent work in operable colorectal cancer has 
pointed to a strong relationship between poor patient physiology (Richards et al. 2010) 
increased cormorbidity (Roxburgh et al. 2010) and an increased mGPS.  Therefore, it may 
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be that an elevated mGPS, prior to surgery, in patients with oesophageal cancer reflects 
poor patient physiology and comorbidity.  Further studies in oesophageal cancer are 
required to define these relationships. Recently, it has also been proposed that there are 
also intrinsic pathways involved in cancer related inflammation, such as the induction of 
genetic instability by inflammatory mediators, leading to the accumulation of genetic 
alterations in cancer cells and progressive tumour growth and dissemination.  Indeed, a 
recent review proposes that cancer related inflammation represents the seventh hallmark of 
cancer (Colotta et al. 2009).   
 Irrespective of the mechanisms involved, there is now evidence that the mGPS is 
useful in the clinical staging (Crumley et al. 2010a) of oesophageal cancer, predicting the 
response to neoadjuvant chemotherapy (Kobayashi et al. 2008) and, in the present study, 
predicting the response to surgery.  However, the clinical use of the mGPS is as yet not 
clear.  Surgery for oesophageal cancer has a high potential for morbidity and mortality and 
recovery to pre-resectional functional status, if ever reached, can take a year or more.  
Therefore, choosing patients with the highest potential for cure is extremely important.  
With reference to how the mGPS might fit into current pre-operative assessment of these 
patients this remains problematical since currently most surgeons would not deny a 
patients surgery where their tumour was localised.  Very recently, Vashist and coworkers 
have published similar findings (Vashist et al. 2011).  They concluded that ‘Preoperative 
evaluation of the GPS may help to stratify oesophageal cancer patients to different risk 
profiles, which is essential in the era of customized therapy’.  We also concur with this 
view that the mGPS should be evaluated prior to surgery and should be used in the risk 
stratification of patients with oesophageal cancer and could be incorporated into future 
prospective randomised trials of surgery in oesophageal cancer.  Furthermore, with the 
increasing use of neoadjuvant therapy in oesophageal cancer prior to surgery and the 
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consequent reduction in the value of pathological findings, the value of the mGPS in 
clinical staging and predicting outcome will be of increasing importance in these patients. 
 In the present study the positive to total lymph node ratio was also independently 
associated with poorer cancer specific survival.  Moreover the positive to total lymph node 
ratio had superior prognostic value compared to TNM stage. These results are consistent 
with recent studies that this ratio is superior to simply assessing nodal status in predicting 
cancer outcome in patients undergoing curative resection of oesophageal cancer (Mariette 
et al. 2008, Hsu et al. 2009, Dhar et al. 2007, Greenstein et al. 2008).  Further work is 
required to establish whether positive to total lymph node ratio can be used routinely to 
supplant current TNM staging in these patients. 
 In summary, an acute-phase protein-based prognostic score, the mGPS, appears to 
be a superior predictor of cancer survival compared with cellular components of the 
systemic inflammatory response in patients undergoing potentially curative resection for 
oesophageal cancer. 
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Table 4-1: The relationship between clinico-pathological characteristics, the systemic inflammatory response and cancer specific survival in patients 
undergoing potentially curative resection for oesophageal cancer. 
 
 Univariate analysis Multivariate analysis 
 Patients 
(n=112) 
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Tumour related factors      
TNM Stage (I/II/III/IV) 20/39/52/1 2.15 (1.39-3.3) 0.001  0.558 
Tumour type (Adeno/ Squamous) 87/25 0.97 (0.51-1.86) 0.937   
Tumour differentiation (well-mod/poor) 68/44 2.44 (1.41-4.22) 0.001  0.161 
Resection Margin (R0/R1) 86/26 1.67 (0.92-3.01) 0.091   
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 41/43/28 2.65 (1.83-3.83) <0.001 2.87 (1.99-4.15) <0.001 
Neo-adjuvant therapy (yes/no) 34/78 0.87 (0.44-1.71) 0.677   
Adjuvant therapy (yes/no) 17/95 0.40 (0.20-0.82) 0.012  0.817 
      
Patient related factors      
Age (<65/65 –74/≥75 years) 68/38/6 0.99 (0.63-1.55) 0.948   
Sex (male/female) 85/27 0.69 (0.35-1.38) 0.292   
White cell count (<8.5/ 8.5–11/ >11x109 l-1) 84/20/8 1.35 (0.89-2.10) 0.165   
Neutrophil count (<7.5/>7.5x10
9
 l
-1
) 100/12 1.59 (0.75-3.39) 0.231   
Lymphocyte count  
(>3.0/1.0 – 3.0/<1.0x109 l-1) 
4/98/10 0.44 (0.14-1.35) 0.151   
Platelet count (<400/>400x10
3
 l
-1
) 107/5 0.72 (0.17-2.95) 0.644   
Neutrophil/lymphocyte ratio (<2.5/2.5-5/>5) 63/34/15 1.08 (0.75-1.56) 0.686   
Platelet/lymphocyte ratio (<150/150-300/>300) 60/44/8 0.94 (0.60-1.48) 0.781   
mGPS (0/1/2) 99/13/0 3.10 (1.61-5.95) 0.001 4.31 (2.20-8.45) <0.001 
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Table 4-2: The relationship between the mGPS and clinicopathological characteristics and cancer specific survival in patients undergoing potentially curative 
resection for oesophageal cancer (n= 112). 
 mGPS 0  
(n= 99) 
mGPS 1/2 
(n= 13) 
P-value 
Tumour related factors    
TNM Stage (I/ II/ III/ IV) 19/ 32/ 47/ 1 1/ 7/ 5/ 0 0.984 
Tumour (Adeno/ Squamous) 79/ 20 8/ 5 0.139 
Tumour differentiation (well-mod/poor) 63/ 36 5/ 8 0.082 
Resection Margin (R0/R1) 76/ 23 10/ 3 0.990 
Total node retrieved (<15/≥15) 30/69 5/8 0.540 
No of positive node (0/1-2/3-6/>6) 34/28/24/13 7/3/2/1 0.204 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 34/ 39/ 26 7/ 4/ 2 0.187 
Neo-adjuvant therapy (yes/no) 31/ 68 3/ 10 0.546 
Adjuvant therapy (yes/no) 14/ 85 3/ 10 0.401 
Patient related factors    
Age (<65/ 65–74/ >75 years) 62/ 32/ 5 6/ 6/ 1 0.278 
Sex (male/ female) 76/ 23 9/ 4 0.552 
White cell count (<8.5/ 8.5–11/ >11x109 l-1) 77/ 17/ 5 7/ 3/ 3 0.018 
Neutrophil count (<7.5/ >7.5x10
9
 l
-1
) 90/ 9 10/ 3 0.127 
Lymphocyte count (>3.0/ 1.0 – 3.0/ <1.0x109 l-1) 3/ 87/ 9 1/ 11/ 1 0.558 
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* Mantel-Cox Log Rank test 
 
Platelet count (<400/ >400x10
3
 l
-1
) 94/ 5 13/ 0 0.409 
Neutrophil/lymphocyte ratio (<2.5/ 2.5-5/ >5) 57/ 31/ 11 6/ 3/ 4 0.143 
Platelet/lymphocyte ratio (<150/ 150-300/ >300) 52/ 40/ 7 8/ 4/ 1 0.651 
    
Survival in months (mean, 95% CI)  82.7 (70.3-95.1) 30.3 (15.5-45.1) 0.001*
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Figure 4-1: The relationship between the positive to total lymph node ratio ((0, ≤ 0.2 and >0.2 from top to bottom) and cancer-specific survival in patients 
undergoing surgery for oesophageal cancer. 
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Figure 4-2: The relationship between mGPS (0 and 1 from top to bottom) and cancer-specific survival in patients undergoing surgery for oesophageal cancer. 
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5 Chapter V: Comparison of the prognostic value of tumour and 
patient related factors in patients undergoing potentially curative 
resection of gastric cancer 
5.1 Introduction 
 Following curative resection for gastric cancer, pathological analysis of tumour 
related factors guide prognosis and treatment.  A variety of high risk features including 
tumour stage, resection margin and nodal status are considered to be important in 
determining cancer recurrence and survival (Siewert et al. 1998, Setala et al. 1996, Wang 
et al. 2009).  
 It is now increasingly recognised that the outcome for patients with cancer is not 
only determined by tumour related factors but also by host related factors, in particular the 
systemic inflammatory response (McMillan 2009, Roxburgh, McMillan 2010).  With 
reference to the gastric cancer an elevated C-reactive protein concentration prior to surgery 
has been reported to have independent prognostic value (Wang, Sun 2009, Chang et al. 
2010).  
 From such work a number of systemic inflammation based prognostic scores have 
been proposed to simplify and standardise the measurement of the systemic inflammatory 
response in routine clinical practice.  These include the modified Glasgow Prognostic 
Score (mGPS), the Neutrophil Lymphocyte Ratio (NLR) and the Platelet Lymphocyte 
Ratio (PLR) all of which have been reported to be independent predictors of survival in 
gastrointestinal cancer (McMillan 2009).  
 Recently, Crumley and co-workers (Crumley et al. 2010a) reported that the mGPS 
improved the pre treatment clinical staging of patients who presented with gastro-
oesophageal cancer thus aiding clinical decision making in these difficult to treat patients.  
More specifically Nozoe and coworkers have recently reported that the mGPS has 
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prognostic value in operable gastric cancer (Nozoe et al. 2011).  An elevated platelet count 
(Ikeda et al. 2002) and neutrophil lymphocyte ratio (Mohri et al. 2010) have also been 
shown to have prognostic value in patients with gastric cancer.   
 In terms of patients who have undergone potentially curative surgery the relative 
prognostic value of the mGPS, NLR and PLR is not clear.  More specifically, it is not clear 
which of these scores best predicts survival in gastric cancer.  Therefore, the aim of the 
present study was to compare the prognostic value of selected markers of the systemic 
inflammatory response together with tumour related factors in patients undergoing 
potentially curative resection for gastric cancer. 
5.2 Patients and Methods 
 One hundred and twenty patients undergoing potentially curative resection of 
gastric cancer (including type III tumours of the gastro-oesophageal junction (Siewert, 
Stein 1996)) in the upper GI surgical unit, Glasgow Royal Infirmary between January 1996 
and May 2009 were included in the study.  Patients had laboratory measurements of white 
cell, neutrophil, lymphocyte and platelet counts, albumin and C-reactive protein in the few 
days prior to surgery as part of their routine work up, irrespective of whether or not they 
had received neo-adjuvant chemotherapy.  
 The tumours were staged according to the tumour node metastasis (TNM) Criteria 
from the 6
th
 edition of the International Union Against Cancer (UICC) Classification of the 
Malignant Tumours (Sobin, Wittekind & editors. April 2002).  Tumours of the gastro-
oesophageal junction were further subdivided according to site, using the Siewert 
classification; Type I and II lesions of the gastro-oesophageal junction were designated, as 
cancers of the oesophagus and were therefore excluded from the study. Type III tumours of 
the cardia were designated as gastric cancers (Siewert, Stein 1996). Furthermore patients 
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only with TNM stage I to III tumours were considered amenable to curative surgical 
resection and included in the study.  
 All patients underwent potentially curative en-bloc resection with majority of them 
had D2 lymph-adenectomy and survived at least 30 days following surgery.  Forty six 
patients received neo-adjuvant chemotherapy, mostly in last two years of study period. 
Gastric cancer patients (including type III gastro-oesophageal junctional tumour patients) 
received 3 cycles of pre operative and post-operative epirubicin, cisplatin and 5-flurouracil 
(ECF) (the MRC Adjuvant Gastric Infusional Chemotherapy; MAGIC trial) (Cunningham 
et al. 2006).  
 Patients who had clinical evidence of infection or other inflammatory condition 
(e.g. vasculitis, connective tissue disorders, rheumatological conditions) were excluded 
from the study. 
 The study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary. 
 The coefficient of variation for the routine laboratory measurements of absolute 
white cell, neutrophil, lymphocyte, and platelet counts, albumin and C-reactive protein, 
over the range of measurement, was less than 10% as established by routine quality control 
procedures. The limit of detection of the assay was a C-reactive protein concentration 
lower than 6 mg/l.  A C-reactive protein concentration of greater than 10 mg/l was 
considered to indicate the presence of a systemic inflammatory response (McMillan et al. 
2001) 
 The mGPS was constructed as previously described (McMillan 2008). Patients with 
an elevated C-reactive protein (>10 mg/l) were assigned a modified GPS score (mGPS) of 
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1 or 2 depending on the absence or presence of hypo-albuminaemia (<35 g/l). Patients in 
whom neither of these abnormalities was present were allocated a score of 0. 
5.2.1 Statistics 
 The laboratory variables were grouped using standard thresholds (Ikeda et al. 2002, 
McMillan et al. 2001, Maltoni et al. 2005, Yamanaka et al. 2007).  Survival analysis of the 
group variables was performed using the Cox proportional hazard model.  Deaths up to the 
end of January 2011 were included in the analysis.  Multivariate survival analysis, 
including all significant covariates (P≤ 0.05) was performed using a stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival.  To remove a variable from the model, the corresponding P-
value had to be greater than 0.05.  The relationships between the mGPS and other variables 
were analysed using the Mantel–Haenszel (X2) test for trend as appropriate.  Analysis was 
performed using SPSS software (SPSS Inc., Chicago IL, USA). 
5.3 Results 
 The relationship between clinico-pathological characteristics, systemic 
inflammatory response and survival in patients with gastric cancer is shown in Table 5-1.  
Overall, the majority of patients were older than 65 years (59%) and male (65%).  The 
majority of patients had white cell (93%), neutrophil (94%), lymphocyte (94%) and 
platelet (93%) counts in the normal range. Of the 120 patients who underwent a curative 
resection for gastric cancer, only 18 (15%) patients had mGPS 1 and 5 (4%) had mGPS of 
2.  
 The median follow up of the survivors was 55 months and the minimum was 17 
months. During this period 44 (37%) patients died of their cancer and 7 (6%) patients died 
of non cancer causes.  On univariate survival analysis only TNM stage (p<0.001), tumour 
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differentiation (p<0.01), resection margin (p<0.05), positive to total lymph node ratio 
(p<0.001) and mGPS (p<0.001) were significantly associated with cancer specific survival 
(Table 5-1).  On multivariate analysis, positive to total lymph node ratio (HR 2.29, 95% CI 
1.57- 3.33, p<0.001, Figure 5-1) and mGPS (HR 2.23, 95% CI 1.40-3.54, p=0.001, Figure 
5-2) retained independent significance (Table 5-1).  
 The relationship between the mGPS and clinico-pathological characteristics in 
gastric cancer patients is shown in Table 5-2.  An increase in the mGPS was associated 
with higher neutrophil lymphocyte ratio (p<0.05).  Patients with mGPS 0 had mean 
survival of 116.4 months and patients with mGPS 1 and 2 had mean survival of 37.7 and 
21.2 months respectively (p<0.001).  
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5.4 Discussion 
 In the present study a comparison of the relationship of a number of cellular 
components of the systemic inflammatory response and cancer specific survival was 
examined in patients undergoing potentially curative resection for gastric cancer.  Of the 
inflammation based prognostic scores, the mGPS, NLR and PLR, only mGPS was 
significantly associated with cancer specific survival and had prognostic value independent 
of pathological TNM stage.   
 In the present study when those patients who did not receive pre-operative 
chemotherapy were compared to those who did received pre-operative chemotherapy, the 
latter group were more likely to have had higher TNM stage (P<0.001), a higher positive to 
total lymph node ratio (p=0.001) and a positive resection margin (p<0.05).  In contrast, the 
patient related factors and survival were similar between the groups (separate analysis 
performed, result not shown).  Given that pre-operative chemotherapy has been used more 
often in recent years, the period of follow-up was shorter in those patients who received 
neo-adjuvant therapy.  Therefore, in the present study it is as yet unclear whether neo-
adjuvant chemotherapy impacts on survival in patients undergoing gastric cancer surgery.  
Indeed, there are various conflicting reports on benefit of neo-adjuvant chemotherapy in 
gastric cancer (Janunger, Hafstrom & Glimelius 2002, Earle et al. 2002) 
 The results of the present study are in apparent contradiction to the recent study of 
Mohri and colleagues (2010) who reported that the NLR was superior to the individual 
components of the mGPS, namely C-reactive protein and albumin(Mohri et al. 2010).  
However, they used a non-standard threshold for C-reactive protein (<3/ >3mg/l), a fact 
that was noted in the invited comment on the paper of Mohri et al, specifically “Therefore, 
a minimal elevation in C-reactive protein might have a less significant impact on outcome 
than a definitive elevation” (Yamashita, Katai 2010).  This has recently also been noted by 
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Nozoe and coworkers (Nozoe et al. 2011).  Therefore, the results of the present study 
confirm the above suspicion and show that the combination C-reactive protein and 
albumin, using the established thresholds in the mGPS, has superior prognostic value to 
that of the NLR in patients undergoing potentially curative resection of gastric cancer.  
They also agree with previous work that compared the prognostic value of the mGPS and 
NLR in patients undergoing potentially curative resection for oesophageal (Chapter 4) and 
colorectal cancer (Leitch et al. 2007).  In the present study the number of patients with an 
mGPS score of 2 and at most risk of increased recurrence and poor survival was small.  
However, the very poor outcome of those patients with a mGPS of 2 are in accord with a 
larger series of patients undergoing surgery for oesophageal cancer (Vashist et al. 2011) 
and would suggest that a mGPS of  2 in patients undergoing surgery for gastric cancer is of 
clinical importance. 
 The above, taken together, would support the contention that the mGPS based on 
the acute-phase proteins, C-reactive protein and albumin, is superior to those based on the 
cellular components of the white cell count, specifically neutrophils, lymphocyte and 
platelets.  It is our opinion that the mGPS should be used in preference to cellular markers 
of the systemic inflammatory response in determining likely outcome in patients 
undergoing surgery for gastrointestinal cancer.   
 The basis of the relationship between the systemic inflammatory response and 
poorer cancer survival in patients with gastric cancer is not clear.  However, the 
components of the mGPS are recognised to be associated with cancer cachexia and loss of 
lean tissue (McMillan 2008, Morley, Thomas & Wilson 2006, Fearon et al. 2006), 
compromised cell-mediated immunity (Du Clos, Mold 2004, Canna et al. 2005) and 
upregulation of growth factors and angiogenesis (de Jong et al. 2004, Krzystek-Korpacka 
et al. 2008).   
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 Therefore, the mechanisms underlying the relationship between systemic 
inflammatory responses and cancer specific survival are likely to be complex.  These 
include extrinsic pathways such as nutritional and functional decline, immune dysfunction 
and tumour angiogenesis, growth and dissemination.  More specifically, recent work in 
operable colorectal cancer has pointed to a strong relationship between poor patient 
physiology (Richards et al. 2010) increased comorbidity (Roxburgh et al. 2010) and an 
increased mGPS.  Therefore, it may be that an elevated mGPS, prior to surgery, in patients 
with gastric cancer reflects poor patient physiology and co-morbidity.  Indeed, Kerem and 
coworkers (2008) reported that the mGPS was associated with weight loss and adipokines 
(Kerem et al. 2008).  
 Irrespective of the mechanisms involved, there is now evidence that the mGPS or 
its component proteins are useful in the clinical staging (Crumley et al. 2010a) of gastric 
cancer, predicting the response to adjuvant chemotherapy (Hashimoto et al. 2010) and, in 
the present study, predicting the response to surgery.   
 However, the clinical use of the mGPS in patients with primary operable gastric 
cancer is as yet not clear. It is of interest that the mGPS gives a pre-operative risk 
assessment whereas the lymph node ratio gives a post-operative risk assessment.  Although 
an elevated pre-operative mGPS would not preclude surgery it would identify the patient at 
high risk of recurrence and therefore would point to more careful tumour staging and 
follow-up of the patient and the need for neo and/ or adjuvant treatment (Clarke et al. 
2011)”.   
 The positive to total lymph node ratio was also independently associated with 
poorer cancer specific survival in the present study.  Moreover the positive to total lymph 
node ratio had superior prognostic value compared to TNM stage. These results are 
consistent with recent studies that this ratio is superior to simply assessing nodal status in 
 
 149 
 149 
predicting cancer outcome in patients undergoing curative resection of gastric cancer 
(Deng et al. 2009, Fukuda et al. 2009, Marchet et al. 2007).  Further work is required to 
establish whether positive to total lymph node ratio can be used routinely to supplant 
current TNM staging in these patients. 
 In summary, an acute-phase protein-based prognostic score, the mGPS, was a 
superior predictor of cancer survival compared with cellular components of the systemic 
inflammatory response in patients undergoing potentially curative resection for gastric 
cancer. 
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Table 5-1: The relationship between clinico-pathological characteristics, the systemic inflammatory response and cancer specific survival in patients 
undergoing potentially curative resection for gastric cancer. 
 Univariate analysis Multivariate analysis 
 Patients 
(n=120) 
Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Tumour related factors      
TNM Stage (I/II/III) 56/27/37 2.30 (1.60-3.31) <0.001  0.209 
Tumour differentiation (well-mod/poor) 69/51 2.33 (1.27-4.29) 0.006  0.210 
Resection Margin (R0/R1) 106/14 2.46 (1.07-5.66) 0.034  0.943 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 67/32/21 2.37(1.64-3.42) <0.001 2.29 (1.57-3.33) <0.001 
Neo-adjuvant therapy (yes/no) 46/74 1.59 (0.77-3.29) 0.208   
      
Patient related factors      
Age (<65/65 –74/≥75 years) 49/51/20 1.38 (0.92-2.09) 0.124   
Sex (male/female) 78/42 1.07 (0.57-2.00) 0.830   
White cell count (<8.5/ 8.5–11/ >11x109 l-1) 87/25/8 0.99 (0.61-1.62) 0.973   
Neutrophil count (<7.5/>7.5x10
9
 l
-1
) 113/7 0.60 (0.14-2.48) 0.477   
Lymphocyte count  
(>3.0/1.0 – 3.0/<1.0x109 l-1) 
5/108/7 0.71 (0.27-1.87) 0.489   
Platelet count (<400/>400x10
3
 l
-1
) 111/9 0.50 (0.12-2.08) 0.343   
Neutrophil/lymphocyte ratio (<2.5/2.5-5/>5) 64/47/9 1.19 (0.76-1.87) 0.454   
Platelet/lymphocyte ratio (<150/150-300/>300) 61/53/6 0.83 (0.49-1.40) 0.483   
mGPS (0/1/2) 97/18/5 2.40 (1.53-3.77) <0.001 2.23 (1.40-3.54) 0.001 
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Table 5-2: The relationship between the mGPS and clinicopathological characteristics and cancer specific survival in patients undergoing potentially curative 
resection for gastric cancer (n= 120). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* Mantel-Cox Log Rank test 
 mGPS 0  
(n= 97) 
mGPS 1 
(n= 18) 
mGPS 2 
(n=5) 
P-value 
Tumour related factors     
TNM Stage (I/ II/ III) 47/23/27 6/4/8 3/0/2 0.363 
Tumour differentiation (well-mod/poor) 58/39/97 8/10 3/2 0.451 
Resection Margin (R0/R1) 87/10 15/3 4/1 0.338 
Total node retrieved (<15/≥15) 36/61 4/14 ¼ 0.182 
No of positive node (0/1-2/3-6/>6) 56/17/17/7 8/4/3/3 3/0/1/1 0.255 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 56/52/16 8/6/4 3/1/1 0.526 
Neo-adjuvant therapy (yes/no) 38/59 5/13 3/2 0.922 
     
Patient related factors     
Age (<65/ 65–74/ >75 years) 42/38/17 6/10/2 1/3/1 0.494 
Sex (male/ female) 65/32 12/6 ¼ 0.108 
White cell count (<8.5/ 8.5–11/ >11x109 l-1) 72/20/5 12/4/2 3/1/1 0.189 
Neutrophil count (<7.5/ >7.5x10
9
 l
-1
) 92/5 16/2 5/0 0.781 
Lymphocyte count (>3.0/ 1.0 – 3.0/ <1.0x109 l-1) 3/99/5 1/15/2 1/4/0 0.410 
Platelet count (<400/ >400x10
3
 l
-1
) 91/6 15/3 5/0 0.544 
Neutrophil/lymphocyte ratio (<2.5/ 2.5-5/ >5) 56/38/3 5/7/6 3/2/0 0.028 
Platelet/lymphocyte ratio (<150/ 150-300/ >300) 49/46/2 9/5/4 3/2/0 0.581 
     
Survival in months (mean, 95% CI)  116.4 (99.4-133.4) 37.7 (24.6-50.7) 21.2 (9.0-33.4) <0.001* 
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Figure 5-1: The relationship between positive to total lymph node ratio ((0, ≤ 0.2 and >0.2 from top to bottom) and cancer-specific survival in patients 
undergoing surgery for gastric cancer. 
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Figure 5-2: The relationship between mGPS (0, 1 and 2 from top to bottom) and cancer-specific survival in patients undergoing surgery for gastric cancer. 
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6 Chapter VI: The relationship between tumour necrosis, tumour 
proliferation, local and systemic inflammation, microvessel density 
and survival in patients undergoing potentially curative resection of 
oesophageal adenocarcinoma 
6.1 Introduction 
 It is increasingly recognised that outcomes for patients with cancer are determined 
by host as well as tumour-related factors. Host-related factors include local and systemic 
inflammatory responses (McMillan 2009, Roxburgh, McMillan 2010, Hanahan, Weinberg 
2011, Colotta et al. 2009) and an increased systemic inflammatory response prior to 
surgery is an independent prognostic factor of survival following resection of oesophageal 
cancer (Nozoe, Saeki & Sugimachi 2001, Ikeda et al. 2003, Shimada et al. 2003, Gockel et 
al. 2006).  For example, on a comprehensive examination of the prognostic value of both 
tumour and patient related factors, only mGPS and positive to total lymph node ratio 
(LNR) were independent predictors of cancer specific survival in oesophageal cancer 
(Chapter 4). 
 With reference to the local inflammatory response, a pronounced tumour 
inflammatory cell infiltrate of gastro-oesophageal carcinomas (assessed on haematoxylin 
and eosin stained sections) has been reported to be associated with improved survival (Ma 
et al. 1994).   It is of interest therefore, that Klintrup, Makinen and colleagues reported a 
simplified subjective assessment of the inflammatory infiltrate at the invasive margin of 
colorectal cancer, including all inflammatory cell types and classifying the infiltrate as low 
or high grade, had independent prognostic value (Klintrup et al. 2005). This method, in 
addition to being validated in an independent cohort of colorectal cancer patients 
(Roxburgh et al. 2009a, Roxburgh et al. 2009b), has also been validated in patients with 
gastro-oesophageal cancer (Crumley et al. 2011).   
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 More specifically, CD8+ T-lymphocytes have been reported to provide prognostic 
information in oesophageal cancer (Cho et al. 2003, Schumacher et al. 2001).  Also, 
tumour associated macrophages (CD68+) may have prognostic value in oesophageal 
cancer (Guo et al. 2007, Koide et al. 2002).   Therefore, it would appear that the type, 
density and location of tumour inflammatory cells are important in determining cancer 
outcome in these patients.  However, to date the few reports e.g. Crumley and coworkers 
(2011) have been in heterogeneous cohorts of patients including esophageal, junctional, 
and gastric sites and squamous and adeno carcinomas.  Therefore, the prognostic value of 
measures of the local inflammatory response in patients with oesophageal cancer, in 
particular in adenocarcinoma, remains to be established. 
 The basis of the relationship between the tumour and local and systemic 
inflammatory responses and outcome is not clear.  However, a plausible hypothesis is that 
rapidly proliferating tumours outgrow their blood supply becoming hypoxic and necrotic 
thereby stimulating both local and systemic inflammatory responses and angiogenesis that, 
in turn, promote tumour progression and metastases (Vakkila, Lotze 2004, Degenhardt et 
al. 2006). Indeed, it has been reported that high tumour proliferative activity is associated 
with poorer survival in oesophageal cancer (Imdahl et al. 2000).  Also, Elpek et al and 
colleagues have reported that CD34+ positive intra tumoral microvessel density was 
associated with poorer survival in oesophageal squamous cell cancer (Elpek et al. 2001).  
Finally, consistent with the above hypothesis is the report that tumour proliferative activity 
was associated with tumour angiogenesis in oesophageal squamous cell cancer (Nomiya et 
al. 2004, Li et al. 2008). 
 Although, the histological evidence of tumour necrosis is recognised to be 
associated with decreased survival in other gastrointestinal malignancies such as pancreas 
and colorectal cancers (Hiraoka et al. 2010, Pollheimer et al. 2010, Richards et al. 2011).   
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To our knowledge the prognostic of value of tumour necrosis in patients with oesophageal 
cancer, either squamous or adeno carcinoma, has not been previously reported.   
 The aim of the present study was to examine the relationship between tumour 
necrosis, tumour proliferation, local and systemic inflammatory responses and microvessel 
density and survival in patients undergoing potentially curative resection of oesophageal 
adenocarcinoma. 
6.2 Patients and Methods 
 One hundred and twenty one patients undergoing potentially curative resection for 
oesophageal carcinoma at Glasgow Royal Infirmary between January 1996 and May 2009 
were included.   
 Carcinomas were staged according to the tumour node metastasis (TNM) criteria, 
6
th
 edition of the International Union Against Cancer (UICC) Classification (Sobin, 
Wittekind & editors. April 2002).  Tumours of the gastro-oesophageal junction were 
further subdivided by site, using the Siewert classification; Type I and II lesions of the 
gastro-oesophageal junction were designated oesophageal cancers and included in this 
study, while type III tumours of the cardia were designated gastric cancer and therefore 
excluded (Siewert, Stein 1996). Only TNM stage I - III tumours were considered amenable 
to curative surgical resection and included in the study.  
 All patients underwent potentially curative en-bloc lymph-adenectomy and 
survived at least 30 days following surgery. Forty-seven patients received neo-adjuvant 
chemotherapy, mostly in last three years of the study period. Oesophageal cancer patients 
and Type I gastro-oesophageal junctional tumour received 2 cycles of pre-operative 
cisplatin and 5-flurouracil as in the MRC OE-O2 study (Medical Research Council 
 
 157 
 157 
Oesophageal Cancer Working Group 2002).  Type II gastro-oesophageal junctional tumour 
was treated with 3 cycles of ECF (Epirubicin, Cisplatin and 5-Flurouracil).   
 This study was approved by the Research Ethics Committee of Glasgow Royal 
Infirmary. 
6.2.1 Biochemical measurements 
 The coefficient of variation for laboratory measurements of albumin and C-reactive 
protein, over the range of measurement, was less than 10% as established by laboratory 
quality control procedures.  The limit of detection of the assay was a C-reactive protein 
concentration lower than 6mg/l.  A C-reactive protein concentration greater than 10mg/l 
was considered to indicate the presence of a systemic inflammatory response (McMillan et 
al. 2001) 
 The mGPS was constructed as previously described (McMillan 2008). An elevated 
C-reactive protein (>10 mg/l) were assigned a modified GPS score (mGPS) of 1 or 2 
depending on the absence or presence of hypo-albuminaemia (<35g/l). Patients in whom 
neither abnormality was present were allocated an mGPS score 0. 
6.2.2 Assessment of tumour necrosis 
 The same routine haematoxylin and eosin slides from the resected tumour 
specimens were used to evaluate tumour necrosis over the entire area of invasive 
carcinoma available.  The scoring method for evaluating necrosis was adapted from a 
previously published protocol (Ikpatt, Ndoma-Egba & Collan 2002) where it was 
subjectively graded into three categories using complete haematoxylin and eosin-stained 
histological sections.  Score 0, absent (no confluent necrosis at all, i.e. only single-cell 
death (apoptosis) identifiable. Score 1, mild: confluent areas of invasive carcinoma cell 
necrosis in fewer than 25% of x40 fields. Score 2, moderate: confluent areas of invasive 
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carcinoma cell necrosis in 25-50% of x40 fields.  Score 3, extensive: Confluent areas of 
invasive carcinoma cell necrosis in >50% of x40 fields.  These scores were aggregated as 
low grade (scores 0 and 1) or high grade (scores 2 and 3) (Figures 6-3 and 6-4 
respectively).  Confluent necrosis was defined as areas of definite death of small or large 
foci of carcinoma cells with some or all of the following features: condensation, darker 
staining, fragmentation or total loss of tumour cell nuclei; increased cytoplasmic 
eosinophilia, loss of cytological detail, granular eosinophilic debris, occasionally with 
calcification.  All cases were scored independently by two observers (SD, JG) blinded to 
clinical outcomes.  In case of disagreement in the score, an agreed score was determined 
by revision of the specimen by both of the observers together in a double headed 
microscope. 
6.2.3 Assessment of Tumour Inflammatory infiltrate 
 The routine haematoxylin and eosin slides from the resected tumour specimens 
were retrieved from the pathology archive and scored as described by Klintrup and 
colleagues (Klintrup et al. 2005).  Tumours were scored based on the appearance at the 
deepest area of tumour invasion on a four point score. A score of 0 indicated that there was 
no increase in the inflammatory cells at the deepest point of the tumours invasive margin; 
score 1 denoted a mild and patchy increase in the inflammatory cells; score 2 denoted a 
prominent inflammatory reaction forming a continuous band at the invasive margin with 
some evidence of destruction of cancer cell islands and score 3 denoted a florid ‘cup-like’ 
inflammatory infiltrate at the invasive edge with frequent destruction of cancer cell islands. 
These scores were then subsequently classified as low grade (scores 0 and 1) or high grade 
(scores 2 and 3) (Figures 6-1 and 6-2 respectively).  All cases were scored independently 
by two observers (SD or AC and JG). Observers were blinded to the clinical outcome of 
the patient.  The inter-observer intraclass correlation coefficient for tumour inflammatory 
infiltrate was 0.81. 
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6.2.4 Tissue micro array (TMA) construction:  
 The routine haematoxylin and eosin slides of the resected tumour specimens along 
with corresponding paraffin blocks were retrieved from the pathology archive for all 
patients in our study group.  A minimum of three representative areas of tumour were 
defined by the researcher (SD) and the pathologist (JG).  Tissue micro arrays were then 
constructed in triplicate cores 0.6-mm in diameter from each tumour which were placed in 
separate TMA blocks (Beecher Scientific, Silver Spring, Maryland , USA) as previously 
described (Kononen et al. 1998).  Sections 2.5 µm thick from each TMA block were 
mounted on silanised glass slides.  These sections were used to perform 
immunohistochemistry for CD8+
 
T cells, CD68+ (tumour-associated macrophages), Ki-67 
(tumour proliferative index) and CD34+ (for microvessel density) (Figure 6-5; A to D 
respectively).  This was performed in the Unit of Experimental Therapeutics, Institute of 
Cancer, College of MVLS University of Glasgow, Western Infirmary, Glasgow. 
6.2.5 Immunohistochemistry 
 Immunohistochemistry of TMA slides was performed using the Dako Envision 
method (Dako, Cambridgeshire, UK).  The primary antibody for CD8+ was monoclonal 
mouse anti-human CD8+, Clone CD8+/144B (DAKO, Glostrup, Denmark) at a dilution of 
1:100 (overnight incubation) and for CD68+ was monoclonal mouse anti-human CD68+, 
Clone PG-M1 (DAKO, Glostrup, Denmark) at a dilution of 1:200 (1 hour incubation).  The 
primary antibody for Ki-67 was monoclonal mouse anti-human Ki-67, Clone MIB-
1(DAKO, Glostrup, Denmark) at a dilution of 1:50 (overnight incubation) and for CD34+ 
was monoclonal mouse anti-human, CD34+ Class II, Clone QBEnd 10 (DAKO, Glostrup, 
Denmark) at a dilution of 1:150 (30 minutes incubation). 
 Cores were dewaxed and rehydrated.  Antigen retrieval was performed by keeping 
the slides in Tris EDTA buffer (pH 8), in pressure cooker for 5 minutes. Endogenous 
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peroxidise was blocked by incubation in 3% hydrogen peroxide for 10 minutes.  The cores 
were then incubated with the normal horse serum at dilution 1:20 for 20 minutes at 25ºC to 
block non- specific binding sites. Respectively primary antibody was added in appropriate 
concentrations.  Sites of binding were detected using the Envision technique (DAKO code 
K5007, Glostrup, Denmark) with DAB (3-3´ diaminobenzidine, Vector code SK 4001, 
USA), a chromogenic substrate, according to the manufacturer’s instruction.  Cores were 
counterstained with haematoxylin, dehydrated and mounted with DPX.  Appropriate 
positive controls were included in each run and negative controls were omission of the 
primary antibody.  
6.2.6 Morphometry 
 For automated image analysis of digitised slides were accessed through the 
Slidepath Image Analysis system and evaluated with the program's nuclear (for Ki-67), 
cytoplasmic (for CD68+) and membranous (for CD8+) scoring algorithm.  
 Individual TMA cores were identified, annotated on the scanned image and 
associated with TMA map entries.  Individual nuclei stained with haematoxylin and/or 
polymerised diaminobenzidine are identified by a thresholding and segmentation algorithm 
which outlines nuclei and separates touching nuclei.  Nuclear size (area) limits can be 
specified to accept or reject individual nuclei to be quantified.  Staining for Ki-67 in each 
nucleus was classified as positive or negative based on the threshold specified by the 
observer.  Pseudo-colours (red/ orange/ yellow/ blue) display these staining intensity 
measurements for individual nuclei, allowing thresholds to be chosen appropriately.  These 
thresholds were chosen using a sample of TMA cores from the whole cohort and once 
chosen were used for analysis over the entire patient cohort without further adjustment.  
For CD68+, intracellular and positive pixel detection algorithm was used and for the 
CD8+, algorithm for thin cell membrane was used.  Each TMA cores were crosschecked 
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by one of the authors (SD) to detect any obvious error.  Moreover, at least 25% of the cases 
were manually scored to produce inter-observer reproducibility.  The inter-observer 
intraclass correlation coefficient values for Ki67, CD68+ and CD8+ were 0.93, 0.87 and 
0.74 respectively.  
 To assess intra tumoural micro-vessel density, immuno-histochemical staining for 
CD34+ was performed.  Quantitative assessment of CD34+ was performed by manual 
counting of CD34+ positive endothelial cells or cluster regardless of whether a vessel 
lumen was seen in each of the TMA cores.  All cores were counted by one of us (SD) and 
at least 25% of the cases were counted by a second observer (ZM) and interclass 
correlation coefficient for CD34+ was 0.83. 
6.2.7 Statistical analysis 
 Survival analysis of the group variables was performed using the Cox proportional 
hazard model including deaths up to the end of May 2011.  Multivariate survival analysis, 
including all covariates with a P value of ≤ 0.1 was performed using a stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival.  To remove a variable from the model, the corresponding P-
value had to be greater than 0.05.  The relationships between the mGPS and other variables 
were analysed using the Mantel–Haenszel (X2) test for trend as appropriate.  Analysis was 
performed using SPSS software (SPSS Inc., Chicago IL, USA). 
6.3 Results 
 One hundred and twenty one patients with oesophageal cancer were included in our 
study (Table 6-1). Overall, the majority of patients were male (81%), less than 65 years of 
age (60%) and had an mGPS of 0 (87%).  Most of the patients had pTNM stage II or III 
(82%), adenocarcinoma (81%), well to moderately differentiated tumour (59%), no 
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resection margin involvement (79%), lymph node involvement (72%) and had high grade 
tumour necrosis (53%).  Twenty seven patients had high grade peri-tumour inflammatory 
infiltrate according to Klintrup-Makinen criteria (22%). The median values for CD8+, 
CD68+ and Ki-67 were 4.7%, 14.5% and 20.3% respectively and for CD34+ the median 
value was 40.  The majority did not receive either neoadjuvant (61%) or adjuvant (85%) 
therapy. 
 The relationship between tumour type (adeno and squamous carcinomas) and 
clinico-pathological characteristics are shown in Table 6-1.  Patients with oesophageal 
adenocarcinoma were more likely to be male (p<0.001), had higher infiltration of CD8+ 
(p<0.001) and CD68+ (p<0.01), had higher TNM stage (p<0.05), had neo-adjuvant therapy 
(p<0.01), and as well as had higher CD34+ positive micro-vessel compared with squamous 
cell carcinoma (p<0.001, Table 6-1).  There was no significant difference in the degree of 
tumour necrosis. 
 Due to the limited number of patients with squamous cancer the relationship 
between clinic-pathological factors and cancer specific survival was examined only in 
those patients with oesophageal adenocarcinomas (n=98, Tables 6-2).  In patients with 
oesophageal adenocarcinoma, the median follow up of survivors was 45 months with a 
minimum of 22 months.  During this period 49 (50%) patients died of their cancer and 4 
(4%) patients died of non-cancer causes.  In patients with oesophageal squamous cell 
carcinoma, median follow up of survivors was 90 months with a minimum of 23 months.  
During this period 11 (48%) patients died of their cancer and 4 (17%) patients died of non-
cancer causes. 
 On univariate analysis, only age (p<0.05), mGPS (p<0.01), TNM stage (p≤0.001), 
tumour differentiation (p≤0.001), resection margin (p<0.10), LNR (p<0.001), Klintrup-
Makinen score (p<0.05), CD8+ (p<0.05), CD68+ (p<0.10) and Ki-67 (p<0.05) were 
 
 163 
 163 
significantly associated with cancer specific survival.  On multivariate analysis, age (HR 
1.93, 95% CI 1.23 – 3.04, p=0.004), mGPS (HR 2.91, 95% CI 1.51-5.62, p=0.001), LNR 
(HR 2.38, 95% CI 1.60-3.52, p<0.001) and CD68+ (HR 1.49, 95% CI 1.02-2.18, p=0.041, 
Figure 6-6) retained independent significance (Table 6-2).  
The relationship between the mGPS and clinicopathological characteristics in 
patients undergoing potentially curative resection for oesophageal adenocarcinoma is 
shown in Table 6-3. There was no association between mGPS and clinic-pathological 
charectristics in this cohort. 
 Interrelationships between clinical and pathological charecteristics are shown in 
Table 6-4.  Male sex was associated with poor tumour differentiation (p<0.01). TNM stage 
was directly associated with poor tumour differentiation (p<0.01), positive resection 
margin (R1) (p<0.001) and LNR(p<0.001).  Poorly differentiated oesophageal 
adenocarcinoma was directly associated with a LNR (p<0.001), inversely with the necrosis 
score (p<0.05) and directly with CD68+ infiltration (p<0.05).  Positive resection margin 
(R1) was directly associated with a LNR(p<0.01) and inversely with CD8+ infiltration 
(p<0.01).  A LNR was directly associated with the Klintrup-Makinen score (p<0.01).  The 
Klintrup-Makinen score was directly associated with CD8+ infiltration (p<0.01).  Tumour 
necrosis was not significantly associated with any tumour measure other than the degree of 
differentiation.  Tumour CD8+ infiltrate was directly associated with CD68+ infiltration 
(p<0.01), CD34+ (p<0.05) and neo-adjuvant therapy (p<0.05).  Tumour CD68+ infiltration 
of the oesophageal adenocarcinoma was directly associated with the Ki-67 proliferation 
index (p<0.001) as well as neo-adjuvant therapy (p<0.01). The tumour Ki-67 proliferation 
index was directly associated with CD34+ micro-vessel density (p=0.05) and neo-adjuvant 
therapy (p<0.001). 
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 Interrelationships between clinical and pathological charecteristics of patents who 
did not receive neo-adjuvant chemotherapy in oesophageal adenocarcinoma are shown in 
Table 6-5 (n=53).  TNM stage was directly associated with poor tumour differentiation 
(p<0.05), positive resection margin (R1) (p=0.001) and LNR(p<0.001).  Poorly 
differentiated oesophageal adenocarcinoma was directly associated with a LNR (p=0.001) 
and directly with CD68+ infiltration (p<0.05).  Positive resection margin (R1) was directly 
associated with a LNR(p<0.05) and inversely with CD8+ infiltration (p<0.05).  A LNR 
was directly associated with the Klintrup-Makinen score (p<0.01) and inversely with 
CD8+ infiltration(p<0.05) .  The Klintrup-Makinen score was directly associated with 
CD8+ infiltration (p<0.05).   
 The relationship between clinic-pathological factors and cancer specific survival 
was examined also in a subgroup of oesophageal adenocarcinoma patients who did not 
receive neo-adjuvant therapy (n=53, Tables 6-6). On univariate analysis, only age 
(p<0.05), mGPS (p≤0.001), TNM stage (p<0.01), tumour differentiation (p<0.05), 
resection margin (p<0.05), LNR (p<0.001), Klintrup-Makinen score (p<0.05), and CD68+ 
(p<0.10) were significantly associated with cancer specific survival.  On multivariate 
analysis, age (HR 2.62, 95% CI 1.27 – 5.39, p=0.009), mGPS (HR 12.71, 95% CI 4.15-
38.94, p<0.001), LNR (HR 3.18, 95% CI 1.77-5.72, p<0.001) and CD68+ (HR 1.88, 95% 
CI 1.12-3.15, p=0.017) retained independent significance. (Table 6-6).  
 When multivariate survival analysis was carried out in those patients with stage III 
adenocarcinoma alone (n=50), only age (HR 1.90, 95%CI 1.14-3.17, p= 0.014) and mGPS 
(HR 2.91, 95%CI 1.12-7.58, p= 0.029) were independently associated with cancer specific 
survival.  None of the markers of inflammatory cell infiltrate, including CD68+ were 
associated with cancer specific survival. 
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6.4 Discussion 
 The results of the present study show that, in patients with oesophageal cancer, the 
extent of the inflammatory infiltrate and angiogenesis was greater in adenocarcinoma 
compared with squamous carcinoma.  Furthermore, within the adenocarcinoma cohort, 
although tumour necrosis was not significantly associated with proliferative activity, 
inflammatory cell infiltrate and angiogenesis, tumour proliferative activity was directly 
associated with the extent of macrophage infiltration.  Also, the generalised inflammatory 
and cytotoxic T-lymphocyte infiltrate were inversely associated with the LNR and 
resection margin respectively.  Moreover, patients with neo-adjuvant therapy had more 
intra tumoral inflammatory cell infiltrate as well as had higher proliferative activity.  When 
the prognostic value of such tissue factors were examined, only the tumour macrophage 
infiltration retained significance.  Taken together these results would suggest that tumour 
necrosis does not link local and systemic inflammatory responses but that the tumour 
inflammatory infiltrate, in particular macrophages, play a role in the control of tumour 
progression and dissemination in patients with oesophageal adenocarcinoma.   
 The present report of tumour necrosis in oesophageal adenocarcinoma is to our 
knowledge unique in the literature and therefore further work is required to establish 
whether it has prognostic value and relationship with patient and tumour related factors in 
oesophageal cancer.  Furthermore, the basis of the differences in the inflammatory cells 
and microvessel density in squamous and adenocarcinomas is not clear.  However, it may 
reflect more aggressive nature of squamous cell carcinoma (Siewert et al. 2001, Stein et al. 
2005).  Irrespective, the results do emphasise the heterogeneous nature of oesophageal 
cancer and may have been a significant confounding factor in previous studies.   
 Given that pre-operative neo-adjuvant chemotherapy might influence the some of 
the clinicopathological characteristics examined in the present study, a subgroup analysis 
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was performed on patients who did not receive neoadjuvant therapy.  Indeed, when 
compared with the no neoadjuvant therapy group, the neoadjuvant therapy group had 
higher Ki-67 proliferation index (p<0.001) and higher densities of both CD8+ T-
lymphocytes (p= 0.016) and CD68+ macrophages (p= 0.004).  In contrast, in the no 
neoadjuvant therapy group alone, the association between higher Ki-67 proliferation index 
and densities of both CD8+ T-lymphocytes and CD68+ macrophages was not significant.  
The basis of this apparent contradiction is not clear however it may suggest that 
neoadjuvant therapy does influence the relationship between Ki-67 proliferation index and 
densities of both CD8+ T-lymphocytes and CD68+ macrophages. 
 The role of Ki67 in oesophageal cancer is also not well established.  It has been 
reported to predict the complete response in oesophageal cancer following chemo-radio 
therapy (Ressiot et al. 2008, Takeuchi et al. 2003).  However, there are some conflicting 
reports on the predictive value of Ki67 on survival in oesophageal squamous cell cancer 
(Youssef et al. 1995, Imdahl et al. 2000, Sarbia et al. 1996).  In the present study, a high 
proliferation index in oesophageal adenocarcinoma was associated with poor outcome (on 
univariate survival analysis) and was also associated with intra-tumoural macrophage 
infiltration (CD68+) and micro-vessel density (CD34+). 
 With reference to the tissue factors examined, the results of the present study are 
consistent with previous literature.  Cho and colleagues have reported the prognostic value 
of CD8+ lymphocyte in 122 patients with oesophageal squamous cell carcinoma(Cho et al. 
2003).  Similarly Tsuchikawa and coworkers reported the prognostic significance of CD8+ 
lymphocytes in 98 patrients with oesophageal squamous cell carcinoma. (Tsuchikawa et al. 
2011).  In contrast, in another study involving 130 patients with oesophageal 
adenocarcinoma, CD8+ lymphocyte was not associated with survival (Zingg et al. 2010).  
Moreover, tumour associated macrophages (CD68+) had been reported to have 
independent prognostic value in oesophageal cancer (Guo et al. 2007, Koide et al. 2002).  
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Indeed, Koide and coworkers reported, in 56 patients, that the CD68+ macrophage 
infiltrate was associated with tumour proliferation index (Ki67) and disease progression in 
oesophageal squamous cell cancer (Koide et al. 2002)  Also, Guo and coworkers (2007) 
reported that, 137 patients with oesophageal squamous carcinoma, a high tumour 
macrophage infiltrate and a low lymphocytic infiltrate were associated with poor outcome.  
However, that the high tumour macrophage infiltrate had superior prognostic value.  In the 
present study, the relationships between tumour necrosis, tumour proliferation, intra 
tumoral inflammatory cell infiltrates and microvessel density and survival in patients 
undergoing potentially curative resection of oesophageal adenocarcinoma was examined.  
Given that, of the tumour inflammatory cell infiltrate, the macrophages were most closely 
associated with survival, it would be of interest to examine the phenotype (eg. M1 and M2) 
of the macrophages in detail, in patients with oesophageal adenocarcinoma.  
 In the context of the present results it is also important to acknowledge that, that 
there is some recent evidence that CD68+ can be expressed on non-myeloid cells including 
carcinomas (Gottfried et al. 2008).  Indeed, Gottfried and coworkers (2008) concluded that 
CD68+ is not a selective macrophage marker but rather a lysosomal protein that is enriched 
in macrophages.  In the present study the morphology of the cell type was clearly 
considered during the assessment of CD68+ expression and, although unlikely, it is 
conceivable that the results of the present study may be have been influenced by 
expression of CD68 by non-macrophages cells.  Further work is required to examine the 
extent of possible confounding in the present study. 
 It was of interest therefore, in the present study, that CD68+ macrophages was 
strongly associated with CD8
 
+ T lymphocytes and tumour proliferative index (Ki67) in 
oesophageal adenocarcinoma.  Taken together with the other results above, this would 
suggest that high tumour lymphocytic infiltrate prevents tumour progression and a high 
tumour macrophage infiltration promotes tumour proliferation.  Given that they are both 
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generally increased together it is likely that the balance of these inflammatory cells 
determines whether there is tumour progression.  However, more work is required to be 
undertaken to better define these relationships in oesophageal adenocarcinoma. 
  In summary, of the tissue based factors examined in the present study, tumour 
macrophage infiltration appeared to play a central role in the proliferative activity and the 
coordination of the inflammatory cell infiltrate and was independently associated with poor 
outcome in patients with oesophageal adenocarcinoma. 
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Table 6-1: Clinico-pathological characteristic of patients undergoing potentially curative 
resection for oesophageal cancer (n=121) 
 
 
*
Log rank test(Mantel- Cox) 
 
 Adeno 
(n=98) 
Squamous 
(n=23) 
P value 
Patient related factors    
Age (<65/65 –74/≥75 years) 57/35/6 15/6/2 0.755 
Sex (Male/ Female) 83/15 10/13 <0.001 
mGPS (0/1/2) 87/9/2 18/5/0 0.362 
Klintrup-Makinen score  
(Low grade/ High grade) 
77/21 17/6 0.591 
CD8+ tertiles (1/2/3) 25/39/34 17/5/1 <0.001 
CD68+ tertiles (1/2/3) 25/35/38 12/9/2 0.002 
    
Tumour related factors    
TNM Stage (I/II/III) 15/33/50 7/11/5 0.011 
Tumour differentiation (well-mod/poor) 60/38 11/12 0.251 
Resection Margin (R0/R1) 75/23 20/3 0.399 
LNR 
(0/≤ 0.2/>0.2) 
35/35/28 11/9/3 0.132 
Necrosis Score (Low grade/ High grade) 48/50 9/14 0.488 
Ki67 tertiles (1/2/3) 34/29/35 5/8/10 0.284 
CD34+ tertiles (1/2/3) 26/33/39 15/8/0 <0.001 
Neo-adjuvant therapy (no/yes) 53/45 21/2 0.001 
Adjuvant therapy (no/yes) 81/17 22/1 0.191 
    
Alive 45 8  
Cancer specific death 49 11  
Non cancer death 4 4 0.893
* 
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Table 6-2: Relationships between clinic-pathological factors and cancer specific survival, in patients selected for potentially curative resection for 
oesophageal adeno-carcinoma (n=98) 
 Univariate analysis Multivariate analysis 
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Patient related factors     
Age (<65/65 –74/≥75 years)  1.69 (1.11-2.59) 0.016 1.93 (1.23-3.04) 0.004 
Sex (male/female) 0.47 (0.17-1.31) 0.148   
mGPS (0/1/2) 2.39 (1.36-4.18) 0.002 2.91 (1.51-5.62) 0.001 
     
Tumour related factors     
TNM Stage (I/II/III) 2.27 (1.42-3.64) 0.001  0.345 
Tumour differentiation (well-mod/poor) 2.52 (1.43-4.44) 0.001  0.202 
Resection Margin (R0/R1) 1.80 (0.99-3.29) 0.053  0.805 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 2.47 (1.71-3.58) <0.001 2.38 (1.60-3.52) <0.001 
Neo-adjuvant therapy (no/yes) 1.39 (0.74-2.61) 0.304   
Adjuvant therapy (no/yes) 1.74 (0.83-3.65) 0.141   
     
Klintrup-Makinen score (Low / High grade) 0.35 (0.15-0.82) 0.016  0.076 
Necrosis score (Low / High grade) 1.12 (0.64-1.97) 0.695   
CD8 tertiles (1/2/3) 0.69 (0.48-0.99) 0.048  0.697 
CD68 tertiles (1/2/3) 1.38 (0.99-1.94) 0.061 1.49 (1.02-2.18) 0.041 
Ki67 tertiles (1/2/3) 1.46 (1.01-2.12) 0.048  0.479 
CD34 tertiles (1/2/3) 0.94 (0.67-1.34) 0.736   
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Table 6-3: The relationship between the mGPS and clinicopathological characteristics in patients undergoing potentially curative resection for 
oesophageal adenocarcinoma (n= 98). 
 
 mGPS 0  
(n= 87) 
mGPS 1&2 
(n= 11) 
P value 
Patient related factors    
Age (<65/65 –74/≥75 years)  53/28/6 4/7/0 0.368 
Sex (male/female) 75/12 8/3 0.222 
    
Tumour related factors    
TNM Stage (I/II/III) 14/29/44 1/4/6 0.812 
Tumour differentiation (well-mod/poor) 55/32 5/6 0.207 
Resection Margin (R0/R1) 68/19 7/4 0.236 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 30/32/25 5/3/3 0.628 
Neo-adjuvant therapy (no/yes) 47/40 6/5 0.615 
Adjuvant therapy (no/yes) 73/14 8/3 0.290 
    
Klintrup-Makinen score (Low / High grade) 68/19 9/2 0.568 
Necrosis score (Low / High grade) 44/43 4/7 0.286 
CD8 tertiles (1/2/3) 20/34/33 5/5/1 0.038 
CD68 tertiles (1/2/3) 22/31/34 3/4/4 0.853 
Ki67 tertiles (1/2/3) 31/25/31 3/4/4 0.736 
CD34 tertiles (1/2/3) 21/32/34 5/1/5 0.563 
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Table 6-4: Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for 
oesophageal adenocarcinoma (n=98). 
 
 
 
 Sex mGPS TNM 
Stage  
 
Tumour 
differenti
ation  
Resection 
Margin  
LNR Klintrup- 
Makinen 
score 
Necrosis 
score 
CD8 
tertiles 
CD68 
tertiles 
Ki67 
tertiles 
CD34 
tertiles 
Neo-
adjuvant 
therapy 
Age  in years (<65/ 65-74/ >75 years ) 0.199 0.248 0.688 0.939 0.991 0.586 0.977 0.505 0.510 0.749 0.110 0.923 0.639 
Sex (male/ female)  0.155 0.605 0.008 1.00 0.170 0.302 0.091 0.609 0.203 0.813 0.693 0.400 
mGPS   0.823 0.616 0.569 0.328 0.894 0.228 0.243 0.838 0.311 0.723 0.988 
TNM Stage (I/ II/ III)    0.008 <0.001 <0.001 0.403 0.754 0.203 0.593 0.430 0.081 0.420 
Tumour differentiation (well-mod/poor)     1.00 <0.001 0.322 0.012 0.422 0.024 0.655 0.922 0.838 
Resection Margin (R0/R1)      0.004 0.144 0.344 0.004 0.362 0.307 0.719 0.242 
LNR       0.009 0.388 0.093 0.332 0.293 0.168 0.417 
Klintrup-Makinen score (Low / High grade)        1.00 0.002 0.078 0.105 0.813 1.00 
Necrosis score (Low / High grade)         0.219 0.724 0.140 0.109 0.839 
CD8 tertiles (1/2/3)          0.002 0.051 0.044 0.016 
CD68 tertiles (1/2/3)           <0.001 0.994 0.004 
Ki67 tertiles (1/2/3)            0.050 <0.001 
CD34 tertiles (1/2/3)             0.261 
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Table 6-5:  Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for 
oesophageal adenocarcinoma without neo-adjuvant therapy (n=53). 
 
 
 Sex mGPS TNM 
Stage  
 
Tumour 
differenti
ation  
Resection 
Margin  
LNR Klintrup- 
Makinen 
score 
Necrosis 
score 
CD8 
tertiles 
CD68 
tertiles 
Ki67 
tertiles 
CD34 
tertiles 
Age  in years (<65/ 65-74/ >75 years ) 0.131 0.262 0.706 0.978 0.674 0.412 0.991 0.266 0.951 0.753 0.375 0.952 
Sex (male/ female)  0.545 0.654 0.070 0.706 0.259 0.416 0.302 0.615 0.580 0.433 0.726 
mGPS   0.624 0.645 0.988 0.085 0.697 0.833 0.661 0.440 0.454 0.806 
TNM Stage (I/ II/ III)    0.034 0.001 <0.001 0.325 0.380 0.169 0.229 0.503 0.183 
Tumour differentiation (well-mod/poor)     1.00 0.001 0.503 0.053 0.906 0.028 0.740 0.849 
Resection Margin (R0/R1)      0.011 0.149 0.074 0.032 0.347 0.789 0.726 
LNR       0.008 0.921 0.042 0.076 0.198 0.318 
Klintrup-Makinen score (Low / High grade)        0.509 0.011 0.722 0.160 0.412 
Necrosis score (Low / High grade)         0.485 0.359 0.051 0.685 
CD8 tertiles (1/2/3)          0.083 0.570 0.799 
CD68 tertiles (1/2/3)           0.259 0.709 
Ki67 tertiles (1/2/3)            0.507 
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 Table 6-6: Relationships between clinico-pathological factors and survival, in patients selected for potentially curative resection for oesophageal 
adeno-carcinoma without neo-adjuvant therapy (n=53) 
 
 Univariate analysis Multivariate analysis 
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Patient related factors     
Age (<65/65 –74/≥75 years)  2.07 (1.13-3.77) 0.018 2.62 (1.27-5.39) 0.009 
Sex (male/female) 0.77 (0.27-2.21) 0.625   
mGPS (0/1/2) 4.14 (1.80-9.51) 0.001 12.71 (4.15-38.94) <0.001 
     
Tumour related factors     
TNM Stage (I/II/III) 2.46 (1.34-4.49) 0.004  0.246 
Tumour differentiation (well-mod/poor) 2.35 (1.13-4.92) 0.023  0.552 
Resection Margin (R0/R1) 2.13 (1.02-4.49) 0.046  0.607 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 2.45 (1.55-3.89) <0.001 3.18 (1.77-5.72) <0.001 
Adjuvant therapy (no/yes) 2.45 (0.83-7.22) 0.105   
     
Klintrup-Makinen score (Low / High grade) 0.28 (0.08-0.92) 0.036  0.055 
Necrosis score (Low / High grade) 1.29 (0.61-2.70) 0.505   
CD8 tertiles (1/2/3) 0.68 (0.43-1.10) 0.117   
CD68 tertiles (1/2/3) 1.49 (0.97-2.28) 0.066 1.88 (1.12-3.15) 0.017 
Ki67 tertiles (1/2/3) 1.35 (0.78-2.35) 0.289   
CD34 tertiles (1/2/3) 0.73 (0.45-1.20) 0.214   
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Figure 6-1: Example of “low grade” local tumor inflammatory infiltrate (low power and high power view). 
 
 
 
Figure 6-2: Example of “high grade” local tumor inflammatory infiltrate (low power and high power view). 
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Figure 6-3: Example of absence of necrosis (low power and high power view). 
 
    
 
Figure 6-4: Example of extensive necrosis (low power and high power view). 
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Figure 6-5: Immunohistochemisry of tissue microarray for CD8+ (A); CD68+ (B); Ki67 (C) and CD34+ (D). Positive cells are stained brown. All pictures are 
in 200x magnification. 
A B 
C D 
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Figure 6-6: The relationship between tumour CD68+ infiltration (top to bottom, tertiles 1/2/3) and cancer specific survival in patients undergoing resection 
for oesophageal adenocarcinoma. 
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7 Chapter VII: The relationship between tumour necrosis, tumour 
proliferation, local and systemic inflammation and microvessel 
density and survival in patients undergoing potentially curative 
resection of gastric adenocarcinoma 
7.1 Introduction 
 It is increasingly recognised that outcomes for patients with cancer are determined 
by host as well as tumour-related factors.  Important host-related factors include local and 
systemic inflammatory responses (McMillan 2009, Roxburgh, McMillan 2010, Hanahan, 
Weinberg 2011, Colotta et al. 2009).  Increased systemic inflammatory response i.e. 
elevated C-reactive protein, prior to surgery in gastric cancer has been reported to have an 
independent prognostic value (Wang, Sun 2009, Chang et al. 2010, Nozoe et al. 2011).  
For example, on a comprehensive examination of the prognostic value of both tumour and 
patient related factors, only mGPS and positive to total lymph node ratio (LNR) were 
independent predictors of cancer specific survival in gastric cancer (Chapter 5). 
With reference to the local inflammatory response, a pronounced tumour 
inflammatory cell infiltrate has been reported to be associated with improved survival in 
gastric cancer (Davessar et al. 1990, Ma et al. 1994, Songun et al. 1996).   It is of interest 
therefore, that Klintrup, Makinen and colleagues reported a simplified subjective 
assessment of the inflammatory infiltrate at the invasive margin of colorectal cancer, 
including all inflammatory cell types and classifying the infiltrate as low or high grade, had 
independent prognostic value (Klintrup et al. 2005).  This method, in addition to being 
validated in an independent cohort of colorectal cancer patients (Roxburgh et al. 2009a, 
Roxburgh et al. 2009b), has also been validated in an unselected cohort of patients with 
gastro-oesophageal cancer (Crumley et al. 2011).   
 More specifically, CD8+ T-lymphocytes have been reported to provide prognostic 
information in gastric cancer (Lee et al. 2008, Milasiene, Stratilatovas & Norkiene 2007).  
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Also, tumour associated macrophages (CD68+
 
) appear to have prognostic value in patients 
with gastric cancer (Ishigami et al. 2003, Kawahara et al. 2010, Ohno et al. 2003, Wang et 
al. 2011) .  Therefore, it would appear that the type and location of tumour inflammatory 
cells are important in determining cancer outcome.  However, to date the few reports e.g. 
Crumley and coworkers (2011) have been in heterogeneous cohorts of patients including 
esophageal, junctional, and gastric sites and squamous and adenocarcinomas (Crumley et 
al 2011).  Therefore, the prognostic value of measures of the local inflammatory response 
in patients with gastric cancer remains to be clearly established. 
 The basis of the relationship between the tumour and local and systemic 
inflammatory responses and outcome is not clear.  However, a plausible hypothesis is that 
rapidly proliferating tumours outgrow their blood supply becoming hypoxic and necrotic 
thereby stimulating both local and systemic inflammatory responses and angiogenesis that, 
in turn, promote tumour progression and metastases (Vakkila, Lotze 2004, Degenhardt et 
al. 2006). Indeed, it has been reported that high tumour proliferative activity is associated 
with poorer survival in gastric cancer (Tzanakis et al. 2009, Solcia et al. 2009).  Also, it has 
been reported that CD34+ positive intra tumoral microvessel density was associated in 
gastric cancer survival (Chen et al. 2008, Osinsky et al. 2011).  It has also been recognised 
the role of hypoxia in neoangiogenesis and tumour progression in gastric cancer (Osinsky 
et al. 2011, Cabuk et al. 2007).   
 This hypothesis has recently been examined in patients undergoing potentially 
curative resection for oesophageal cancer (Chapter 6).  It was shown that the extent of the 
inflammatory infiltrate and angiogenesis was greater in oesophageal adenocarcinoma 
compared with squamous carcinoma.  Within the adenocarcinoma cohort, although tumour 
necrosis was not associated with tumour proliferative activity, inflammatory cell infiltrate 
and angiogenesis, tumour proliferative activity was directly associated with the extent of 
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macrophage infiltration and intra-tumoral macrophage infiltration had independent 
predictive value (Chapter 6). 
 To our knowledge the prognostic of value of tumour necrosis in patients with 
gastric adenocarcinoma, has not been previously reported.  However, histological evidence 
of tumour necrosis is recognised to be associated with decreased survival in other 
gastrointestinal malignancies such as gastrointestinal stromal tumour, pancreas and 
colorectal (Hiraoka et al. 2010, Pollheimer et al. 2010, Fujimoto et al. 2003).    
 The aim of the present study was to examine the relationship between tumour 
necrosis, tumour proliferation, local and systemic inflammation and micro vessel density 
and survival in patients undergoing potentially curative resection of gastric cancer. 
7.2 Patients and Methods 
 One hundred and four patients undergoing potentially curative resection of gastric 
cancer (including type III tumours of the gastro-oesophageal junction (Siewert, Stein 
1996)) in the upper GI surgical unit, Glasgow Royal Infirmary between January 1996 and 
May 2009 were included in the study.   
 The tumours were staged according to the tumour node metastasis (TNM) Criteria 
from the 6
th
 edition of the International Union Against Cancer (UICC) Classification of the 
Malignant Tumours (Sobin, Wittekind & editors. April 2002).  Tumours of the gastro-
oesophageal junction were further subdivided according to site, using the Siewert 
classification; Type I and II lesions of the gastro-oesophageal junction were designated, as 
cancers of the oesophagus and were therefore excluded from the study.  Type III tumours 
of the cardia were designated as gastric cancers (Siewert, Stein 1996).  Furthermore, only 
patients with TNM stage I to III tumours were considered amenable to curative surgical 
resection and included in the study.  
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 All patients underwent potentially curative en-bloc resection and the majority had 
D2 lymph-adenectomy and survived at least 30 days following surgery.  Thirty six patients 
received neo-adjuvant chemotherapy, mainly in last two years of study period. Gastric 
cancer patients (including type III gastro-oesophageal junctional tumour patients) received 
3 cycles of pre operative and post-operative epirubicin, cisplatin and 5-flurouracil (ECF) 
(the MRC Adjuvant Gastric Infusional Chemotherapy; MAGIC trial) (Cunningham et al. 
2006).  
The study was approved by the Research Ethics Committee of Glasgow Royal Infirmary. 
7.2.1 Biochemical data 
 The coefficient of variation for laboratory measurements of albumin and C-reactive 
protein, over the range of measurement, was less than 10% as established by laboratory 
quality control procedures.  The limit of detection of the assay was a C-reactive protein 
concentration lower than 6mg/l.  A C-reactive protein concentration greater than 10mg/l 
was considered to indicate the presence of a systemic inflammatory response (McMillan et 
al. 2001) 
 The mGPS was constructed as previously described (McMillan 2008).  An elevated 
C-reactive protein (>10 mg/l) were assigned a modified GPS score (mGPS) of 1 or 2 
depending on the absence or presence of hypo-albuminaemia (<35g/l).  Patients in whom 
neither abnormality was present were allocated an mGPS score 0. 
7.2.2 Assessment of tumour necrosis 
 The same routine haematoxylin and eosin slides from the resected tumour 
specimens were used to evaluate tumour necrosis over the entire area of invasive 
carcinoma available.  The scoring method for evaluating necrosis was adapted from a 
previously published protocol (Ikpatt, Ndoma-Egba & Collan 2002) where it was 
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subjectively graded into three categories using full haematoxylin and eosin-stained 
histological sections. Score 0, absent (no confluent necrosis at all, i.e. only single-cell 
death (apoptosis) identifiable. Score 1, mild: confluent areas of invasive carcinoma cell 
necrosis in fewer than 25% of x40 fields. Score 2, moderate: confluent areas of invasive 
carcinoma cell necrosis in 25-50% of x40 fields.  Score 3, extensive: confluent areas of 
invasive carcinoma cell necrosis in >50% of x40 fields.  These scores were aggregated as 
low grade (scores 0 and 1) or high grade (scores 2 and 3).  Confluent necrosis was defined 
as areas of definite death of small or large foci of carcinoma cells with some or all of the 
following features: condensation, darker staining, fragmentation or total loss of tumour cell 
nuclei; increased cytoplasmic eosinophilia, loss of cytological detail, granular eosinophilic 
debris, occasionally with calcification.  All cases were scored independently by two 
observers (SD, JG) who were blinded to clinical outcomes.  The cases with different scores 
were reviewed by both of the observers together and an agreed score was determined.  
7.2.3 Assessment of Tumour Inflammatory infiltrate 
 The routine haematoxylin and eosin slides from the resected tumour specimens 
were retrieved from the pathology archive and scored as described by Klintrup and 
colleagues (Klintrup et al. 2005).  Tumours were scored based on the appearance at the 
deepest area of tumour invasion on a four point score.  A score of 0 indicated that there 
was no increase in the inflammatory cells at the deepest point of the tumours invasive 
margin; score 1 denoted a mild and patchy increase in the inflammatory cells; score 2 
denoted a prominent inflammatory reaction forming a continuous band at the invasive 
margin with some evidence of destruction of cancer cell islands and score 3 denoted a 
florid ‘cup-like’ inflammatory infiltrate at the invasive edge with frequent destruction of 
cancer cell islands.  These scores were then subsequently classified as low grade (scores 0 
and 1) or high grade (scores 2 and 3).  All cases were scored independently by two 
observers (SD or AC and JG).  Observers were blinded to the clinical outcome of the 
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patient.  The inter-observer intraclass correlation coefficient for tumour inflammatory 
infiltrate was 0.86. 
7.2.4 Tissue micro array (TMA) construction:  
 The routine haematoxylin and eosin slides of the resected tumour specimens along 
with corresponding paraffin blocks were retrieved from the pathology archive for all 
patients in our study group.  A minimum of three representative areas of tumour were 
defined by the researcher (SD) and the pathologist (JG).  Tissue micro arrays were then 
constructed in triplicate cores 0.6-mm in diameter from each tumour which were placed in 
separate TMA blocks (Beecher Scientific, Silver Spring, Maryland , USA) as previously 
described (Kononen et al. 1998).  Sections 2.5 µm thick from each TMA block were 
mounted on silanised glass slides.  These sections were used to perform 
immunohistochemistry for CD8+
 
T cells, CD68+ (tumour-associated macrophages), Ki-67 
(tumour proliferative index) and CD34+ (for micro vessel density).  This was performed in 
the Department of Pathology, Western Infirmary, Glasgow. 
7.2.5 Immunohistochemistry 
 Immunohistochemistry of TMA slides was performed using the ChemMate Dako 
Envision method (Dako, Cambridgeshire, UK).  The primary antibody for CD8+ was 
monoclonal mouse anti-human CD8+, Clone CD8+/144B (DAKO, Glostrup, Denmark) at 
a dilution of 1:100 (overnight incubation) and for CD68+ was monoclonal mouse anti-
human CD68+, Clone PG-M1 (DAKO, Glostrup, Denmark) at a dilution of 1:200 (1 hour 
incubation).  The primary antibody for Ki-67 was monoclonal mouse anti-human Ki-67, 
Clone MIB-1(DAKO, Glostrup, Denmark) at a dilution of 1:50 (overnight incubation) and 
for CD34+ was monoclonal mouse anti-human, CD34+ Class II, Clone QBEnd 10 
(DAKO, Glostrup, Denmark) at a dilution of 1:150 (30 minutes incubation). 
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 Cores were dewaxed and rehydrated.  Antigen retrieval was performed by keeping 
the slides in Tris EDTA buffer (pH 8), in pressure cooker for 5 minutes.  Endogenous 
peroxidise was blocked by incubation in 3% hydrogen peroxide for 10 minutes.  The cores 
were then incubated with the normal horse serum at dilution 1:20 for 20 minutes at 25ºC to 
block non- specific binding sites.  Respectively primary antibody was added in appropriate 
concentrations.  Sites of binding were detected using the Envision technique (DAKO code 
K5007, Glostrup, Denmark) with DAB (3-3´ diaminobenzidine, Vector code SK 4001, 
USA), a chromogenic substrate, according to the manufacturer’s instruction.  Cores were 
counterstained with haematoxylin, dehydrated and mounted with DPX.  Appropriate 
positive controls were included in each run and negative controls were run with the 
omission of the primary antibody.  
7.2.6 Morphometry 
 For automated image analysis of digitised slides were accessed through the 
Slidepath Image Analysis system and evaluated with the program's nuclear (for Ki-67), 
cytoplasmic (for CD68+) and membranous (for CD8+) scoring algorithm.  
 Individual TMA cores were identified, annotated on the scanned image and 
associated with TMA map entries.  Individual nuclei stained with haematoxylin and/or 
polymerised diaminobenzidine were identified by a thresholding and segmentation 
algorithm which outlines nuclei and separates touching nuclei.  Nuclear size (area) limits 
can be specified to accept or reject individual nuclei to be quantified.  Staining for Ki-67 in 
each nucleus is classified as positive or negative based on the threshold specified by the 
observer.  Pseudo-colours (red / orange / yellow / blue) display these staining intensity 
measurements for individual nuclei, allowing thresholds to be chosen appropriately.  These 
thresholds were chosen using a sample of TMA cores from the whole cohort and once 
chosen were used for analysis over the entire patient cohort without further adjustment.  
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 For CD68+, intracellular and positive pixel detection algorithm was used and for 
the CD8+, algorithm for thin cell membrane was used.  Each of the TMA cores were 
crosschecked by one of the authors (SD) to detect any obvious error.  Moreover, at least 
25% of the cases were manually scored to produce inter-observer reproducibility.  The 
inter-observer intraclass correlation coefficient values for Ki67, CD68+ and CD8+ were 
0.96, 0.86 and 0.75 respectively.  
 To assess intra-tumoral micro-vessel density, immuno-histochemical staining for 
CD34+ was performed.  Quantitative assessment of CD34+ was performed by manual 
counting of CD34+ positive endothelial cells or cluster regardless of whether a vessel 
lumen was seen in each of the TMA cores.  All cores were counted by one of us (SD) and 
at least 25% of the cases were counted by a second observer (ZM) and interclass 
correlation coefficient for CD34+ was 0.87. 
7.2.7 Statistical analysis 
 Survival analysis of the group variables was performed using the Cox proportional 
hazard model including deaths up to the end of May 2011.  Multivariate survival analysis, 
including all significant covariates (P≤ 0.1) was performed using a stepwise backward 
procedure to derive a final model of the variables that had a significant independent 
relationship with survival.  To remove a variable from the model, the corresponding P-
value had to be greater than 0.05.  The relationships between the mGPS and other variables 
were analysed using the Mantel–Haenszel (X2) test for trend as appropriate.  Analysis was 
performed using SPSS software (SPSS Inc., Chicago IL, USA). 
7.3 Results 
 One hundred and four patients with gastric adenocarcinoma were included in our 
study.  Overall, the majority of patients were male (66%), less than 75 years of age (82%) 
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and had an mGPS of 0 (80%).  Most of the patients had TNM stage I or II (65%), had well 
to moderately differentiated tumour (54%), clear resection margin (89%) and LNR ≤0.2 
(80%).  Only 27 patients had high grade peri-tumour inflammatory infiltrate according to 
Klintrup-Makinen criteria (26%) and 36 patients had high grade necrosis score (35%). The 
median values for CD8+, CD68+ and Ki-67 were 5.3%, 17.2% and 19.7% respectively and 
for CD34+ the median value was 43.  The majority did not receive neo-adjuvant (65%) 
therapy. 
 The relationship between patients without neo-adjuvant therapy and with neo-
adjuvant therapy and clinico-pathological characteristics are shown in Table 7-1.  Patients 
with neo-adjuvant therapy had higher infiltration of CD8+ (p<0.01) and higher Ki67 
proliferation index (p<0.05).  Whereas patients without neo-adjuvant therapy had higher 
TNM stage (p=0.001) and higher positive to total lymph node ratio (p<0.01).  Cancer 
specific survival was better in patients with neo-adjuvant therapy (p<0.001).   
 The relationship between clinic-pathological factors and cancer specific survival 
was examined also in a subgroup of gastric cancer patients who did not receive neo-
adjuvant therapy (n=68, Tables 7-2).  In patients with gastric cancer, the median follow up 
of survivors was 62 months with a minimum of 21 months.  During this period 44 (42%) 
patients died of their cancer and 7 (7%) patients died of non-cancer causes.  On univariate 
analysis, only mGPS (p=0.001), TNM stage (p=0.001), tumour differentiation (p<0.01), 
LNR (p<0.001) and tumour necrosis (<0.01) were significantly associated with cancer 
specific survival.  On multivariate analysis only, mGPS (HR 2.22, 95% CI 1.16-4.27, 
p=0.017), tumour differentiation (HR 2.44, 95% CI 1.10-5.42, p=0.028), LNR (HR 1.82, 
95% CI 1.06-3.14, p=0.030) and tumour necrosis (HR 2.43, 95% CI 1.10-5.40, p=0.029) 
retained independent significance (Tables 7-2 and Figure 7-1).  
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The relationship between the mGPS and clinicopathological characteristics in 
patients undergoing potentially curative resection for gastric adenocarcinoma without neo-
adjuvant therapy is shown in Table 7-3. There was no association between pre operative 
mGPS and clinicopathological parameters in this cohort. 
Interrelationships between clinical and pathological charecteristics of patents who 
did not receive neo-adjuvant chemotherapy are shown in Table 7-4 (n=68).  TNM stage 
was directly associated with poor tumour differentiation (p=0.001) and LNR(p<0.001).  
Poor differentiation was directly associated with a LNR (p<0.05).  Positive resection 
margin (R1) was directly associated with necrosis (p<0.05) and CD68+ infiltration 
(p<0.05).  The Klintrup-Makinen score was directly associated with CD8+ infiltration 
(p<0.05), CD68+ infiltration (p=0.001) and Ki67 proloferation index (p<0.05).  The CD8 
infiltration was positively associated with CD68 (p<0.001). CD68+  infiltration in gastric 
cancer was directly associated with Ki67 proliferation index (p<0.05). 
   Interrelationships between clinical and pathological charecteristics of patents who 
did receive neo-adjuvant chemotherapy  are shown in Table 7-5 (n=36).  Advanced age 
was associated with higher necrosis score (p<0.01).  TNM stage was directly associated 
with positive resection margin (p<0.05) and LNR(p<0.001).  Poor differentiation was 
directly associated with a positive resection margin (p<0.01) and higher CD68+ infiltration 
(p<0.01).  Positive resection margin (R1) was directly associated with LNR (p<0.05).  The 
Klintrup-Makinen score was directly associated with CD68+ infiltration (p=0.01) and Ki67 
proloferation index (p<0.01). CD68+  infiltration in gastric cancer was directly associated 
with Ki67 proliferation index (p<0.05). 
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7.4 Discussion 
 The results of the present study show that, infiltration of  CD8+ lymphocytes and 
proliferation index is higher in patients who received neo-adjuvant chemotherapy for their 
gastric cancer.  Moreover, tumour proliferative activity was directly associated with the 
extent of macrophage infiltration, although tumour necrosis was not associated with 
proliferative activity, inflammatory cell infiltrate and angiogenesis.  When the prognostic 
value of such tissue factors were examined, only tumour necrosis retained significance 
independent of the lymph node ratio and the systemic inflammatory response.  Taken 
together these results would suggest that the relationship tumour necrosis and the 
inflammatory responses is more complex than proposed but that tumour necrosis plays a 
role in cancer survival following resection of gastric cancer.  
In the present study tumour necrosis was an independent predictor of survival in 
patients who did not receive neo-adjuvant therapy.  These results are consistent with the 
recent review reporting the prognostic value of tumour necrosis in other solid organ 
malignancies such as breast, renal, lung and colorectal cancer (Richards et al. 2011).  
Therefore, the basis of the impact of tumour necrosis on cancer survival is worthy of 
further study.   
Low grade peri-tumoral inflammatory infiltrate was reported to be associated with 
poorer cancer specific survival in gastro-oesophageal cancer (Crumley et al. 2011)  and 
colorectal cancer (Klintrup et al. 2005, Roxburgh et al. 2009a, Roxburgh et al. 2009b).  
The results of the present study suggest that role of the Klintrup-Makinen score as a 
prognostic indicator is inferior to that of tumour necrosis in gastric cancer.   
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 With reference to the other tissue factors examined, the results of the present study 
are consistent with previous literature.  Indeed, some previously reported studies in gastric 
cancer did not find any relationship between CD34+ microvessel density and Ki-67 
proliferaration index and survival (Mao et al. 2007, Kim et al. 2002, Tenderenda et al. 
2001, Suzuki et al. 2010, Li, Wei & Xue 2009) (Muller et al. 1996, Setala et al. 1998, 
Victorzon et al. 1997).  Similarly, CD8+ inflammatory cell infiltrate was not associated 
with survival (Haas et al. 2009, Chiaravalli et al. 2006, Shen et al. 2010).  However, there 
have been conflicting reports regarding the predictive value of the macrophages in gastric 
cancer.  Ishigami and colleagues reported that higher infiltration of macrophages was 
associated with poorer outcome in gastric cancer (Ishigami et al. 2003).  In contrast, Ohno 
et al reported a better outcome of patients with high tumour infiltration of macrophages in 
a study with similar number of patients with gastric cancer (Ohno et al. 2003). In the 
present study, intra tumoral macrophages were not associated with cancer specific survival. 
Although, it was associated with peri-tumoral inflammatory infiltrate, intra tumoral CD8+ 
lymphocyte infiltration, tumour proliferation and tumour differentiation.  
 In summary, of the tissue factors examined in the present study, tumour necrosis 
appeared to play a dominant role in the poor outcome in patients with gastric cancer. 
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Table 7-1: Clinico-pathological characteristic of patients undergoing potentially curative 
resection for gastric cancer (n=104) 
 
 
*Log rank test 
 
 No neo-adjuvant 
(n=68) 
Neo-adjuvant 
(n=36) 
P value 
Patient related factors    
Age (<65/65 –74/≥75 years) 29/28/11 11/18/7 0.300 
Sex (Male/ Female) 46/22 23/13 0.828 
mGPS (0/1/2) 53/13/2 28/5/3 0.620 
Klintrup-Makinen score  
(Low grade/ High grade) 
52/16 25/11 0.485 
CD8+ tertiles (1/2/3) 29/21/18 7/10/19 0.004 
CD68+ tertiles (1/2/3) 22/26/20 13/8/15 0.617 
CD34+ tertiles (1/2/3) 24/23/18 10/10/16 0.238 
    
Tumour related factors    
TNM Stage (I/II/III) 22/14/32 20/12/4 0.001 
Tumour differentiation (well-mod/poor) 38/30 18/18 0.680 
Resection Margin (R0/R1) 63/5 29/7 0.104 
LNR (0/≤ 0.2/>0.2) 27/24/17 27/5/4 0.003 
Necrosis Score (Low grade/ High grade) 45/23 23/13 0.831 
Ki67 tertiles (1/2/3) 26/24/17 8/11/17 0.023 
    
Alive/ Cancer specific death/  Non 
cancer death 
28/33/7 25/11/0 <0.001* 
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Table 7-2: Relationships between clinico-pathological factors and survival, in patients selected for potentially curative resection for gastric without neo-
adjuvant therapy (n=68) 
 
 Univariate analysis Multivariate analysis 
 Hazard ratio (95% CI) P-value Hazard ratio (95% CI) P-value 
Patient related factors     
Age (<65/65 –74/≥75 years)  1.01 (0.98-1.05) 0.501   
Sex (male/female) 1.27 (0.61-2.62) 0.522   
mGPS (0/1/2) 2.60 (1.45-4.67) 0.001 2.22 (1.16-4.27) 0.017 
     
Tumour related factors     
TNM Stage (I/II/III) 2.20 (1.37-3.53) 0.001  0.737 
Tumour differentiation (well-mod/poor) 2.74 (1.34-5.63) 0.006 2.44 (1.10-5.42) 0.028 
Resection Margin (R0/R1) 2.08 (0.62-6.96) 0.234   
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 2.35 (1.48-3.72) <0.001 1.82 (1.06-3.14) 0.030 
     
Klintrup-Makinen score (Low / High grade) 0.45 (0.17-1.17) 0.103   
Necrosis score (Low / High grade) 2.50 (1.26-4.97) 0.009 2.43 (1.10-5.40) 0.029 
CD8 tertiles (1/2/3) 0.98(0.64-1.50) 0.925   
CD68 tertiles (1/2/3) 0.87 (0.56-1.35) 0.541   
Ki67 tertiles (1/2/3) 0.78 (0.51-1.24) 0.316   
CD34 tertiles (1/2/3) 0.99 (0.63-1.54) 0.950   
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Table 7-3: The relationship between the mGPS and clinicopathological characteristics in patients undergoing potentially curative resection for 
gastric adenocarcinoma without neo-adjuvant therapy (n= 68). 
 
 mGPS 0  
(n= 53) 
mGPS 1&2 
(n= 15) 
P value 
Patient related factors    
Age (<65/65 –74/≥75 years)  24/20/9 5/8/2 0.695 
Sex (male/female) 37/16 9/6 0.337 
    
Tumour related factors    
TNM Stage (I/II/III) 17/12/24 5/2/8 0.793 
Tumour differentiation (well-mod/poor) 32/21 6/9 0.134 
Resection Margin (R0/R1) 50/3 13/2 0.303 
Positive to total lymph node ratio (0/≤ 0.2/>0.2) 21/19/13 6/5/4 0.940 
    
Klintrup-Makinen score (Low / High grade) 40/13 12/3 0.506 
Necrosis score (Low / High grade) 36/17 9/6 0.390 
CD8 tertiles (1/2/3) 23/16/14 6/5/4 0.879 
CD68 tertiles (1/2/3) 18/21/14 4/5/6 0.367 
Ki67 tertiles (1/2/3) 24/16/12 2/8/5 0.065 
CD34 tertiles (1/2/3) 16/20/14 8/3/4 0.339 
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Table 7-4: Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for gastric without 
neo-adjuvant therapy (n=68). 
 
 
 
 Sex mGPS TNM 
Stage  
Tumour 
differentia
tion  
Resection 
Margin  
LNR Klintrup
Makinen 
score 
Necrosis 
score 
CD8+ 
tertiles 
CD68+ 
tertiles 
Ki67 
tertiles 
CD34+ 
tertiles 
Age  in years (<65/ 65-74/ >75 years ) 0.172 0.400 0.206 0.721 0.137 0.120 0.926 0.148 0.422 0.910 0.469 0.746 
Sex (male/ female)  0.195 0.418 0.541 0.476 0.293 0.415 0.051 0.649 0.832 0.733 0.497 
mGPS   0.890 0.222 0.486 0.878 0.567 0.522 0.941 0.440 0.104 0.458 
TNM Stage (I/ II/ III)    0.001 0.235 <0.001 0.909 0.181 0.816 0.073 0.575 0.362 
Tumour differentiation (well-mod/poor)     0.613 0.049 0.602 0.085 0.800 0.069 0.557 0.433 
Resection Margin (R0/R1)      0.111 0.335 0.041 0.306 0.015 0.438 0.789 
LNR       0.342 0.159 0.625 0.802 0.402 0.353 
Klintrup-Makinen score (Low / High 
grade) 
       0.528 0.022 0.001 0.027 0.852 
Necrosis score (Low / High grade)         0.690 0.688 0.988 0.992 
CD8+ tertiles (1/2/3)          <0.001 0.902 0.131 
CD68+ tertiles (1/2/3)           0.033 0.180 
Ki67 tertiles (1/2/3)            0.645 
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Table 7-5: Interrelationships between different pathological and clinical parameters in patients selected for potentially curative resection for gastric with neo-
adjuvant therapy (n=36). 
 
 
 Sex mGPS TNM 
Stage  
Tumour 
differentia
tion  
Resection 
Margin  
LNR Klintrup
Makinen 
score 
Necrosis 
score 
CD8+ 
tertiles 
CD68+ 
tertiles 
Ki67 
tertiles 
CD34+ 
tertiles 
Age  in years (<65/ 65-74/ >75 years ) 0.231 0.766 0.789 0.638 0.644 0.876 0.156 0.008 0.482 0.635 0.374 0.707 
Sex (male/ female)  0.260 0.267 1.00 1.00 0.724 1.00 0.292 0.884 0.066 0.067 0.632 
mGPS   0.462 0.423 0.561 0.421 0.834 0.568 0.210 0.906 0.801 0.301 
TNM Stage (I/ II/ III)    0.055 0.013 <0.001 0.563 0.542 0.474 0.183 0.763 0.443 
Tumour differentiation (well-mod/poor)     0.008 0.222 0.471 0.489 1.00 0.009 0.836 0.237 
Resection Margin (R0/R1)      0.032 0.076 1.00 0.479 0.447 0.361 0.561 
LNR       0.606 0.241 0.917 0.527 0.701 0.406 
Klintrup-Makinen score (Low / High 
grade) 
       0.708 0.287 0.010 0.005 0.354 
Necrosis score (Low / High grade)         0.884 0.619 0.914 0.632 
CD8+ tertiles (1/2/3)          0.301 0.428 0.801 
CD68+ tertiles (1/2/3)           0.014 0.296 
Ki67 tertiles (1/2/3)            0.385 
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Figure 7-1: Relationship between tumour necrosis (top to bottom, low-grade and high grade) and cancer-specific survival in patients undergoing resection for 
gastric cancer without neo-adjuvant therapy. 
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8 Chapter VIII: Discussion 
 The overall aim of the thesis was to examine the relationships between tumour 
based factors, patient co-morbidity and the inflammatory responses (local and systemic) 
and outcome in patients undergoing resection for oesophageal and gastric cancer.   
An underlying hypothesis in the present thesis work is that a sustained elevation of 
the systemic inflammatory response whether pre-, peri- or postoperative will compromise 
both short and long term survival through its relationship with the tumour 
microenvironment in patients undergoing surgery for oesophageal and gastric cancer.  
The results of the present work have demonstrated that, in addition to tumour based 
factors, pre operative patient comorbidity and systemic inflammation have a role in 
predicting post operative outcome (short term and long term respectively) in patients with 
oesophageal and gastric cancer.  Moreover, the perioperative systemic inflammatory 
response was useful in predicting the likelihood of developing a post-operative infective 
complication.  These results parallel those recently reported in patients with colorectal 
cancer (Richards et al. 2011a).   
In terms of short term outcome, the present studies did not confirm the pre 
operative elevated systemic inflammatory response predicts the post operative 
complications.  This is in contrast to that reported in colorectal cancer (Richards et al. 
2011a, Moyes et al. 2009) and oesophageal cancer (Vashist et al. 2011) in larger cohorts.  
It may be that the present studies were not large enough to detect a significant association.  
However, in large series of patients with curative resection of gastric cancer (n=1071) it 
was reported that preoperative elevated systemic inflammation was not associated with 
post operative complication but was a predictor of long term survival (Kubota et al. 2012).  
Therefore, further studies in larger patient’s cohorts are required to define the relationship 
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between the presence of a pre-operative systemic inflammatory response and post-
operative complications in patients with oesophageal and gastric cancer.   
It is also of interest that although there have been reports of a relationship between 
post operative infective complications such as anastomotic leak are associated with poor 
long term outcome in colorectal cancer (McArdle, McMillan & Hole 2005, Walker et al. 
2004) as well as in gastric cancer (Kubota et al. 2012, Nagasako et al. 2012, Sierzega et al. 
2010). This was not confirmed in the present thesis work.  Again, it may be that the present 
studies were not large enough to detect a significant association.  Therefore, further studies 
in larger patients’ cohorts are required to define the relationship between the presence of a 
post-operative systemic inflammatory response and complications and long term survival 
in patients with oesophageal and gastric cancer. 
In terms of long term outcome, a pre-operative systemic inflammatory response 
was significantly associated with poor outcome in both oesophageal and gastric cancer.  
These results are consistent with a large number of studies in patients undergoing surgery 
for a variety of common solid tumours (Roxburgh and McMillan, 2010; Vashist et al. 
2011; Jiang et al. 2012)). 
Therefore, in long term survival, it would appear that the pre-operative systemic 
inflammatory response is of more importance compared with the peri-operative systemic 
inflammatory response.  The results are consistent with recent work in patients with 
colorectal cancer (Richards et al. 2011a).  
 The mechanisms by which the systemic inflammatory response impacts on cancer 
specific survival is, however, still unclear.  The present work confirmed the relationship 
between local inflammatory response and aggressive tumour behaviour. However, there 
was no significant relationship between the tumour inflammatory cell infiltrate and the 
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systemic inflammatory response, as evidenced by the mGPS, in patients with oesophageal 
and gastric cancer.  One possible explanation of the enhanced malignant potential of 
tumour in presence of chronic elevated systemic inflammatory response is that the 
systemic inflammatory response is a surrogate for occult metastases.  If this were the case 
it may be that more extensive pre-operative tumour staging will shed further light on this 
relationship.  Alternatively, the use of neoadjuvant therapy would also be useful in teasing 
out this relationship.   
However, this theory of occult metastasis is unlikely to fully explain the ability of 
the systemic inflammatory response to consistently and independently predict poor cancer 
survival in a variety of tumour types and at different stages of disease (Roxburgh, 
McMillan 2010; McMillan, 2012).  From these reports and the results of the present study, 
it is more likely that the presence of a systemic inflammatory response enhances the 
malignant potential of the tumour.  Indeed, it has been suggested that pre operative anti 
inflammatory intervention might reduce the recurrence rate and improve survival 
(Roxburgh, McMillan 2010; Clarke et al. 2011; McMillan, 2012). Clearly these issues of 
targeted anti-inflammatory therapies need to be evaluated by prospective controlled trials.  
In the present thesis it was also hypothesised that the link between systemic 
inflammatory response and the local inflammatory response might be tumour hypoxia and 
necrosis.  Whereby tumour necrosis activates tumour cells and macrophages to produce 
pro-inflammatory cytokines and growth factors such as vascular endothelial growth factor. 
As a result of that lympho-vascular invasion and tumour dissemination is increased.  
Indeed, tumoural necrotic cell death releases pro-inflammatory signals into the tumour 
microenvironment i.e. necrosis can recruit inflammatory cells which has tumouricidal 
activity.  Also, such necrotic cells can release bio active regulatory factors like IL-1∞ that 
in turn stimulates tumour proliferation (Grivennikov, Greten & Karin 2010) and induces 
IL-6 production that stimulate hepatocytes to produce C-reactive protein.  A recent review 
 
 200 
200 
 
by Guthrie and coworkers (2013) has developed such a scheme and have proposed IL-6 as 
a key mediator of the relationship between tumour necrosis, local and systemic 
inflammatory response and outcome in patients with colorectal cancer (Guthrie et al. 2013.   
The results from the thesis do not support such scheme in oesophageal and gastric cancer 
since a direct relationship between the tumour necrosis, inflammatory cell infiltrate and the 
systemic inflammatory response was not demonstrated. Therefore, it may be that the 
molecular link between tumour necrosis, local and systemic inflammatory response in 
oesophageal and gastric cancer is more complex. A detailed study of such relationships of 
IL-6 and pro-inflammatory cytokines may be useful.  
 Tumour associated macrophages have been reported to be one of the most 
important players in the tumour associated inflammatory responses.  They may have anti-
tumour as well as pro-tumour activity.  However, generally a high tumour infiltrate of 
macrophages is associated with poor prognosis (Grivennikov, Greten & Karin 2010).  
Indeed, there was some support for the tumour promoting role of the macrophages in 
oesophageal adenocarcinoma in the present thesis.  
Macrophages infiltrate the tumour at a very early stage of tumorigenesis and 
usually precede other leucocytes (e.g. lymphocytes; Clark et al. 2007).  Detailed research 
in the last decade has enhanced our understanding of the promoting role of macrophages in 
tumour progression, metastasis and angiogenesis (Allavena, Mantovani 2012).  Tumour 
associated macrophages can be of two subtypes i.e. M1 and M2.  M1 macrophages are 
thought to have anti-tumour immune response whereas M2 subtype is thought to have a 
tumour progression role.  Tumour associated macrophages are known to produce IL-6 in 
the tumour tissue by NF-kB signaling pathway.  Moreover macrophages are known to 
accumulate in the hypoxic areas of the tumour and hypoxia induced factor (HIF) -1 alpha 
activates NF-kB pathways in such macrophages.  In turn, IL-6 is known to activate the 
signal transducer and activator of transcription 3 (STAT3) pathways that in turn promotes 
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tumour proliferation and progression (Aggarwal, Vijayalekshmi & Sung 2009).  Lastly, 
tumour associated macrophages are known to stimulate angiogenic switches in the tumour 
through vascular endothelial growth factor (VEGF) and other angiogenic molecules.  In the 
present work there was not a significant relationship between intra tumoural microvessel 
density and intra tumoural macrophage counts.  Therefore more detailed studies involving 
subtypes of tumour associated macrophages (M1 and M2), IL-6, VEGF expression and 
hypoxia-inducible factor 1 alpha (HIF1∞) and various signalling pathways (i.e. STAT3 
and NF-kB) may provide a more detailed insight into the complex interplay between the 
tumour and host responses.   
There is an accumulating body of evidence indicates that several anticancer 
chemotheraputic agents target tumour specific immune responses (Galluzzi et al. 2012).  
Furthermore, several large clinical studies are currently underway to examine the 
predictive value of various immune infiltrates in solid tumour (Senovilla et al. 2012).  The 
potential pro-tumourigenic role of macrophages has made them an attractive target for anti 
cancer therapy and such therapy has been reported to have a better effect compared with 
conventional chemotherapy and anti-angiogenic therapy (Marigo et al. 2008, Bianchi et al. 
2011, De Palma et al. 2007, Welford et al. 2011, Ferrara 2010).  In the era of preoperative 
anti cancer treatment (neo-adjuvant) in oesophageal and gastric cancer, the role of tumoral 
and systemic inflammatory response biomarkers are likely to become more crucial to the 
determination of therapeutic response, risk stratification and long term outcome. 
Therefore, as discussed above the work in the present thesis points to a number of 
avenues of future research.  In particular, (a) the better stratification and allocation of 
treatment in patients with oesophago-gastric cancer.   Although there are consistent reports 
in observational studies that markers of the local and systemic inflammatory responses 
have prognostic value independent of tumour characteristics. The next step is for such 
markers is that they will be shown to stratify patients in post-hoc analysis of existing 
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randomised controlled trials (RCTs). Once the post hoc RCTs analysis confirms the 
clinical utility of these factors they will then become stratification factors for prospective 
RCTs.  There is evidence that markers of the systemic inflammatory response such as the 
GPS and the NLR are reaching this stage (McMillan 2013) (b) further examination of the 
complex interplay between local and systemic inflammatory response and survival. For 
example, the present thesis work does not distinguish whether an impaired local 
inflammatory response or an elevated systemic inflammatory response merely reflects the 
presence of occult metastases or whether these promote the development of 
micrometastases.  In this case treatments that target the tumour (such as neoadjuvant 
therapy) or treatments that target the local and systemic inflammatory responses (such as 
NSAIDs administration) will provide further insight into the mechanisms underlying the 
observations of the present thesis.    
From the above it is clear that the pre operative systemic inflammatory response, as 
evidenced by the mGPS, is of paramount importance (compared with cellular components 
of the local and systemic inflammatory responses) in determining long term outcome 
following oesophageal and gastric cancer resection.  Furthermore, the mGPS is a simple 
and objective measure which is well standardised and easily reproducible and can be 
readily included in the clinical staging of all patients.  Therefore, it would be reasonable to 
incorporate inflammatory biomarkers into pre operative stratification of patients with 
oesophageal and gastric cancer that it is possible to select those patients who will benefit 
from the extensive surgery and those who are unlikely to derive benefit.  Also, pre-
operative optimisation of patients is likely to become of increasing importance in achieving 
better survival especially in the modern era of neo-adjuvant therapy for oesophageal and 
gastric cancer.  Further prospective studies are required to establish the complex interplay 
between patient’s pre operative condition and survival in oesophageal and gastric cancer.  
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